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Abstract 
The strength, functional significance and origins of parasympathetic (vagal) 
control of left ventricular function remain controversial. Experimental studies 
conducted on rats and mice using methods of genetic neuronal targeting, functional 
neuroanatomical mapping, and pharmaco- and optogenetics were employed to test 
the hypothesis that parasympathetic control of the left ventricle is provided by vagal 
preganglionic neurones of the dorsal motor nucleus (DVMN). The results of the 
experiments described in this thesis suggest that (i) activity of the DVMN vagal 
preganglionic neurones are responsible for tonic parasympathetic control of 
ventricular excitability, likely to be mediated by nitric oxide; (ii) synuclein 
deficiency (a model relevant to Parkinson’s disease) results in a reduction in the 
activity of the DVMN neurones affecting the electrophysiological properties of the 
ventricle; (iii) tonic muscarinic influence on left ventricular contractility is provided 
by a subpopulation of vagal preganglionic neurones located in the caudal region of 
the left DVMN; (iv) reduced activity of the DVMN neurones is associated with a 
severely compromised aerobic exercise capacity; (v) increased activity of the DVMN 
neurones improves left ventricular performance and exercise capacity; and (vi) 
recruitment of the DVMN activity is sufficient to preserve exercise capacity and left 
ventricular function in heart failure developing after a myocardial infarction. These 
findings provide the first insight into the central nervous substrate that underlies 
functional parasympathetic innervation of the ventricles and highlight its importance 
in controlling cardiac function. The data obtained suggest that the DVMN neuronal 
projections provide tonic restraining influence on the ventricular arrhythmic potential 
and contractility, and have a trophic effect maintaining the ability of the heart to 
mount an appropriate inotropic response during exercise. As such, DVMN activity 
has a significant beneficial effect on the healthy left ventricle as well as ventricular 
myocardium compromised by occlusion of a major coronary artery. 
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Chapter 1  Background  1 
Chapter 1 Background 
1.1 Evolution of the parasympathetic nervous system 
In the seventeenth century, William Harvey suggested a link between the 
brain and heart when he wrote:  
“Every affection of the mind that is attended with either pain or pleasure, 
hope or fear, is the cause of an agitation whose influence extends to the 
heart” (Harvey, 1628). 
Over the last century, there have been numerous anatomical and 
physiological studies of the autonomic nervous system, principally responsible for 
the integrated cardiovascular control involving sympathetic (facilitatory) and 
parasympathetic (inhibitory) arms. Complex interactions between them at different 
levels of the brain and spinal cord (the neuraxis) as well as on the periphery ensure 
effective control of cardiac function to meet ever changing behavioural and 
physiological demands (Ondicova & Mravec, 2010).  
It appears that evolutionary development of the parasympathetic nervous 
system preceded the development of its sympathetic counterpart (Kuntz, 1911). 
Significant work on the phylogenetic history of the nervous system has concluded 
that ancestral vertebrates did not possess a nervous structure equivalent to any part of 
the mammalian sympathetic nervous system, and bodily functions were largely 
controlled by the vagi (Marcus, 1909). In the evolution of the parasympathetic 
nervous system itself, unmyelinated vagal fibres appeared first. 
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1.2 Neurochemical transmission of the vagus 
1.2.1 A brief history 
Since the discovery of the inhibitory influence of the vagus nerve on the heart 
in 1845 by Ernst and Eduard Weber, the vagal control of cardiac function has been a 
topic of intense scrutiny. Earlier attempts to understand the role of both the left and 
right vagi began with electrical stimulation and characterisation of the resultant 
effects on the rate of atrial and ventricular contraction and velocities of measured 
potentials in conducting tissues. 
With the discovery of acetylcholine (ACh) and its major role in 
parasympathetic chemical transmission, various methods were developed to detect 
the presence of key enzymes involved in its metabolism. While these methods 
allowed identification of the vagal innervation of the atria, the sinoatrial (SA) and 
atrioventricular (AV) nodes and conducting tissue, the significance of the 
parasympathetic innervation of the ventricles always remained an area of ambiguity. 
Physiological experiments conducted to better understand vagal control of the 
ventricular function all had varying levels of success (Coote, 2013). Vagus nerve 
stimulation (VNS) has been shown to have an effect on contractility, automaticity 
and electrical stability of the ventricles (Degeest et al., 1965c; Vassalle et al., 1967; 
Zuanetti et al., 1987). Moreover, both ACh and nitric oxide (NO) have been 
suggested to mediate vagal effects on the ventricle. On the other hand, in vitro 
studies on isolated ventricular cardiomyocytes demonstrated changes in their 
contractile behaviour following the application of ACh and NO.  
The central nervous sites harbouring vagal preganglionic neurones (VPNs) 
projecting to the heart have been identified in many mammalian species (Spyer, 
1994) although the nature of their anatomical and functional organisation has yet to 
be fully realised. 
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1.2.2 Acetylcholine 
Walter Dixon was one of the first to focus on the mechanisms of how vagal 
nerve stimulation inhibits the heart. At the time of Dixon’s medical training in 
London, Bayliss and Starling demonstrated intestinal production of secretin which 
triggered the release of digestive enzymes (Bayliss & Starling, 1902). Dixon 
extrapolated this observation to the heart and proposed that VNS results in the 
conversion of intracardiac stores of proinhibitin to inhibitin. Later he described the 
results of an experiment in which purified extract obtained from a vagally inhibited 
dog’s heart (the donor) slowed a frog’s heart (the recipient) and this effect was 
inhibited by atropine (Dixon, 1906; Dixon, 1907).  
This was then followed by the classical work of Otto Loewi. He isolated two 
frog hearts (one with vagal innervation intact) and perfused them with a salt solution 
which mimicked the composition of extracellular fluid (Ringer, 1883). Following a 
few minutes of VNS, Ringer’s solution was transferred from the donor to the 
recipient; the heart rate (HR) was reduced mimicking the effect of VNS. This 
demonstrated that the vagus nerve produces its effect through the release of an 
inhibitory substance which Loewi named “Vagusstoff” or “vagus substance” (Loewi, 
1921). Atropine was found to abolish these effects by a mechanism other than 
inhibition of release (Loewi, 1926; Loewi & Navratil, 1926). Vagusstoff was then 
characterised as a choline ester exhibiting effects similar to those of ACh (Dale, 
1934a; Dale, 1934b; Dale & Feldberg, 1934). This was accepted by Loewi and he 
agreed to refer to it as such in his Nobel Prize lecture (Loewi, 1936). This work laid 
the foundations of modern concepts of neurohumoral (now neurochemical) 
transmission and the investigation of its role in the autonomic control of many 
organs. 
1.2.3 Nitric Oxide   
NO was first identified as “nitrous air” by Joseph Priestly (Priestley, 1775) 
and has long been considered an air pollutant. In 1980, Robert Furchgott investigated 
the role of ACh on vasculature and found that relaxation of blood vessels only 
occurred when endothelial cells were present in the preparation. He observed that in 
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the absence of endothelia ACh was not able to cause vasodilation, suggesting that 
endothelial cells produce a substance that mediates the effects of ACh. This 
substance was subsequently named “endothelial derived relaxing factor” (Furchgott 
& Vanhoutte, 1989). Moreover, in 1977, Ferid Murad independently investigated the 
mechanism underlying nitroglycerin (used widely for the treatment of angina) and 
discovered that it relaxes smooth muscle cells. In 1986, Louis Ignarro identified 
endothelial-derived growth factor as having the same properties as the NO gas. This 
was the first time a gas was demonstrated to have a physiological role. For this 
discovery, Furchgott, Murad and Ignarro were awarded the Nobel Prize in 
Physiology or Medicine in 1998 (SoRelle, 1998). 
NO is produced by the enzyme nitric oxide synthase (NOS), which exists in 
inducible as well as in constitutive endothelial (eNOS) and neuronal (nNOS) 
isoforms (Moncada et al., 1991). The physiological effects of NO are predominantly 
mediated through activation of cytosolic guanylate cyclase, resulting in an increased 
production of cyclic guanosine monophosphate (cGMP) and leading to the activation 
of many downstream signalling pathways (Ignarro, 1991). NO is released by many 
cells in virtually all tissues of the body (Danson & Paterson, 2005). There is evidence 
that NO may mediate some vagal effects on the heart (Conlon et al., 1998; Patel et 
al., 2008) in addition to its characteristic role in the control of coronary circulation 
(Paterson, 2001; Rastaldo et al., 2007). NO-induced stimulation of cGMP production 
has been demonstrated to have an effect on pacemaker current (If) in nodal tissue 
leading to increases in HR (Musialek et al., 1997). Presynaptic actions of NO 
generated by nNOS within the intrinsic cardiac ganglia (Tanaka et al., 1993; Choate 
et al., 2001) have also been demonstrated to potentiate the magnitude of bradycardia 
(Herring et al., 2000) during VNS through the facilitation of ACh release (Herring & 
Paterson, 2001).  
1.2.4 Functional interactions of vagal signalling molecules 
The functional interactions between NO- and ACh-mediated signalling 
pathways in the context of cardiac innervation has been difficult to fully discern 
(Danson & Paterson, 2005). nNOS is expressed by intracardiac cholinergic neurones 
in many species (Klimaschewski et al., 1992; Mawe et al., 1996; Choate et al., 2001; 
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Pauza et al., 2014). Inhibition of nNOS has been found to result in a substantial 
reduction of vagally-mediated bradycardia in vivo in the ferret and guinea pig 
(Conlon & Kidd, 1999) tested, while a smaller effect was observed in the dog (Elvan 
et al., 1997). No effect of nNOS blockade was reported in the rabbit heart (Liu et al., 
1996; Sears et al., 1998). 
NO donors have been shown to increase the high frequency component of 
heart rate variability (HRV) - an index of cardiac vagal tone (Chowdhary & 
Townend, 1999). Both NO donors and the cGMP analogue 8-bromo-cGMP were 
reported to potentiate bradycardia induced by vagal nerve stimulation (Sears et al., 
1999). However, application of NOS or guanylate cyclase inhibitors had no effect on 
bradycardia induced by carbamylcholine (the stable analogue of ACh), supporting 
the view of NO as an important presynaptic modulator of vagal neurotransmission 
(Hebeiss & Kilbinger, 1996; Morot Gaudry-Talarmain et al., 1997; Sears et al., 
1999; Herring et al., 2000).  
Certain neuropeptides are expressed through cardiac postganglionic vagal 
neurones (Weihe & Reinecke, 1981; Weihe et al., 1984; Lundberg & Hökfelt, 1986). 
ACh is well established to co-localise with vasoactive intestinal peptide [(VIP); 
(Lundberg et al., 1979; Bartfai et al., 1988)]. ACh and VIP were first demonstrated 
to be co-localised in vagal postganglionic neurones of cats, where VIP was found to 
potentiate ACh release in preparation for the submandibular gland (Polak, 1969; 
Szerb, 1979). ACh co-release with other neurotransmitters paints a complicated 
picture of autonomic regulation of HR (Christophe et al., 1984). For example, in 
conditions of combined β-adrenoceptor and muscarinic blockade, tachycardia 
induced by VNS was found to be blocked by VIP antagonism (Henning, 1992). 
Voltage clamp experiments demonstrated an increased magnitude of If in response to 
VIP (Shvilkin et al., 1994). This has been suggested to be an endogenous mechanism 
to prevent excess bradycardia during periods of increased vagal activity (Shvilkin et 
al., 1994).  
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1.3 Vagal innervation 
1.3.1 The vagal nuclei 
Unmyelinated parasympathetic fibres originating from the dorsal vagal motor 
nucleus [(DVMN); (Figure 1-1; Figure 1-2] possess pre- and postganglionic 
muscarinic receptors. Only mammals have myelinated vagal fibres which originate 
from the nucleus ambiguus [(NA); (Figure 1-1)] and possess preganglionic nicotinic 
receptors and postganglionic muscarinic receptors (Porges, 2009). The ontogenesis 
of the DVMN in metamorphosing amphibians undergoing anatomical and 
physiological changes during the shift from water to air breathing helps identify the 
DVMN as the primary vagal nucleus. Developing cardiorespiratory interactions 
introduces a phasic component in cardiac vagal tone and this required migration of a 
subset of the DVMN neurones ventrally giving rise to a compact formation of the 
NA (Burggren & Infantino, 1994; Smatresk, 1994; Burggren, 1995). DVMN 
neurones with C fibre axons (Ciriello & Calaresu, 1980; Nosaka et al., 1982; Jones et 
al., 1998) are therefore considered to be phylogenetically older and provide the tonic 
vagal supply. The intermediate zone between them is a likely remnant of the 
migrating population post nuclear division (Taylor et al., 1999; Jones, 2001). 
The majority of studies that have applied tracers, such as horseradish 
peroxidase (HRP), identified that cardiac vagal innervation is provided by VPNs 
residing in the NA and the DVMN, with some isolated neurones scattered in the 
intermediate zone. This has been demonstrated in rats (Nosaka et al., 1979; Nosaka 
et al., 1982; Stuesse, 1982; Izzo et al., 1993), cats (Sugimoto et al., 1979; Ciriello & 
Calaresu, 1980; Geis & Wurster, 1980b; Kalia & Mesulam, 1980; Bennett et al., 
1981; Geis et al., 1981; Miura & Okada, 1981; Ciriello & Calaresu, 1982), dogs 
(Bennett et al., 1981; Hopkins & Armour, 1982, 1984; Plecha et al., 1988) and pigs 
(Hopkins et al., 1984; Hopkins et al., 1997).  
Recordings of antidromic potentials generated by electrical stimulation of the 
cardiac vagal branch have identified significant cardiac innervation by neurones 
residing in the NA (McAllen & Spyer, 1976; McAllen & Spyer, 1978b, a; Ciriello & 
Calaresu, 1982). These neurones were shown to be activated by pulmonary C-fibre 
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afferent stimulation (Wang et al., 2000). Subsequently, neurones of the NA have 
been found to have rhythmic, respiratory-related patterns of discharge (Gilbey et al., 
1984) with B fibre axons innervating nodal tissue. Rhythmic activity of the NA 
neurones underlies the respiratory sinus arrhythmia [(RSA); (McAllen & Spyer, 
1978b; Neff et al., 2003)]. The relative proportion of DVMN neurones projecting to 
the heart is believed to be lower (Jones, 2001), and their functional significance in 
the control of cardiac function remains unknown. DVMN neurones have long latency 
C fibre (unmyelinated) axons (Ciriello & Calaresu, 1980; Nosaka et al., 1982; Jones 
et al., 1995). It has been suggested from anterograde tracing studies that vagal 
control of the heart involves the convergence and integration of distinct projections 
from both nuclei projecting to cardiac plexuses (Cheng et al., 1999; Cheng & 
Powley, 2000).  
1.3.2 The effect of vagal nerve stimulation 
Studies involving VNS established that it controls HR (the chronotropic state) 
and AV conduction velocity (the dromotropic state). The left vagus mostly 
innervates the AV node with the corresponding negative dromotropic effect, whilst 
the right vagus mainly innervates the SA node exerting a profound negative 
chronotropic effect (Gaskell, 1882; Cohn, 1912; Gesell, 1916; Haney et al., 1943).  
Many of these studies concluded that there is no effect of the vagus nerve on 
the ventricular function (Roy & Adami, 1891; Bayliss & Starling, 1892; Henderson 
& Barringer, 1913; Drury, 1923; Rothberger & Scherf, 1930; Ullrich et al., 1954; 
Carlsten et al., 1957; Schreiner et al., 1957; Denison & Green, 1958; Sarnoff et al., 
1960; Reeves & Hefner, 1961). It was still evident to some, however, that inhibition 
of the ventricular rhythm was different in mammals compared to those of lower 
vertebrates such as the eel, frog or tortoise, where ventricular asystole would arise if 
the atria were arrested, i.e. the mammalian ventricle had a more powerful 
independent rhythmic action inherent to the ventricular tissue (McWilliam, 1888; 
Howell & Duke, 1906; Patterson et al., 1914; Wiggers & Katz, 1922). In other 
studies involving mammals, a reduced ventricular automaticity and rate were 
observed in dogs with complete atrioventricular block (Eliakim et al., 1961) and in 
the area of the His bundle (Gonzalas-Serrato & Alanis, 1962; Higgins et al., 1973).  
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Left VNS has been shown to reduce ventricular contractility independent of HR 
changes and β-adrenergic input (Degeest et al., 1965c; Lewis et al., 2001). In cats, 
VNS (Gatti et al., 1997) and electrical stimulation of the DVMN (Geis & Wurster, 
1980a) produced similar effects. 
1.3.3 The cardiac ganglia 
VPNs project from the medulla oblongata to vagal postganglionic neurones 
within the cardiac ganglia (Randall & Wurster, 1994; Rossi, 1994; Spyer et al., 
1994). The postganglionic neurones project to the atrial and ventricular musculature 
in addition to SA and AV nodes (Carlson et al., 1992; Randall & Wurster, 1994). 
Activation of them triggers chronotropic, dromotropic and inotropic effects (Levy & 
Martin, 1984; Carlson et al., 1992). Sympathetic preganglionic neurones of the 
spinal cord receive excitatory inputs from the hypothalamus and the brainstem and 
project to paravertebral ganglia innervating the heart (Gilbey, 2007). Sensory 
afferent neurones are located in the dorsal root ganglia, nodose ganglia and in the 
cardiac ganglia (Ardell, 1994; Armour, 1994; Randall & Wurster, 1994; Spyer et al., 
1994) and mediate long- and short-distance (local) reflexes (Ardell, 1994; Randall & 
Wurster, 1994; Spyer et al., 1994). 
Cardiac ganglia are typically found in fat pads at the level of the SA and AV 
nodes (McFarland & Anders, 1913; Francillon, 1928; Davies et al., 1952; 
Navaratnam, 1965; Smith, 1971b; Rossi, 1994). Cardiac ganglia near the SA node 
have been reported to be located near the superior left atrial surface (Leonhardt, 
1986; Singh et al., 1996), the interatrial groove and the coronary sulcus junction 
(King & Coakley, 1958). Ganglia have also been found on the aorta, left pulmonary 
veins (Leonhardt, 1986; Singh et al., 1996) and caval surfaces (Leonhardt, 1986). 
Although some studies have reported the absence of ganglia at the level of the 
ventricles (Davies et al., 1952), many other studies have found ganglia within this 
vicinity (Lee, 1849; Blackhall-Morison, 1926; Smith, 1971b, a). Collections of 
cardiac ganglia have also been found near the ventricular coronary vasculature 
(Singh et al., 1996).  
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1.4 The controversy: vagal innervation of the ventricle 
1.4.1 Immunohistochemical evidence 
Sympathetic nerves innervate the SA and AV nodes, the atria, ventricles and 
the conducting tissue. While the vagal innervation of the atria, the SA and AV nodes 
and conducting tissues has been well established, the terminal parasympathetic 
innervation of the ventricles has been a subject of on-going controversy (Levy, 
1971a; Coote, 2013). Some of the first histological (Cullis & Tribe, 1913; Nonidez, 
1939, 1941) and physiological (Carlsten et al., 1957) data indicated that the 
mammalian ventricles lack any significant parasympathetic innervation except at the 
AV junction (Roy & Adami, 1891). 
Acetylcholinesterase staining was one of the first methods applied to provide 
indirect histological evidence of ventricular parasympathetic innervation (Karnovsky 
& Roots, 1964; Broderson et al., 1974). ACh release results in either muscarinic or 
nicotinic receptor activation at either pre- or post-synaptic membranes, where ACh is 
hydrolysed into choline and acetate by acetylcholinesterase (Kuhar & Murrin, 1978). 
The staining methods operated on the basis that parasympathetic fibres would stain 
more deeply than sympathetic fibres and therefore may not be entirely specific to 
parasympathetic innervation (Nilsson, 1976). Initial reports found no vagal 
innervation of the ventricular myocardium using this method (Carbonell, 1956; 
James, 1967). In other studies, moderate ventricular cholinesterase activity was 
detected. Some (Nonidez, 1939; Tcheng, 1951; Higgins et al., 1973) but not all 
(Robb & Kaylor, 1945; Stotler & Mc, 1947) silver impregnation techniques were 
able to visualise low-density cholinergic fibres in the canine and feline ventricles 
beyond the extensive plexuses found in the atria. Rich cholinergic innervation of 
epicardial and endocardial ventricular surfaces has since been found in human (Kent 
et al., 1974; Pauza et al., 2000), pig (Crick et al., 1999; Ulphani et al., 2010) and rat 
hearts (Mastitskaya et al., 2012). 
The high-affinity choline transporter (CHT1) is specifically expressed in 
cholinergic neurones and constitutes a rate-limiting step for acetylcholine synthesis. 
Choline undergoes reuptake into the presynaptic terminals by via CHT1 in Na
+
-
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dependant process (Kobayashi et al., 2002; Okuda & Haga, 2003). Techniques 
involving northern blot and in situ hybridisation have demonstrated that CHT1 
protein is expressed specifically by cholinergic neurones (Misawa et al., 2001; 
Kobayashi et al., 2002; Lips et al., 2002) and has since been found in the murine 
myocytes (Kakinuma et al., 2012). 
1.4.2 In vitro evidence 
A direct effect of ACh has been described in isolated cardiomyocytes in the 
rat (McMorn et al., 1993), cat (Hommers et al., 2003), guinea-pig (Zang et al., 
2005b) and ferret (Ito et al., 1995). Ferret myocytes displayed a 10% reduction in 
their twitch shortening in response to the application of ACh (Dobrzynski et al., 
2002). It was proposed that ACh mediates its action on ventricular myocytes via 
phosphorylation of the G protein-coupled inwardly rectifying K
+
 channels 
(GIRK/Kir), in particular Kir3.1 and Kir3.4, which are abundant throughout the heart 
(Dobrzynski et al., 2001), and reducing basal Ca
2+
 currents (Belardinelli et al., 1995; 
Dobrzynski et al., 2002).  
Ventricular myocytes have also been shown to express eNOS as well as 
soluble guanylate cyclase (Balligand et al., 1993; Kojda et al., 1997). In isolated 
electrically stimulated (contracting) guinea pig myocytes, NO has been shown to 
attenuate the magnitude of contractions by >20% via the production of cGMP (Patel 
et al., 2008). Complementary to this, non-specific NOS blockade has demonstrated a 
potentiation of contraction (Balligand et al., 1995; Kaye et al., 1996). This effect was 
not observed in mice with genetic deletion of eNOS (Vandecasteele et al., 1999). 
nNOS has been found to be associated with sarcolemmal proteins (Sears et al., 2003) 
and the sarcoplasmic reticulum (Xu et al., 1999), and may also play a role in 
inhibition of contraction (Ashley et al., 2002) through the inhibition of an L-type 
calcium current (Sears et al., 2003). However, this effect is not consistently observed 
(Barouch et al., 2002). Despite this, a preparation has yet to be developed that 
isolates the role of nNOS to establish the true integrative role (Danson & Paterson, 
2005).  
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1.5 Resolving this controversy: Targeting the DVMN 
In the context of the existing controversial evidence of vagal innervation of 
the cardiac ventricle, this thesis aims to determine the functional significance of 
vagal innervation of the ventricle through a comprehensive programme of carefully 
designed experiments using the latest advances in molecular neuroscience and in 
vivo animal models. Studies of the ontogenesis of the dorsal vagal column in 
metamorphosing amphibians (such as in the axolotl) undergoing anatomical and 
physiological changes during transition from water to air breathing identified the 
DVMN as the primary vagal nucleus. Indeed, in the neotenous axolotl, all VPNs are 
located in the DVMN (Taylor, 1994). The developing mechanisms of 
cardiorespiratory coupling requires a phasic vagal component, therefore migration of 
a subpopulation of DVMN VPNs closer to the ventral respiratory group is essential 
to acquire respiratory modulation of activity (Burggren & Infantino, 1994; Smatresk, 
1994; Burggren, 1995).  
Based on these previous studies, the DVMN, being evolutionarily older, are 
hypothesised to be the main group of VPNs that innervate cardiac ventricle. Indeed, 
a recent study has shown that when DVMN VPNs are selectively recruited using an 
optogenetic approach has a potent cardioprotective effect (via a muscarinic 
mechanism) on ventricular cardiomyocytes against acute ischemia/reperfusion injury 
(Mastitskaya et al., 2012), thus suggesting that this may be the case. This study on 
the DVMN is consistent with the evidence of a potent cardioprotective effect of ACh 
(which is as potent as adenosine in reducing myocardial injury) reported previously 
(Richard et al., 1995; Qian et al., 1996; Yamaguchi et al., 1997; Cohen et al., 2001). 
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1.6 Main Hypothesis and Aims 
Experimental studies described in this thesis tested the hypothesis that 
functionally significant parasympathetic control of the left ventricle (LV) of the heart 
is provided by VPNs of the DVMN. Methods of genetic neuronal targeting, 
functional neuroanatomical mapping, pharmaco- and optogenetics applied in in vivo 
animal (rat and mouse) models were used to address the following specific aims: 
1. To determine the role of DVMN VPNs in controlling electrical properties of the 
ventricle (Chapter 2); 
  
2. To determine the role of DVMN VPNs in controlling LV contractility                   
(Chapter 3); 
 
3. To determine the role of DVMN VPNs in controlling exercise capacity                   
(Chapter 4); 
  
4. To determine the effect of DVMN stimulation on progression of LV dysfunction 
developing after a myocardial infarction [(MI); (Chapter 5)].  
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1.7 Distribution of choline acetyl-transferase-expressing neurones along 
the rostro-caudal extent of the brainstem 
 The candidate’s own atlas showing distribution of VPNs in the dorsal vagal 
complex was generated by immunostaining of coronal sections of an adult rat 
brainstem for choline acetyl-transferase (ChAT). Adult Sprague-Dawley rats (400 g) 
were terminally anaesthetised with pentobarbitone sodium (200 mg kg
-1
, i.p) 
perfused through the ascending aorta with 0.9% saline followed by 4% phosphate-
buffered (0.1 M, pH 7.4) paraformaldehyde. After 12 hours of post-fixation and 
subsequent cryoprotection (30% sucrose), the brainstem was isolated and sliced. 30-
μm-thick coronal sections were collected along the rostro-caudal extent of the 
medulla oblongata. Sections were processed for immunohistochemical detection of 
ChAT. Tissue was incubated in goat anti-ChAT antibody (1:500, Chemicon) 
followed by incubation with donkey anti-goat antibody conjugated with Alexa 
Fluor568 (1:500, Abcam).  
ChAT-positive DVMN and NA neurones were distinctly identifiable on the 
coronal sections of the rat brainstem (Figure 1-2). On the caudal brainstem sections, 
the DVMN shows as a discrete group of neurones located in proximity to the central 
canal and dorsally to the hypoglossal (XII) nucleus containing large motor neurones 
also expressing ChAT (Paxinos & Watson, 1998). Rostral groups of DVMN 
neurones are found near the dorsomedial edge of the brainstem (Figure 1-2).  
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Figure 1-1: Identification of choline acetyltransferase (ChAT) expressing neurones in the coronal section of the rat medulla oblongata 
Confocal image of a coronal section of the rat brainstem illustrating the location of the DVMN and NA vagal preganglionic neurones. Immunohistochemistry 
identified the ChAT-positive, i.e. cholinergic (red) neurones. XII, hypoglossal motor nucleus. 
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Figure 1-2:  Distribution of choline acetyltransferase (ChAT)-expressing neurones in the dorsal aspect of the rat medulla oblongata 
Confocal images of the coronal sections of the rat brainstem illustrating the distribution of the DVMN VPNs. Immunohistochemistry identified ChAT-
positive, i.e. cholinergic (red) neurones. 4V, fourth ventricle; XII, hypoglossal motor nucleus; CC, central canal. 
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 Control of Ventricular Excitability Chapter 2
2.1 Introduction 
Sudden circulatory collapse is often due to malignant arrhythmias, such as 
ventricular tachycardia (VT). Predictors of sudden cardiac death include conventional 
coronary risk factors and conditions, such as congestive heart failure, as well as 
markers of vagal dysfunction, including reduced HRV and reduced baroreflex 
sensitivity (La Rovere et al., 1998; Olshansky et al., 2008).  
Atrial arrhythmias such as atrial fibrillation also have a well-established relationship 
with both sympathetic and parasympathetic signalling (Coumel et al., 1978). This 
association has been extended to primary ventricular arrhythmias (which predispose 
to sudden death) in addition to the modulation of arrhythmia risk within the context 
of inherited dysfunction of cardiac ion channels, i.e. cardiac channelopathies. These 
studies have mainly focused on evaluating the effect of increased sympathetic 
activity. It has been well documented that reduced HRV and a raised HR develop 
before VT in humans (Shusterman et al., 1998). Furthermore, stimulation of the left 
stellate sympathetic ganglia in dogs to increase sympathetic activity induced QT 
prolongation and preceded ventricular arrhythmia and sudden death (Zhou et al., 
2008). More recently, the role of the vagus in ventricular arrhythmias, particularly in 
specific channelopathies, such as idiopathic ventricular fibrillation (VF), is more 
recoginised. Patients with idiopathic VF with J-wave syndrome were associated with 
high vagal tone. This manifested as potentiated J-wave elevation during bradycardia 
and increased propensity to sleeping VF events, each associated with an increased 
vagal tone (Mizumaki et al., 2012). The predisposition of the ostensibly normal heart 
to potentially fatal VT with loss of vagal regulation, however, has remained 
unexplored. 
With regard to conditions of raised sympathetic activity, it is not surprising 
that VNS is being explored as a therapeutic option in heart failure and one 
component of its potential benefit may be an antiarrhythmic effect (Hauptman et al., 
2012; Shen & Zipes, 2014). Experimental studies on animal models have 
demonstrated profound antiarrhythmic effects of VNS (Waxman et al., 1989; Vanoli 
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et al., 1991; Ng et al., 2007). It effectively reduces the restitution slope, prevents 
alternans and increases the ventricular effective refractory period [(vERP); (Ng et al., 
2007)]. VNS also decreases the incidences of ventricular arrhythmia associated with 
heightened sympathetic activity during myocardial infarction (MI) (Vanoli et al., 
1991). There is clinical evidence that vagal tone suppresses an accelerated 
ventricular rhythm (Waxman et al., 1988), and experimental data showing that the 
vagal influence on ventricular refractoriness and arrhythmia threshold is tonic and 
could be abolished by bilateral vagotomy or systemic muscarinic receptor blockade 
(Schwartz et al., 1977). Studies from a collaborating laboratory demonstrated that 
global genetic deletion of the inhibitory G-protein Gαi2 (which mediates muscarinic 
influences on the heart) in mice is associated with a reduced vERP, prolonged 
corrected QT interval (QTC) and a predisposition to VT (Zuberi et al., 2010). There is 
also evidence that the protective vagal influence on cardiac electrical stability might 
be mediated by NO, which is produced by nNOS (Brack et al., 2009; Brack et al., 
2011). 
Despite this evidence, there has been no attempt to study the central nervous 
mechanisms underlying parasympathetic antiarrhythmic influences thus far. In this 
study the aim was to identify a population of VPNs that provide functional 
parasympathetic innervation of the ventricles and control the ventricular excitability. 
VPNs projecting to cardiac ganglia are located in the brainstem. Neuronal tracing 
experiments in different species (Hopkins et al., 1997; Jones et al., 1998) have 
identified the DVMN as one such population of neurones with long latency C-fibre 
axons converging upon cardiac plexuses (Jones et al., 1998). Since the activities of 
the DVMN neurones appear to protect ventricular cardiomyocytes against acute 
ischemia/reperfusion injury (Mastitskaya et al., 2012), it is hypothesised that 
functional ventricular innervation is provided by the DVMN neuronal projections. 
Autonomic dysfunction is of increasing clinical importance as it contributes 
to the pathogenesis of Parkinson’s disease (Goldberg et al., 2012; Greene, 2014). 
Parkinson’s disease is the second most common neurodegenerative disorder (de Lau 
& Breteler, 2006) characterised by a loss of dopaminergic neurones, with consequent 
motor impairment as well as DVMN dysfunction, resulting in a host of autonomic 
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abnormalities (Braak et al., 2002; Goldberg et al., 2012). Aggregation of α-synuclein 
is a major molecular event in the development of this disease due to the toxicity of 
certain intermediate products of this process. Age-dependent decline of substantia 
nigra pars compacta synaptic function has been reported in α-synuclein deficient 
mice (Al-Wandi et al., 2010). These changes appeared to be even more pronounced 
in triple-synuclein-null (αβγ-/-) mice that have been generated to limit functional 
compensation by other members of the synuclein family (Anwar et al., 2011). In this 
study αβγ-/- mice are used to determine whether synuclein deficiency leads to a 
reduction in the activity of the DVMN neurones and is associated with changes in 
ventricular electrophysiology. 
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2.2 Methods 
All the experiments were performed in accordance with the European 
Commission Directive 2010/63/EU (European Convention for the Protection of 
Vertebrate Animals used for Experimental and Other Scientific Purposes) and the 
United Kingdom (UK) Home Office (Scientific Procedures) Act (1986), with project 
approval from the Institutional Animal Care and Use Committee.  
2.2.1 Cardiac Electrophysiology 
Cardiac pacing using extrastimulation was performed using S88-Grass 
stimulator. Adult male Sprague-Dawley rats (380–450 g), wild-type (WT) and αβγ-/- 
mice were under urethane anaesthesia (1.3 g kg
-1
, i.p.), and an octapolar 
electrophysiology catheter (1.6 F for rats and 1.1 F for mice) was positioned in the 
right atrium and the right ventricle (RV) via the jugular vein, or in the LV via the 
right common carotid artery. For the assessment of vERP, 10 paced beats (10xS1) 
were applied, using a cycle length of 85 ms in mice and 100 ms in rats, followed by a 
gradually shortened extra single paced beat (S2) until failure of ventricular capture. 
The maximum S1-S2 coupling interval was measured as the vERP. VT threshold (in 
rats only) was evaluated by application of 15 paced beats (15xS1), shortening the 
cycle length from 100 ms to 20 ms in 4 ms increments (10 to 60 Hz burst pacing). 
One episode of VT was defined as at least 10 consecutive broad complex systoles (all 
of which were noted to self cardiovert). The definitions of VT were similar to that in 
recent publications (Zuberi et al., 2010). 
For the assessment of the AV node effective refractory period (AVNERP) in 
rats, 10 paced beats (10xS1) using a cycle length of 141 ms were applied followed by 
a gradually shortened extra single paced beat (S2) until failure of ventricular capture. 
Wenkebach point was determined by shortening the cycle length (from 150 ms) until 
a 2:1 block was observed. The sinus node recovery time (SNRT) was measured as 
the period between the last paced beat and the onset of the first P wave after 30 s of 
atrial pacing (cycle length 141 ms). 
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2.2.2 Pharmacological Study 
To determine the presence of tonic parasympathetic influence on cardiac 
electrical stability in the main experimental model used in the present study (rat 
under urethane anaesthesia) systemic β-adrenoceptor blockade was applied (atenolol, 
2 mg kg
-1
 h
-1
 i.v.). The effects of sequential systemic muscarinic (atropine methyl 
nitrate, 2 mg
-1
 kg
-1
 h
-1
 i.v.) and nNOS (7-Nitroindazole [7-NI], 20 mg
-1
 kg
-1
 i.p.) 
blockade on AVNERP, SNRP, Wenkebach point, left and right vERP and left and 
right VT were determined. 
2.2.3 Genetic targeting of the DVMN vagal preganglionic neurones 
VPNs of the DVMN characteristically express the transcriptional factor 
Phox2 and can be targeted to express the gene of interest using viral vectors with 
Phox2 activated promoter – PRSx8 (Lonergan et al., 2005). DVMN neurones along 
the whole rostro-caudal extent of the left and right nuclei were transduced with 
lentiviral vectors (LVV) to express either the Gi-protein-coupled Drosophila 
allatostatin receptor (AlstR) or enhanced green fluorescent protein (eGFP, control). 
The original PRSx8-AlstR-eGFP-LVV construct was thoroughly validated in 
previous studies (Marina et al., 2010; Marina et al., 2011). Validation of the 
transgene specificity in targeting DVMN neurones to express AlstR and efficacy of 
the natural ligand of AlstR, the insect peptide allatostatin, to produce a highly 
selective, rapid and reversible silencing of neurones expressing AlstR have been 
described in detail previously (Mastitskaya et al., 2012).  
Male Sprague-Dawley rats (50 g) were anaesthetised with ketamine (60 mg 
kg
-1
, i.m.) and medetomidine (250 µg kg
-1
, i.m.). Adequate depth of surgical 
anaesthesia was confirmed by the absence of a withdrawal response to a paw pinch. 
With the head fixed prone in the stereotaxic frame the dorsal surface of the brainstem 
was exposed. DVMN neurones were targeted on each side with two microinjections 
(0.25 µl; 0.05 µl min
-1
) of a solution containing viral particles of PRSx8-AlstR-
eGFP-LVV (Figure 2-1) or PRSx8-eGFP-LVV (Figure 2-2). The established titres at 
the time of production were within the range of 1 x 10
9
 and 1 x 10
10
 transducing 
units ml
-1
. The injections were made at 0.5 mm rostral, 0.6 mm lateral, 0.8 mm 
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ventral and at 1.0 mm rostral, 0.8 mm lateral, 0.6 mm ventral from the calamus 
scriptorius. Anaesthesia was reversed with atipemazole (1 mg kg
-1
, i.m.). For post-
operative analgesia, rats were administered with buprenorphine (0.05 mg kg
-1
 d
-1
, 
s.c.) for three days and caprofen (4 mg kg
-1
 d
-1
, i.p.) for five days. One rat injected 
with PRSx8-AlstR-eGFP-LVV developed a middle ear infection and was excluded 
from the study. Rats weighed 300-400g at the time of the experimentations. 
The activity of VPNs transduced to express AlstR along the left and the right 
extent of the DVMN was reduced by allatostatin infusion into the cisterna magna. 
The effects of this treatment on vERP and VT threshold were determined in 
conditions of intact sympathetic tone. 
In a separate experiment, conducted in conditions of systemic β-adrenoceptor 
(atenolol) and muscarinic (atropine) blockade, atrial and ventricular pacing protocols 
were applied before and after acute bilateral silencing of the DVMN neurones by 
targeted microinjections of a potent GABAA receptor agonist muscimol. Rats (n=8) 
were anaesthetised, instrumented for cardiac electrophysiology as described above 
and the head was fixed in the stereotaxic frame with the dorsal side up. An occipital 
craniotomy was performed to expose dorsal brainstem. A multi-barrelled glass 
micropipette (tip size 20-25 µm) was used for microinjections of a vehicle (saline) or 
muscimol (0.1 M; 40 nl; pH 7.4) into the left and right DVMN (coordinates: 0.3 mm 
rostral, 0.7 mm lateral, 0.8 mm ventral from the calamus scriptorius). The injections 
were made using pressure over a period of 5-10 s and were monitored using a 
dissecting microscope with a calibrated micrometer disk. 
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Figure 2-1: PRSx8-AlstR-eGFP-LVV Vector circle map 
A vector circle map showing the proteins involved in the construction of the viral plasmid.  
 
PRSx8 promoter 
pTYF-PRSx8-AstR-IRES2-eGFP 
10372 base pairs 
 
IRES2-eGFP 
AstR 
I-SceI2 
I-SceI1 
pGHpA 
Chapter 2 Control of Ventricular Excitability 23 
 
 
 
 
Figure 2-2: PRSx8-eGFP-LVV Vector circle map 
A vector circle map showing the proteins involved in the construction of the viral plasmid.  
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2.2.4 Derivations of QT interval 
 
Needle electrodes were used to acquire lead II ECG. ECG was acquired for 
15 minutes prior to programmed electrical stimulation and 15 minutes after 
allatostatin applications in rats expressing AlstR or eGFP in the DVMN, 15 minutes 
after saline or muscimol microinjections into the DVMN and in αβγ-/- and WT mice 
at baseline. In the pharmacological experiments, ECG was acquired for 15 minutes 
before and after the administration of each drug.  
Three different approaches to deriving QTC were used due to the established 
controversies concerning its derivation in rodents (Hayes et al., 1994; Karjalainen et 
al., 1994). Corrected QT interval (QTC) was derived using (i) Bazett’s formula 
QTBC = QT ÷ √(RR ÷ F) (where RR is in ms and f=100 ms for mice and f=150 ms 
for rats) (Kmecova & Klimas, 2010; Zuberi et al., 2010); (ii) Fridericia cubic root 
formula QTFC = QT × ∛(RR ÷ F) (where f=100 ms for mice and f=150 ms for rats); 
and (iii) nomogram correction QTNC = QT + 0.384 × (150 − RR) for rats and QT +
0.156 × (100 − RR) for mice (Hayes et al., 1994; Karjalainen et al., 1994). QTC 
was analysed using a Tukey-Kramer multiple comparison test following a three-way 
ANOVA, comparing the effects of constructs (rats) or genotype (mice), 
allatostatin/vehicle (rats), age (mice) and QTC derivation formula. As a surrogate 
measure of ventricular repolarisation avoiding rate dependency, raw QT 
measurements from vERP measurements were also analysed. 
2.2.5 Humane end-points 
At the end of the experiments the animals were euthanised with an overdose 
of pentobarbitone sodium (200 mg kg
-1
, i.p.). 
2.2.6 Recording the activity of the DVMN neurones 
 
The electrophysiological recordings were kindly conducted by the 
collaborating lab of Dr. Stefan Trapp. Coronal (200 µm) brainstem slices were 
obtained from 12-18 month old WT (n=5) and αβγ-/- (n=4) mice terminally 
anaesthetised with halothane. Brains were dissected in ice-cold low [Na
+
] solution 
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containing 200 mM sucrose, 2.5 mM KCl, 28 mM NaHCO3, 1.25 mM NaH2PO4, 3 
mM pyruvate, 7 mM MgCl2, 0.5 mM CaCl2 and 7 mM glucose (pH 7.4). After 
recovery at 34 °C for 30 minutes in a solution containing 118 mM NaCl, 3 mM KCl, 
25 mM NaHCO3, 1.2 mM NaH2PO4, 7 mM MgCl2, 0.5 mM CaCl2 and 2.5 mM 
glucose (pH 7.4), slices were kept at 34 °C in artificial cerebrospinal fluid (aCSF) 
containing 118 mM NaCl, 3 mM KCl, 25 mM NaHCO3, 1 mM MgCl2, 2 mM CaCl2, 
and 10 mM glucose saturated with 95% O2 and 5% CO2 (pH 7.4). 
Recording pipettes (3-6 MΩ) were pulled from thin-walled borosilicate 
capillaries and recordings were performed in the cell-attached mode using an EPC-9 
amplifier and Pulse/Pulsefit software (Heka Elektronik, Lambrecht, Germany). 
Electrodes were filled with 120 mM K-gluconate, 5 mM HEPES, 5 mM BAPTA, 1 
mM NaCl, 1 mM MgCl2, 1 mM CaCl2, and 2 mM K2ATP (pH 7.2). Recordings were 
carried out in aCSF saturated with 95% O2 and 5% CO2 at 28-32 °C. Currents were 
filtered at 1 kHz and digitised at 3 kHz. Mean action potential frequency was 
determined by taking the average frequency over a period of three minutes. 
Recordings were analysed using Strathclyde Electrophysiology Software 
(WinEDR/WinWCP; University of Strathclyde).   
2.2.7 Histology 
At the end of the experiments the rats were perfused through the ascending 
aorta with 0.9% NaCl solution followed by 500 ml 4% phosphate-buffered (0.1 M, 
pH 7.4) paraformaldehyde; the brains were removed and stored in the same fixative 
overnight at 4 °C. After cryoprotection in 30% sucrose, the brainstem was isolated 
and a sequence of transverse slices (30 µm) was cut. The extent of AlstR-eGFP or 
eGFP expression and the sites of microinjections were identified histologically using 
confocal microscopy and mapped using a stereotaxic atlas (Paxinos & Watson, 
1998). All drugs and reagents were sourced from SigmaAldrich (UK) unless stated 
otherwise. 
  
Chapter 2 Control of Ventricular Excitability 26 
 
 
2.2.8 Data analysis 
 
Data are expressed as means ± standard errors. Interactions between groups 
and/or treatments were analysed using an ANOVA with a Tukey-Kramer multiple 
comparison test, non-parametric Mann-Whitney-U test or paired t-test as appropriate. 
DVMN neuronal recordings from each animal were averaged and analysed using a 
Wilcoxon Rank-Sum test for difference in the medians.  
 
  
Chapter 2 Control of Ventricular Excitability 27 
 
 
2.3 Results 
2.3.1 Experiment 1. The effects of systemic muscarinic receptor and nitric 
oxide blockade on cardiac excitability 
Parasympathetic control of cardiac excitability mediated by ACh and NO is 
preserved under urethane anaesthesia. In conditions of β-adrenoceptor blockade 
(atenolol), atropine administration reduced AVNERP (62±6 vs 77±3 ms at baseline; 
p=0.003, Tukey-Kramer; Figure 2-3A), SNRT (171±7 vs 219±5 ms at baseline; 
p=0.002, Tukey-Kramer; Figure 2-3B) and lowered the S1 coupling interval required 
to achieve 2:1 heart block (64±1 vs 73±2 ms at baseline; p=0.0008, Tukey-Kramer; 
Figure 2-3C). No significant changes were observed following subsequent systemic 
nNOS blockade with 7-NI or during the course of the experiment in the group of 
time/vehicle control animals (Figure 2-3).  
  
Chapter 2 Control of Ventricular Excitability 28 
 
 
 
Figure 2-3: Tonic muscarinic influence on the electrical properties of nodal 
tissue 
Summary data obtained in rats under urethane anaesthesia in conditions of systemic β-
adrenoceptor blockade illustrating changes in A), AV node effective refractory period 
(AVNERP); B) SA node recovery time (SNRT) and C) coupling interval required to achieve 
2:1 heart block after sequential systemic administration of atropine methyl nitrate (AMN) 
and neuronal nitric oxide synthase inhibitor 7-Nitroindazole (7-NI), or respective control 
vehicles (saline for AMN and peanut oil for 7-NI). Asterisk denotes significance with respect 
to baseline. ***P<0.001; ****P<0.0001. 
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In the ventricular pacing paradigm (in conditions of systemic β-adrenoceptor 
blockade), atropine had no effect on the left or right vERP and VT threshold (Figure 
2-4). Addition of systemic nNOS blockade was associated with a reduction of both 
left (40±2 vs 49±2 ms at baseline; p=0.001, Tukey-Kramer; Figure 2-4A) and right 
(41±2 vs 49±2 ms at baseline; p=0.03, Tukey-Kramer; Figure 2-4B) vERP. 7-NI 
administration produced a modest QTC prolongation measured during vERP 
assessment protocols in the LV only (74±2 vs 67±3 ms at baseline; p=0.02, Tukey-
Kramer; Figure 2-4B). This was concordant with the surface ECG data pooled from 
all atrial and ventricular pacing experiments, revealing a modest prolongation in two 
derivations of QTC (Table 2-1). nNOS blockade also resulted in lowering of the left 
(28±3 vs 54±3 ms at baseline; p=0.0002, Tukey-Kramer; Figure 2-4C) and right 
(45±6 vs 60±0 ms at baseline; p=0.001, Tukey-Kramer; Figure 2-4C) VT thresholds. 
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Figure 2-4: Tonic nitric oxide-mediated influence on the electrical properties of the ventricles 
Summary data obtained in rats under urethane anaesthesia in conditions of systemic β-adrenoceptor blockade illustrating changes in A) left and right 
ventricular effective refractory period (LvERP and RvERP); B) left ventricle (LV) and right ventricle (RV) raw QT (QT500, measurements taken during vERP 
assessment protocol), and C) left and right ventricular tachycardia (LVT and RVT) thresholds after sequential systemic administration of AMN and 7-NI, or 
respective control vehicles (saline for AMN and peanut oil for 7-NI). Asterisk denotes significance with respect to baseline. *P<0.05; **P<0.01; 
****P<0.0001. 
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Table 2-1 The effects of muscarinic and nNOS blockade on ECG Morphology 
Parameters of ECG morphology recorded in rats under urethane anaesthesia in conditions of 
systemic β-adrenoceptor blockade following sequential systemic administration of atropine 
methyl nitrate and neuronal nitric oxide synthase inhibitor 7-Nitroindazole (7-NI) or 
respective control vehicles (saline for atropine and peanut oil for 7-NI).  
 
 R-R (ms) P-R (ms) QTBC (ms) QTFC (ms) QTNC (ms) 
      
Time/Vehicle Controls  
(n=18) 
    
Baseline 187 ± 3 45 ± 1 89 ± 1 106 ± 2 85 ± 2 
Saline 186 ± 3 45 ± 1 90 ± 2 107 ± 2 86 ± 2 
Oil 184 ± 3 44 ± 1 88 ± 1 105 ± 1 84 ± 2 
      
Muscarinic/nNOS blockade 
(n=18) 
   
Baseline 184 ± 3 45 ± 1 89 ± 1 106 ± 1 85 ± 2 
AMN  154 ± 3* 48 ± 1 92 ± 1 94 ± 2 86 ± 2 
7-NI  170 ± 14 46 ± 2 96 ± 4* 110 ± 14 110 ± 15* 
      
 
Values are presented as means ± SEM. 
7-NI = 7-Nitroindazole; AMN = atropine methyl nitrate; QTBC = QT correction using 
Bazett’s formula; QTFC = QT correction using Fridericia’s formula; QTNC = QT correction 
using the nomogram formula. Asterisk denotes significance with respect to baseline and 
control values. *P<0.05. 
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2.3.2 Experiment 2. The effects of reduced DVMN activity on ventricular 
excitability 
Application of allatostatin in rats expressing AlstR in the DVMN (Figure 2-5) resulted in 
vERP shortening (33±1 vs 42±1 ms at baseline; p=0.002, Tukey-Kramer; Figure 2-6A, B) in 
the absence of HR changes (p=0.8; Table 2-2). vERP reduction is known to be pro-
arrhythmic in situations of both re-entry and triggered activity. Analyses of averaged ECG 
waveforms have demonstrated a prolongation of QTC according to all three correction 
formulae (p=0.028, Tukey-Kramer; Table 2-2; Figure 2-6C). Measurements obtained during 
the vERP assessment protocol have also demonstrated QT prolongation in conditions of 
DVMN inhibition (60±4 vs 52±2 ms at baseline; p=0.04, Tukey-Kramer; Figure 2-6D). VT 
threshold (manifesting in this case as either monomorphic or polymorphic tachycardia) was 
lowered following DVMN inhibition (22±4 vs 44±9 Hz at baseline; p=0.007, Tukey-Kramer; 
Figure 2-6E, F). Application of allatostatin in rats expressing eGFP in the DVMN had no 
effect on vERP (42±4 vs 44±0.4 ms at baseline), VT threshold (51±6 vs 52±5 Hz at baseline) 
or QTC (Table 2-2). Four rats expressing eGFP remained negative for VT (up to 60 Hz) 
throughout the course of the experiment. Three animals expressing AlstR in the DVMN, 
which were negative for VT before allatostatin administration, displayed reduced VT 
thresholds 30 min after application of the peptide. 
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Figure 2-5: Targeting DVMN neurones to reduce their activity 
Schematic drawings showing the location of the DVMN in the rat brain. Below: a confocal 
image of a coronal section of the rat brainstem, targeted to express allatostatin receptor 
(AlstR) in the DVMN. DVMN neurones are transduced to express AlstR-eGFP. CC, central 
canal. 
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Figure 2-6: The effects of reducing the activity of the DVMN VPNs on the 
electrical properties of the heart 
A) Representative in vivo cardiac electrophysiology data produced by programmed electrical 
stimulation (PES) showing an example of vERP shortening in rats expressing AlstR in the 
DVMN after administration of allatostatin; B) Summary data illustrating vERP shortening 
after inhibition of the DVMN neurones; C) Representative signal averaged ECG recordings 
illustrating QT prolongation in rats expressing AlstR in the DVMN after administration of 
allatostatin; D) Summary data showing QT500 prolongation after inhibition of the DVMN 
neurones; E) Representative in vivo cardiac electrophysiology data produced by burst pacing 
in increasing frequencies showing an example of a lower VT threshold in rats expressing 
AlstR in the DVMN after allatostatin application; F) Summary data illustrating decreased VT 
threshold in rats after DVMN activity is reduced. eGFP - rats expressing enhanced green 
fluorescent protein in the DVMN. Asterisk indicates significance of allatostatin with respect 
to baseline. *P<0.05; **P<0.01.  
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Table 2-2 The effects of reducing DVMN activity on ECG morphology 
Parameters of ECG morphology in rats expressing eGFP or AlstR in the neurones of the 
DVMN before and after administration of allatostatin  
 
 R-R (ms) P-R (ms) QTBC (ms) QTFC (ms) QTNC (ms) 
      
eGFP (n=6)      
Baseline 149 ± 9 51 ± 3 67 ± 4 66 ± 4 70 ± 4 
Alst 146 ± 8 49 ± 6 66 ± 4 65 ± 5 70 ± 4 
      
AlstR (n=5)      
Baseline 152 ± 6 50 ± 3 67 ± 4 67 ± 4 71 ± 4 
Alst 145 ± 4 47 ± 2 83 ± 5* 80 ± 6* 85 ± 5* 
      
 
Values are presented as means ± SEM. 
 
Alst = allatostatin (ligand for AlstR); AlstR = allatostatin receptor (animals transduced to 
express AlstR in the DVMN), eGFP = enhanced green fluorescent protein (animals 
transduced to express eGFP in the DVMN); QTBC = QT correction using Bazett’s formula, 
QTFC = QT correction using Fridericia’s formula; QTNC = QT correction using the 
nomogram formula. Asterisk denotes significance with respect to baseline considering gene-
treatment-QT correction interactions. *P<0.05. 
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In conditions of systemic β-adrenoceptor and muscarinic blockade, inhibition 
of the DVMN neurones by bilateral microinjections of muscimol reduced left vERP 
(45±22 vs 54±2 ms at baseline; p=0.02, Tukey-Kramer) and VT threshold (51±4 vs 
60±0 Hz at baseline; p=0.03, Tukey-Kramer) (Figure 2-7). In the conditions of β-
adrenoceptor and muscarinic blockade, DVMN inhibition resulted in a small increase 
of SNRT (169±2 vs 162±2 ms at baseline; p=0.02, Tukey-Kramer) and had no effect 
on AVNERP, the coupling interval required to achieve 2:1 heart block or QTC 
(Figure 2-7). 
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Figure 2-7: The effects of bilateral inhibition of the DVMN neurones by targeted microinjections of muscimol on the electrical properties 
of the heart in conditions of combined β-adrenoceptor and muscarinic blockade 
Summary data illustrating AVNERP, SNRT, the coupling interval required to achieve 2:1 heart block, left vERP, left ventricular QT500 and left VT threshold 
values after bilateral saline and muscimol microinjections into the DVMN. Asterisk denotes significance of muscimol with respect to saline. *P<0.05; 
**P<0.01.
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2.3.3 Experiment 3. The effects of synuclein pathology on DVMN neurones 
and ventricular electrophysiology 
Reduced activity of the DVMN neurones in aging αβγ-/- mice is associated 
with altered electrical properties of the heart. Six-month old αβγ-/- mice and their 
WT counterparts showed no significant differences in cardiac electrophysiology: 
both vERP (37±5 vs 37±3 ms; Figure 2-8A) and ECG features including QTC were 
similar. In contrast, 12 to18-month old αβγ-/- mice displayed a shorter vERP (31±1 
vs 43±3 ms in the WTs; p=0.002, Mann-Whitney-U; Figure 2-8B) and a prolonged 
QTC (P<0.05; Table 2-3 Figure 2-8C). Electrophysiological recordings taken from 
the DVMN neurones in acute brainstem slices showed a markedly reduced level of 
DVMN activity (~60%) in older αβγ-/- mice (1.2±0.1 vs 2.3±0.2 Hz in the WTs; 
p=0.04, Wilcoxon Rank-Sum test; Figure 2-8D, E). 
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Figure 2-8: Reduced activity of the DVMN neurones in aging triple-synuclein-null (αβγ-/-) mice is associated with altered electrical 
properties of the heart 
A) At 6 months of age there is no difference in vERP between wild type (WT) and αβγ-/- mice; B) At 12-18 months, αβγ-/- mice had a significantly shorter 
vERP than WT animals; C) Representative signal averaged ECG recordings illustrating QT prolongation in αβγ-/- mice; D) Representative recordings of the 
electrical activity of the DVMN neurones in WT and αβγ-/- mice; E) DVMN neurones of older αβγ-/- mice have a significantly reduced firing frequency 
compared to age- and sex-matched WT counterparts. Asterisk denotes significance with respect to WT. *P<0.05; **P<0.01. 
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Table 2-3 The effects of synuclein pathology on ECG morphology 
Parameters of ECG morphology in young and aging wild type and αβγ synuclein deficient 
mice. 
 
 R-R (ms) P-R (ms) QTBC (ms) QTFC (ms) QTNC (ms) 
      
6 month old     
WT (n=6)   94 ± 1 32 ± 2 22 ± 2 20 ± 1 40 ± 18 
αβγ-/- (n=6)  108 ± 10 38 ± 3 21 ± 1 22 ± 1 21 ± 2 
      
12-18 month old     
WT (n=6)  101 ± 4 33 ± 2 22 ± 1 22 ± 1 21 ± 1 
αβγ-/- (n=6)   92 ± 2 39 ± 3 26 ± 2* 24 ± 2* 26 ± 2* 
      
 
Values are presented as means ± SEM. 
WT = wild type mice; αβγ-/- = triple α,β,γ synuclein protein knockout mice; QTBC = QT 
correction using Bazett’s formula; QTFC = QT correction using Fridericia’s formula; QTNC = 
QT correction using the nomogram formula. Asterisk denotes significance with respect to 
WT considering age-phenotype-QT correction interactions. *P<0.05. 
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2.4 Discussion 
 
The data obtained in the present study demonstrate that reduced activity of 
the DVMN VPNs has a significant impact on cardiac electrical properties with 
changes consistent with a potential for ventricular arrhythmia. Targeted reduction of 
DVMN activity in a rat model is associated with vERP shortening and a reduced VT 
threshold. The absence of changes in R-R and P-R intervals, vERP shortening and 
reduced VT threshold with no associated lowering of AVNERP or SNRT, observed 
during reduced DVMN activity in conditions of β-adrenoceptor and muscarinic 
blockade, would suggest preferential innervation of the ventricles by the DVMN 
neuronal projections. 
 
Tonic parasympathetic influence on cardiac electrical stability is preserved in 
experimental animals kept under urethane anaesthesia. In conditions of β-
adrenoceptor blockade, sequential systemic muscarinic and nNOS inhibition 
confirmed that vagal effects are mediated by the actions of ACh and NO. Systemic 
atropine administration led to a reduction in AVNERP, SNRT and coupling interval 
required to achieve 2:1 heart block and had no effect on vERP and VT. Systemic 7-
NI treatment had no further effect on AVNERP, SNRT and coupling interval, but led 
to a significant reduction in both left and right vERP and VT. These data suggest that 
the vagal effects are mediated by a muscarinic mechanism at the level of atria/nodal 
tissue and by NO at the level of the ventricles. The latter conclusion is concordant 
with the most recent academic literature (Brack et al., 2009; Brack et al., 2011). 
This NO-mediated parasympathetic influence on the heart appears to stem 
from the activity of the DVMN neurones. Indeed, when the activity of the DVMN 
was reduced in conditions of combined muscarinic and β-adrenoceptor blockade, 
only reductions in vERP and VT (and not in AVNERP or SNRT) were observed. 
The cholinergic component is established to largely originate from the population of 
VPNs of the NA, which are believed to provide the most important source of phasic 
parasympathetic control of the SA and AV nodes (Taylor et al., 1999). 
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Having previously demonstrated that synuclein deficiency results in age-
dependent synaptic abnormalities by a collaborating laboratory (Anwar et al., 2011), 
αβγ-/- mice were used as a model of age-dependent autonomic dysfunction relevant to 
Parkinson’s disease. In aging αβγ-/- mice reduced activity of the DVMN neurones 
was found to be associated with altered electrical properties of the heart similar to 
that observed in rats following acute DVMN inhibition.  
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2.5 Study Limitations 
In both models (rats and mice), changes in the QTc interval were measured 
and a prolongation associated with vagal withdrawal was found. The magnitude of 
the recorded QTc changes, however, was variable depending on the experimental 
protocol. There are a number of considerations concerning the interpretation of these 
findings. The combination of shortened vERP and prolonged QTc is paradoxical 
although this has been observed previously in mice with global genetic deletion of 
Gαi2 (Zuberi et al., 2010). These differences have been explained by the rate 
dependence of changes in the dynamics of repolarisation. In addition, it is worth 
noting that vERP and action potential duration are not always strictly correlated 
(Coronel et al., 2012). Finally, there is some debate with regards to the nature of the 
T wave in rodents and how it exactly relates to ventricular repolarisation (Zhang et 
al., 2014). 
The use of anaesthesia can also alter ventricular excitability and 
predisposition to arrhythmia (Wong et al., 1993; Lorente et al., 2000). Arrhythmias 
were observed only during electrical stimulation designed to evoke arrhythmia, i.e. 
the rodents did not develop spontaneous arrhythmias. Replication of these findings in 
conscious rats or mice with cardiac telemetry monitoring to evaluate the native 
cardiac rhythm would enhance the clinical applicability of these results. Future 
experiments should thus employ techniques for chronic DVMN inhibition in 
conscious rodents in longitudinal studies. 
Allatostatin does not cross the blood-brain barrier however and cannulation is 
required for brainstem access, making chronic inhibition and in vivo conscious 
studies difficult. Transducing the DVMN with inhibitory G-protein coupled receptor 
based DREADD receptors would overcome the need to deliver the ligand via an 
intrathecal cannula, as clozapine N-oxide can be administered via intraperitoneal 
injection or drinking water (Armbruster et al., 2007). DREADDs further open the 
possibility of combinatorial experiments by using inhibitory and excitatory receptors 
that have been differentially targeted to either a subset of sympathetic or 
parasympathetic neurones through combinations of viral and transgenic approaches. 
This would allow in vivo analyses of models with selective functional silencing and 
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excitation of autonomic neurones, as well as expanded mapping of key central neural 
circuits influencing autonomic output (Armbruster et al., 2007). The viral titres for 
the constructs used were not reliably known. Acceptable expression was 
predetermined by injection in test subjects allowing four weeks prior to conducting 
histology. The extent of expression could have instead been evaluated via 
polymerase chain reaction as titres would inevitably vary, given the titre loss of the 
lentiviral constructs immediately after thawing.  
Also, rodents are not the ideal models for studying disorders of cardiac 
repolarisation as the K
+
 currents affected differ according to the species tested (Davis 
et al., 2011). Various murine models of cardiac arrhythmia have been developed, 
such as those with Na
+
 channel defects and autonomically driven arrhythmias 
associated with engineered defects in Ca
2+
 handling (Cerrone et al., 2005). However, 
the basic organisational, developmental and signalling pathways between the brain 
and the heart are broadly conserved across small and large mammals, which gives 
the fundamental observations based on the reported data from these experiments a 
clear translational relevance (Yutzey & Robbins, 2007). Also, as rats and mice are 
both identified as being largely sympathetic animals, establishing a significant 
parasympathetic component to the functional innervation of the ventricles should be 
regarded as an important finding given that it may have a larger contribution within 
humans and other larger mammals.   
In summary, a rat model was employed in this study to determine the effects 
of acute DVMN inhibition and a mouse model was used to study the effects of age-
dependent decline in DVMN activity, relevant to the development of Parkinson’s 
disease. Both models demonstrated that reduced activity of DVMN neurones have a 
significant impact on cardiac electrical properties, with changes consistent with the 
development of a ventricular pro-arrhythmic phenotype. Vagal influence on 
ventricular excitability generated by the DVMN is likely to be mediated by NO. 
These findings are the first of their kind to provide a fundamental insight into the 
central nervous substrate that underlie functional parasympathetic innervation of the 
ventricles and thus highlight its vulnerability in the context of neurodegenerative 
diseases.  
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 Control of Ventricular Contractility Chapter 3
3.1 Introduction 
The heart is controlled by the parasympathetic and sympathetic limbs of the 
autonomic nervous system. Sympathetic nerves innervate the sinoatrial and 
atrioventricular nodes, the atria, ventricles and the conducting tissue. 
Parasympathetic efferent fibres are known to control nodal tissues and atria. The role 
of the vagal innervation of the ventricles, however, remains controversial (Coote, 
2013). The majority of physiology textbooks state that the vagal innervation of the 
ventricle is sparse and direct parasympathetic control of ventricular contractility is 
insignificant. This view persists in both the scientific and educational literature 
despite evidence obtained in various species (from mouse to man) demonstrating the 
presence of ChAT-positive nerve fibres, acetylcholinesterase and muscarinic 
receptors in both ventricles (for a recent review, see Coote, 2013). Rich cholinergic 
innervation of epicardial and endocardial ventricular surfaces was demonstrated in 
human (Kent et al., 1974; Pauza et al., 2000), pig (Crick et al., 1999; Ulphani et al., 
2010), and rat hearts (Zang et al., 2005a; Mastitskaya et al., 2012). 
Although the functional significance of direct parasympathetic influence on 
ventricular contractility at resting condition remains unknown, data obtained from 
dogs, pigs and humans have demonstrated that VNS decreases the force of 
ventricular contraction independent of HR changes (Eliakim et al., 1961; Degeest et 
al., 1965c; Lewis et al., 2001). These data are also supported by the results of the in 
vitro studies conducted on isolated rat (McMorn et al., 1993), cat (Hommers et al., 
2003), guinea pig (Zang et al., 2005b) and ferret (Ito et al., 1995) cardiomyocytes. 
For example, ferret ventricular cardiomyocytes respond to a prototypical effector 
molecule of the parasympathetic nervous system - ACh - with a reduction in the 
magnitude of their muscle twitch shortening (Dobrzynski et al., 2002). These effects 
of ACh are mediated via rapid phosphorylation of certain inwardly rectifying 
potassium channels (in particular Kir3.1 and Kir3.4, expressed throughout the heart 
including the ventricles) (Dobrzynski et al., 2001) potentiating K
+
 currents and/or 
reduction of Ca
2+
 currents (Belardinelli et al., 1995; Dobrzynski et al., 2002). 
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Neuronal tracing studies conducted in rats (Nosaka et al., 1979; Nosaka et al., 
1982; Stuesse, 1982; Izzo et al., 1993), cats (Sugimoto et al., 1979; Ciriello & 
Calaresu, 1980; Geis & Wurster, 1980b; Kalia & Mesulam, 1980; Bennett et al., 
1981; Geis et al., 1981; Miura & Okada, 1981; Ciriello & Calaresu, 1982; Jones et 
al., 1995), dogs (Bennett et al., 1981; Hopkins & Armour, 1982, 1984; Plecha et al., 
1988), and pigs (Hopkins et al., 1984; Hopkins et al., 1997) identified the anatomical 
locations of cardiac VPNs primarily residing within the brainstem NA and the 
DVMN. Neurones of the NA have rhythmic, respiratory-related patterns of discharge 
with B fibre axons innervating nodal tissue (McAllen & Spyer, 1976; McAllen & 
Spyer, 1978b, a; Ciriello & Calaresu, 1982). The relative proportion of DVMN 
neurones projecting to the heart is believed to be low (Jones, 2001) and their 
functional significance in the control of cardiac function remains unknown. DVMN 
neurones have slowly conducting C fibre (unmyelinated) axons (Ciriello & Calaresu, 
1980; Nosaka et al., 1982; Jones et al., 1995) and are not modulated by respiratory 
networks. There is evidence that the activities of these neurones protect (via a 
muscarinic mechanism) ventricular cardiomyocytes against acute 
ischemia/reperfusion injury (Mastitskaya et al., 2012) and control ventricular 
excitability (Chapter 2), which suggests that the DVMN contains a population of 
VPNs that innervate the LV. 
In the present study, an anaesthetised rat model was used to test the 
hypothesis that DVMN VPNs contribute to the control of LV contractility. First, the 
presence of tonic vagal influence on LV inotropy was confirmed (demonstrated by 
systemic muscarinic receptor blockade). Next, the effects of reducing the activity of 
DVMN neurones on LV contractility were determined and finally the anatomical 
location of the functional subpopulation of the DVMN neurones was identified, 
which are responsible for parasympathetic control of LV contractility. 
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3.2 Methods 
All the experiments were performed in accordance with the European 
Commission Directive 2010/63/EU (European Convention for the Protection of 
Vertebrate Animals used for Experimental and Other Scientific Purposes) and the 
UK Home Office (Scientific Procedures) Act (1986) with project approval from the 
Institutional Animal Care and Use Committee.  
3.2.1 Animal preparation 
Adult male Sprague-Dawley rats (Charles River Laboratories, Oxford, UK) 
weighing 380–450 g were anaesthetised with urethane (1.3 g-1 kg-1; i.p.; following 
4% isoflurane induction) or pentobarbitone sodium (Animalcare, York, UK) 
(induction 60 mg kg
-1
 i.p.; maintenance 10-15 mg kg
-1
 h
-1
 i.v.). Since anaesthesia is 
known to have a significant impact on vagal activity, experiments designed to reveal 
tonic parasympathetic influence on the LV (Experiments 1, 2 and 3) were conducted 
on animals anaesthetised with urethane, which has been shown to preserve the level 
of chronotropic vagal tone similar to that in decerebrate animals (O'Leary & Jones, 
2003). Experiments designed to recruit vagal activity (Experiment 3) were conducted 
in rats anaesthetised with pentobarbital, which reduces vagal tone (O'Leary & Jones, 
2003). 
Adequate anaesthesia was ensured throughout the experiment through 
continuous monitoring of HR and arterial blood pressure (ABP) stability and the 
absence of a withdrawal response to a paw pinch. With the animal in a supine 
position, the femoral artery and both femoral veins were cannulated for measurement 
of the systemic ABP, fluid infusion and administration of drugs. A 2F Millar 
pressure catheter (SPR-320NR, Millar instruments, Texas, USA) was advanced via 
the right carotid artery and positioned within the chamber of the LV to monitor 
changes in LV pressure (LVP) (Figure 3-1A). The trachea was cannulated and the 
animal was ventilated with room air using a small rodent ventilator (Model 683, 
Harvard Apparatus, Massachusetts, USA) with a tidal volume of ~8-10 ml kg
-1
 set at 
a normal respiratory frequency of ~60 strokes min
-1
. Body temperature was 
maintained with a servo-controlled heating pad at 37.0±0.5 °C. Partial pressures of 
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O2 and CO2 as well as pH of the arterial blood were measured every hour 
(RAPIDLab 348EX, Siemens, Surrey, UK). The rate and volume of mechanical 
ventilation were adjusted and oxygen was added to the respiratory gas mixture (if 
required) to maintain blood gases within the physiological ranges. ABP, LVP, 
tracheal pressure and standard lead II ECG were recorded using a Power1401 
interface and Spike2 software (Cambridge Electronic Design, Cambridge, UK). 
Average waveforms were used to determine systolic blood pressure (SBP), diastolic 
blood pressure (DBP), mean arterial blood pressure (MAP), LV end systolic pressure 
(LVESP), and LV end diastolic pressure (LVEDP). The differential of LV pressure 
(LVdP/dt) was derived from the LVP recording using the slope function. 
3.2.2 Assessment of left ventricular contractility 
The atria were paced at a rate of 10 or 20% above the resting HR using silver 
wire electrodes advanced via the oesophagus to the level of the heart (Figure 3-1A). 
To remove sympathetic influences, β-adrenoceptor blocker atenolol was 
administered (initial bolus dose 2 mg kg
-1
 i.v., followed by 3 mg
-1
 kg
-1
 h
-1
 i.v. 
infusion) and the spinal cord was transected at the cervical level (C1). To restore 
arterial blood pressure (MAP ~100 mmHg) after C1 transection, vasopressin (0.15 
nM in saline) was infused intravenously at a rate of 10 µl min
-1
 (Figure 3-1B). The 
maximum of the first differential of LVP (LVdP/dtmax, mmHg s
-1
) measures the 
inotropic state but with a caveat of load dependency. Systemic β-adrenoceptor 
blockade, C1 transection and vasopressin infusion remove sympathetic influences, 
provide constant loading conditions and fixed filling times (whilst pacing), allowing 
the use of LVdP/dtmax as a measure of LV contractility (further assessment of the LV 
contractile function by indexing of the maximum of the first differential to 
instantaneous LVP [(LVdP/dtmax)/LVP] or deriving the maximum instantaneous ratio 
of this [(LVdP/dt)/LVP]max was not used due to known limitations (Van den Bos et 
al., 1973)).  
 
  
Chapter 3 Control of Ventricular Contractility 49 
 
 
 
Figure 3-1: Experimental approaches used for the assessment of left ventricular 
contractility in anaesthetised rats 
A) Representative recordings obtained in pentobarbital-anaesthetised rat illustrating 
simultaneous monitoring of heart rates (HR), arterial blood pressure (ABP), left ventricular 
pressure (LVP), derived mean arterial blood pressure (MAP) and the first differential of left 
ventricular pressure (LVdP/dt); Inset: Scheme illustrating placement of a 2F Millar pressure 
catheter in the LV chamber (advanced via the right common carotid artery) and positioning 
of atrial pacing electrodes in the lumen of the oesophagus at the level of the right atrium; B) 
Representative example of simultaneous monitoring of HR, MAP, ABP, LV end-systolic 
pressure (LVESP) and maximum of the first differential of the LV pressure (LVdP/dtmax) in 
conditions of systemic β-adrenoceptor blockade and spinal cord transection at C1 level 
before and during intravenous infusion of vasopressin (0.15 nM, 10 µl min
-1
) to restore MAP 
to ~100 mmHg. Normal arterial pH, PCO2 and PO2 were maintained by adjusting parameters 
of mechanical ventilation and providing supplemental oxygen in the inspired gas mixture. 
Sympathetic blockade and vasopressin infusion provide constant loading conditions and 
fixed filling times whilst pacing, allowing the use of LVdP/dtmax as a measure of LV 
contractility.  
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3.2.3 Ultrasound imaging of the LV 
LV pressure-area loop analysis was performed by a combined measurement 
of LVP using a 2F Millar pressure catheter and LV imaging using a Vevo
®
 2100 
ultrasound system (VisualSonics, Amsterdam, The Netherlands). A MS250 13-
24MHz linear array transducer was used to provide a parasternal long-axis view 
(Figure 3-2A). Precautions were taken to minimise the effects of cardiac preload 
using the approach previously described (Lewis et al., 2001). With a suture 
positioned sub-diaphragmatically around the inferior vena cava as a snare to lower 
SBP by ~25 mmHg while pacing at a rate of 10% above resting HR, LVP-area data 
were acquired in segments each comprised of 15 heart beats (Figure 3-2B). 
Measurements were made before and after systemic β-adrenoceptor blockade with 
atenolol (3 mg kg
-1
 i.v.) and again following systemic muscarinic receptor blockade 
with atropine methyl nitrate (2 mg kg
-1
; i.v.). Using LV cross-sectional area (mm
2
) as 
a surrogate measure of LV volume, the regression slope of the end-systolic LVP-area 
relationship was used to determine the end-systolic elastance (Ees, mmHg mm
-2
; 
Figure 3-2B) – an index of LV inotropic state which is insensitive to loading 
conditions.  
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Figure 3-2: An ultrasound approach combined with invasive measurements for 
the assessment of left ventricular contractility in anaesthetised rats 
A) A B-Mode ultrasound image of a parasternal long axis view of the LV with a Millar 
pressure catheter placed in the LV chamber for simultaneous recordings of the LVP and LV 
area; B) Representative LV pressure-area relationships obtained in a urethane-anaesthetised 
rat in conditions of systemic β-adrenoceptor blockade (atenolol). Atrial pacing at 400 bpm 
was combined with occlusion of the inferior vena cava to provide a family of pressure-area 
loops. To determine end-systolic elastance (Ees), a regression line was drawn between the 
LVESP-area points of each loop ensuring r
2
>0.9. 
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3.2.4 Genetic targeting of the DVMN vagal preganglionic neurones  
Young male Sprague-Dawley rats (50-60 g) were anaesthetised with 
ketamine (Vetalar, Zoetis, London, UK) (60 mg kg
-1
 i.m.) and medetomidine 
(Domitor, Elanco, Animal Health, Hampshire, UK) (250 µg kg
-1
 i.m.). Adequate 
depth of surgical anaesthesia was confirmed by the absence of a withdrawal response 
to a paw pinch. With the head fixed prone in a stereotaxic frame, lignocaine 
(Norbrook, Cumbria, UK) (2 ml of 0.2% solution) was injected subcutaneously 
before a midline dorsal neck incision was made to expose the atlanto-occipital 
membrane and then the dorsal surface of the brainstem. DVMN was targeted 
bilaterally with two microinjections per side (0.25 µL at a rate of 0.05 µL min
-1
) of a 
solution containing viral particles of PRSx8-AlstR-eGFP-LVV or PRSx8-eGFP-
LVV. The established titres at the time of production were within the range of 1 x 
10
9
 and 1 x 10
10
 transducing units ml
-1
. Taking the calamus scriptorius as the 
reference point, the injections were made at 0.5 mm rostral, 0.6 mm lateral, 0.8 mm 
ventral and at 1.0 mm rostral, 0.8 mm lateral, 0.6 mm ventral. Anaesthesia was 
reversed with atipemazole (Antisedan, Elanco, Animal Health, Hamspshire, UK) (1 
mg kg
-1
; i.m.). For post-operative analgesia, the rats were administered with 
buprenorphine (Vetergesic, York, UK) (0.05 mg
-1
 kg
-1
 d
-1
; s.c.) for three days and 
caprofen (Caprieve, Norbrook, Cumbria, UK) (4 mg
-1
 kg
-1
 d
-1
; i.p.) for five days. The 
rats weighed 380-450 g at the time of the experiments.  
3.2.5 Glutamate and muscimol microinjections into the DVMN  
The animals were anaesthetised and instrumented as described above, and the 
head was fixed in the stereotaxic frame dorsal side up. An occipital craniotomy was 
performed and the cerebellum was partially removed to expose the dorsal surface of 
the brainstem. A three-barrelled glass micropipette (tip size 20-25 µm) was used for 
microinjections of either glutamate or muscimol in discrete locations along the 
rostro-caudal extent of the left and right DVMN. Microinjections were randomised 
and inserted into the three DVMN locations separated by distances of 0.5 mm. 
Taking the calamus scriptorius as the reference point, the microinjections were made 
at 1.5 mm rostral, 0.8 mm lateral, 0.9 mm ventral (rostral area), 1.0 mm rostral, 0.75 
mm lateral, 0.7 mm ventral (intermediate area), and 0.3 mm rostral, 0.7 mm lateral, 
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0.8 mm ventral (caudal area). The barrels of the micropipette contained glutamate or 
muscimol, with vehicle and saline containing 5% of fluorescent beads (Invitrogen, 
Paisley, UK). The injections were made using pressure over a period of 5-10 s and 
were monitored using a dissecting microscope with a calibrated micrometer disk. 
3.2.6 Histology 
At the end of the experiments the rats were perfused through the ascending 
aorta with 0.9% NaCl solution followed by 500 ml 4% phosphate-buffered (0.1 M, 
pH 7.4) paraformaldehyde; the brains were removed and stored in the same fixative 
overnight at 4 °C. After cryoprotection in 30% sucrose, the brainstem was isolated 
and a sequence of transverse slices (30 µm) was cut. The extent of AlstR-eGFP or 
eGFP expression and the sites of microinjections were identified histologically using 
confocal microscopy and mapped using a stereotaxic atlas (Paxinos & Watson, 
1998). All drugs and reagents were sourced from SigmaAldrich (UK) unless 
otherwise stated. 
3.2.7 Experiment 1. The effects of systemic muscarinic receptor blockade on 
left ventricular contractility  
The animals were anaesthetised with urethane (maintains a level of vagal 
tone) or pentobarbital (reduces vagal tone), prepared as described above and left to 
stabilise for 15-30 min before measurements of baseline cardiovascular variables 
were taken. The effects of systemic muscarinic receptor blockade (atropine methyl 
nitrate, 2 mg kg
-1
 i.v.) on LV contractility was evaluated during atrial pacing (10% 
above resting HR) in conditions of systemic β-adrenoceptor blockade (atenolol) 
combined with C1 transection to remove sympathetic influences (sympathetic 
blockade). In a separate cohort of animals, LV pressure recordings and ultrasound 
LV area imaging were conducted followed by LV pressure-area loop analysis to 
determine the effects of atropine methyl nitrate on LV end-systolic elastance. 
3.2.8 Experiment 2. The effects of reduced DVMN activity on left ventricular 
contractility  
The animals transduced to express AlstR-eGFP or eGFP by the DVMN 
neurones were anaesthetised with urethane and prepared as described above. To 
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achieve acute and selective inhibition of DVMN neurones expressing AlstR, a small 
occipital craniotomy was performed and a miniature polyethylene catheter was 
placed in the cisterna magna to deliver allatostatin (4 µl of 100 µM solution in 
aCSF). The animals were left to stabilise for 15-30 min. The measurements of 
cardiovascular variables were taken before and after allatostatin application in rats 
expressing AlstR-eGFP (reduced DVMN activity) or eGFP (control). 
3.2.9 Experiment 3. To identify the region of the DVMN responsible for the 
control of left ventricular contractility  
The animals were anaesthetised with pentobarbital (reduces vagal tone) and 
prepared as described above. The dorsal surface of the brainstem was exposed (to 
allow microinjections into the DVMN) and the animals were left to stabilise for 15-
30 min. Neurones in discrete locations along the rostro-caudal extent of the left and 
right DVMN were activated following microinjections of an excitatory amino-acid 
L-glutamate (10 mM; 40 nl; pH 7.4) and the effects of these treatments on 
cardiovascular variables were assessed at resting HR conditions, during atrial pacing 
(10% above resting HR) and after systemic β-adrenoceptor blockade (atenolol) 
combined with C1 transection to remove sympathetic influences. In a separate cohort 
of animals anaesthetised with urethane, caudal DVMN areas (identified as having a 
significant impact on LV contractility as a result of studies with the use of glutamate 
microinjections) were inhibited by microinjections of a potent GABAA receptor 
agonist muscimol (0.1 M; 40 nl; pH 7.4), and the effects of this treatment on LV 
contractility was assessed. Microinjections of a vehicle (0.9% NaCl; 40 nl) were used 
to determine the effects of the delivery of a given volume. The order of DVMN 
microinjections was randomised between the left and right sites. 
3.2.10 Humane end-points 
At the end of the experiments the animals were euthanised with an overdose 
of pentobarbitone sodium (200 mg kg
-1
, i.p.). 
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3.2.11 Data analysis  
Recordings of the cardiovascular variables were analysed using Spike2 
software (Cambridge Electronic Design). LV pressure-area loop analysis was 
performed using Lab Chart 8 software (ADInstruments, Oxford UK). Differences 
between the experimental groups were assessed for statistical significance using 
GraphPad Prism 6 software (GraphPad Software, California, USA). Comparisons 
were made using a two-way ANOVA (followed by Sidak’s p value correction for 
multiple comparisons) or Student’s paired or unpaired t test, as appropriate. Data are 
reported as individual values and means ± s.e.m. Differences with P<0.05 were 
considered to be significant. 
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3.3 Results 
3.3.1 Experiment 1. The effects of systemic muscarinic receptor blockade on 
left ventricular contractility  
In rats anaesthetised with urethane and in conditions of systemic β-
adrenoceptor blockade (atenolol) combined with C1 transection (to remove 
sympathetic influences), intravenous administration of atropine methyl nitrate (2 mg 
kg
-1
) led to significant increases in HR, ABP, LVESP and LVdP/dtmax (Table 3-1). 
Increases in MAP, LVESP and LVdP/dtmax following atropine administration were 
also observed during atrial pacing (Figure 3-3A; Table 3-1). On the other hand, in 
rats anaesthetised with pentobarbital, systemic atropine had no effect on 
cardiovascular variables during atrial pacing in conditions of sympathetic blockade 
(Figure 3-3A; Table 3-1).  
In a separate series of experiments, LV pressure-area loop analysis has 
demonstrated decreases in LV contractility following systemic atenolol 
administration both in urethane-anaesthetised animals (decrease in Ees from 2.5±0.2 
to 1.4±0.2 mmHg mm
-2
; p=0.0004; Figure 3-3B), as well as in animals anaesthetised 
with pentobarbital (decrease in Ees from 2.3±0.2 to 1.3±0.2; p=0.0001; Figure 3-3B). 
Subsequent systemic administration of atropine increased end-systolic elastance in 
urethane- (increase in Ees from 1.3±0.2 to 1.7±0.2 mmHg mm
-2
; p=0.007; Figure 3-
3C), but not in pentobarbital- (1.1±0.1 vs 1.0±0.1 mmHg mm
-2
; p=0.3; Figure 3-3C) 
anaesthetised animals. These data confirm the existence of a tonic inhibitory 
muscarinic influence on LV contractility, which in rats is preserved under urethane 
anaesthesia and is suppressed by pentobarbital.  
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Table 3-1 The effects of systemic muscarinic receptor blockade with atropine 
methyl nitrate on cardiovascular variables in conditions of β-adrenoceptor 
blockade and C1 transection to remove sympathetic influences 
Anaesthesia  Urethane Pentobarbital 
    
 Unpaced Paced Paced 
n 6 6 7 
 
LVdP/dt max 
(mmHg s-1) 
   
Saline 5500 ± 487 4642 ± 127 4708 ± 184 
AMN 6894 ± 664 5253 ± 215 4760 ± 203 
Mean difference 1394 ± 224 611 ± 95 50 ± 79 
p 0.002 0.001 0.5 
    
LVESP 
(mmHg) 
   
Saline 120 ± 3 118 ± 4 120 ± 3 
AMN 138 ± 5 132 ± 6 119 ± 3 
Mean difference 18 ± 4 14 ± 3 1 ± 2 
p 0.006 0.004 0.5 
    
LVEDP 
(mmHg) 
   
Saline 4 ± 2 5 ± 1 6 ± 1 
AMN 5 ± 2 5 ± 1 5 ± 1 
Mean difference 1 ± 1 0 ± 1 0 ± 1 
p 0.8 0.4 0.7 
    
MAP 
(mmHg) 
   
Saline 98 ± 2 95 ± 2 103 ± 4 
AMN 110 ± 3 108 ± 3 101 ± 3 
Mean difference 12 ± 2 13 ± 3 2 ± 2 
p 0.003 0.004 0.4 
    
HR 
(bpm) 
   
Saline 353 ± 6   
AMN 374 ± 8   
Mean difference 21 ± 6   
p 0.01   
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Figure 3-3: Tonic restraining muscarinic influence on LV contractility is 
preserved under urethane anaesthesia and is abolished by pentobarbital 
A) Summary data illustrating average (means ± SEM) values of LVdP/dtmax obtained in 
conditions of atrial pacing and systemic β-adrenoceptor blockade (atenolol) combined with 
C1 transection (to remove sympathetic influences) before and after intravenous 
administration of atropine methyl nitrate (2 mg kg
-1
) in rats anaesthetised with pentobarbital 
or urethane; B) Summary data illustrating average (means ± SEM) values of end-systolic 
elastance (Ees) before and after intravenous administration of atenolol (2 mg kg
-1
) in rats 
anaesthetised with pentobarbital or urethane; C) Summary data illustrating average (means ± 
SEM) values of Ees in conditions of β-adrenoceptor blockade (atenolol) before and after 
intravenous administration of atropine methyl nitrate (2 mg kg
-1
) in rats anaesthetised with 
pentobarbital or urethane.  
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3.3.2 Experiment 2. The effects of reduced DVMN activity on left ventricular 
contractility  
In rats (urethane anaesthesia), bilateral inhibition of the DVMN VPNs 
transduced to express AlstR (Figure 3-4) was achieved by application of allatostatin 
in the cisterna magna. This experiment was conducted on animals with intact 
sympathetic tone. Inhibition of the DVMN neurones increased LVESP (by 16±2 
mmHg; P<0.001; Table 3-2), LVdP/dtmax (by 922±232 mmHg s
-1
; p=0.001; Table 
3-2) and MAP (by 7±4 mmHg; p=0.009; Table 3-2; Figure 3-5A, B). DVMN 
inhibition had no effect on HR or LVEDP (Table 3-2). No significant changes in all 
recorded cardiovascular variables were observed following allatostatin application 
into the cisterna magna in rats expressing control transgene (eGFP) in the DVMN 
(Table 3-2; Figure 3-5A, B). These data suggest that tonic activity of the DVMN 
VPNs have a significant inhibitory effect on LV contractile function. 
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Figure 3-4: Targeting DVMN neurones to reduce their activity 
Confocal images of the coronal sections of the rat brainstem targeted to express allatostatin 
receptor (AlstR) in the DVMN neurones. Figure 3-4 illustrates a representative example of 
the distribution of VPNs transduced to express AlstR/eGFP in the caudal and intermediate 
regions of the nucleus. 4V, fourth ventricle. XII, hypoglossal motor nucleus. CC, central 
canal. 
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Table 3-2 The effects of reducing DVMN activity (allatostatin application) on 
cardiovascular variables in anaesthetised (urethane) rats 
Transgene eGFP 
(control) 
 
AlstR 
n 6 6 
 
LVdP/dt max 
(mmHg s
-1
) 
  
Baseline 9099 ± 969 10914 ± 537 
Allatostatin 9170 ± 991 11837 ± 388 
Mean difference 71 ± 113 922 ± 232 
p 0.7 0.001 
   
LVESP 
(mmHg) 
  
Baseline 146 ± 10 156 ± 6 
Allatostatin 149 ± 10 172 ± 5 
Mean difference 4 ± 1 16 ± 2 
p 0.1 <0.0001 
   
LVEDP 
(mmHg) 
  
Baseline 3 ± 1 3 ± 1 
Allatostatin 3 ± 1 3 ± 1 
Mean difference 0 ± 1 0 ± 0 
p 0.7 0.9 
   
MAP 
(mmHg) 
  
Baseline 91± 4 102 ± 3 
Allatostatin 98± 8 109 ± 2 
Mean difference 6 ± 4 7 ± 4 
p 0.2 0.2 
   
HR 
(bpm) 
  
Baseline 430 ± 18 461 ± 8 
Allatostatin 430 ± 18 466 ± 10 
Mean difference 0 ± 2 5 ± 4 
P 0.9 0.2 
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Figure 3-5: Inhibition of VPNs in the dorsal motor nucleus of the vagus nerve 
(DVMN) increases left ventricular contractility 
A) Raw traces illustrating the recordings of HR, MAP, ABP, LVESP and LVdP/dtmax before 
and after allatostatin application into the cisterna magna of rats expressing eGFP or AlstR in 
the DVMN (urethane anaesthesia). No significant changes in all recorded cardiovascular 
variables were observed following allatostatin application in rats expressing eGFP. 
Inhibition of the DVMN neurones increases LVESP and LVdP/dtmax. eGFP, animal 
transduced to express eGFP in the DVMN. AlstR, animal transduced to express AlstR/eGFP 
in the DVMN; B) Summary data illustrating individual and average (means ± SEM) values 
of LVdP/dtmax obtained before and after allatostatin application into the cisterna magna of 
rats expressing eGFP (n=6) or AlstR (n=6) in the DVMN (urethane anaesthesia, intact 
sympathetic tone). 
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3.3.3 Experiment 3. To identify the region of the DVMN responsible for the 
control of left ventricular contractility  
In rats anaesthetised with pentobarbital, neurones in discrete locations along 
the rostro-caudal extent of the left and right DVMN (Figure 3-6) were activated by 
glutamate microinjections; the effects of these treatments on cardiovascular variables 
were first assessed at resting HR conditions (Table 3-3;). Activation of neurones in 
the left caudal area of the DVMN (Table 3-3) induced profound decreases in 
LVdP/dtmax, LVESP, ABP and HR (Figure 3-6; Table 3-3). Activation of the 
intermediate DVMN area located 0.5 mm rostrally (Figure 3-6) decreased 
LVdP/dtmax and MAP (Table 3-3); however, the magnitude of the evoked changes 
was smaller compared to the responses elicited by glutamate actions at the caudal 
site. Activation of the most rostral area of the left DVMN or any area along the 
rostro-caudal extent of the right DVMN had no effect on cardiovascular variables 
(Table 3-3; Table 3-4). Sites of microinjections were marked by fluorescent beads 
and were confirmed to lie within the targeted DVMN regions (Figure 3-6B, C).   
Under constant HR conditions (pacing at 10% above resting HR), activation 
of neurones in the left caudal DVMN area was also associated with significant 
decreases in LVdP/dtmax, LVESP and MAP with no effect on LVEDP (Table 3-5; 
Figure 3-7; Figure 3-8). Smaller yet significant decreases in LVdP/dtmax, LVESP and 
MAP were evoked by stimulation of neurones in the left caudal DVMN under 
constant HR conditions, combined with systemic β-adrenoceptor blockade and C1 
transection (Table 3-5; Figure 3-7; Figure 3-8). Responses triggered by glutamate-
induced activation of the left caudal DVMN were abolished by atropine (Table 3-5).  
  
Chapter 3 Control of Ventricular Contractility 64 
 
 
 
 
Figure 3-6: Histological identification of microinjection sites along the rostro-
caudal extent of the left and right DVMN 
A) Scheme of the rat brainstem viewed from its dorsal surface illustrating targeting of the 
rostral, intermediate and caudal aspects of the left and right DVMN; B) Schemes of the 
coronal sections of the rat brainstem illustrating the locations of the rostral, intermediate and 
caudal microinjection sites identified by deposition of fluorescent beads. AP, area postrema. 
NTS, nucleus of the solitary tract. S, solitary tract; C) Microphotographs of the coronal 
sections of the rat brainstem illustrating microinjection sites targeting rostral, intermediate 
and caudal regions of the left and right DVMN. 
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Table 3-3 The effects of left DVMN activation in discrete locations along the 
rostro-caudal extent of the left and right nuclei (glutamate microinjections) on 
cardiovascular variables in anaesthetised (pentobarbital) rats 
 Left DVMN 
  
 Rostral Intermediate Caudal 
n 6 6 11 
 
LVdP/dt max 
(mmHg s
-1
) 
   
Saline 4999 ± 186 5232 ± 222 5671 ± 225 
Glutamate 4845 ± 176 4813 ± 252 4030 ± 333 
Mean difference 154 ± 74 420 ± 112 1641 ± 134 
p 0.6 0.01 <0.0001 
    
LVESP 
(mmHg) 
   
Saline 124 ± 3 127 ± 5 125 ± 2 
Glutamate 122 ± 4 121 ± 5 97 ± 5 
Mean difference 3 ± 1 6 ± 2 28 ± 3 
p 0.8 0.2 <0.0001 
    
LVEDP 
(mmHg) 
   
Saline 4 ± 0 5 ± 1 4 ± 1 
Glutamate 4 ± 0 5 ± 1 4 ± 1 
Mean difference 0 ± 0 0 ± 0 1 ± 0 
p >0.9 0.9 0.2 
    
MAP 
(mmHg) 
   
Saline 95 ± 2 99 ± 5 98 ± 3 
Glutamate 94 ± 3 89 ± 7 72 ± 3 
Mean difference 1 ± 1 10 ± 3 26 ± 3 
p 0.9 0.001 <0.0001 
    
HR 
(bpm) 
   
Baseline 385 ± 14 396 ± 17 398 ± 11 
Glutamate 383 ± 14 396 ± 18 378 ± 9 
Mean difference 0 ± 1 1 ± 3 20 ± 6 
p >0.9 >0.9 0.01 
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Table 3-4 The effects of right DVMN activation in discrete locations along the 
rostro-caudal extent of the left and right nuclei (glutamate microinjections) on 
cardiovascular variables in anaesthetised (pentobarbital) rats 
 Right DVMN 
  
 Rostral Intermediate Caudal 
 
n 6 6 6 
 
LVdP/dt max 
(mmHg s
-1
) 
   
Saline 5132 ± 191 5168±219 5190 ± 293 
Glutamate 4930 ± 219 4987 ± 195 4879 ± 457 
Mean difference 203 ± 61 180 ± 109 312 ± 179 
p 0.3 0.4 0.08 
    
LVESP 
(mmHg) 
   
Saline 125 ± 2 127 ± 4 120 ± 2 
Glutamate 122 ± 3 123 ± 6 115 ± 3 
Mean difference 2 ± 1 3 ± 1 5  ± 2 
p 0.8 0.5 0.3 
    
LVEDP 
(mmHg) 
   
Saline 5 ± 0 5 ± 1 5 ± 1 
Glutamate 4 ± 0 5 ± 0 5 ± 1 
Mean difference 1 ± 0 1 ± 0 2 ± 2 
p 0.9 0.9 >0.9 
    
MAP 
(mmHg) 
   
Saline 98 ± 3 101 ± 5 102 ± 3 
Glutamate 96 ± 3 101 ± 6 98 ± 2 
Mean difference 2 ± 3 1 ± 2 4 ± 3 
p 0.6 >0.9 0.3 
    
HR 
(bpm) 
   
Baseline 389 ± 18 401 ± 15 392 ± 19 
Glutamate 393 ± 15 402 ± 14 393 ± 19 
Mean difference 3 ± 4 0 ± 2 0 ± 1 
p 0.3 >0.9 >0.9 
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Table 3-5. The effect of neuronal activation in the left caudal DVMN (glutamate 
microinjections) on cardiovascular variables at resting conditions, during atrial 
pacing at 10% above resting HR, and during pacing in conditions of β-
adrenoceptor blockade combined with C1 transection (sympathetic blockade, 
SB) before and after systemic administration of atropine methyl nitrate (AMN) 
(pentobarbital-anaesthetised rats) 
 
 
 Left DVMN 
     
 Unpaced Paced Paced/SB Paced/SB/ 
Atropine 
     
n 11 8 11 7 
 
LVdP/dt max 
(mmHg s
-1
) 
    
Saline 5671 ± 225 6043 ± 327 5141 ± 261 4759 ± 203 
Glutamate 4030 ± 333 4506 ± 252 4667 ± 201 4726 ± 219 
Mean Difference 1641 ± 134 1536 ± 164 475 ± 140 33 ± 175 
p <0.0001 <0.0001 0.004 0.9 
     
LVESP 
(mmHg) 
    
Saline 125 ± 2 126 ± 4 126 ± 6 119 ± 3 
Glutamate 97 ± 5 107 ± 3 118 ± 5 118 ± 3 
Mean Difference 28 ± 3 19 ± 4 9 ± 4 0 ± 5 
p <0.0001 0.0002 0.04 0.9 
     
LVEDP 
(mmHg) 
    
Saline 4 ± 1 4 ± 1 4 ± 1 5 ± 1 
Glutamate 4 ± 1 6 ± 1 5 ± 1 5 ± 1 
Mean Difference 1 ± 0 2 ± 2 1 ± 2 0 ± 2 
p 0.2 0.8 0.9 >0.9 
     
MAP 
(mmHg) 
    
Saline 98 ± 3 96 ± 6 108 ± 4 101 ± 3 
Glutamate 72 ± 3 73 ± 3 100 ± 4 101 ± 3 
Mean Difference 26 ± 3 23 ± 3 8 ± 3 0 ± 4 
p <0.0001 <0.0001 0.02 >0.9 
Chapter 3 Control of Ventricular Contractility 68 
 
 
 
 
 
Figure 3-7: Raw traces showing activation of neurones in the caudal region of 
the left DVMN decreases left ventricular contractility 
Raw traces illustrating recordings of HR, MAP, ABP, LVESP and LVdP/dtmax before and 
after glutamate microinjections into the caudal region of the left DVMN at resting HR 
conditions, during atrial pacing (10% above resting HR) and after systemic β-adrenoceptor 
blockade (atenolol) combined with spinal cord (C1) transection to remove sympathetic 
influences (pentobarbital anaesthesia). L-glu, L-glutamate. SB, sympathetic blockade.  
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Figure 3-8: Summary data showing activation of neurones in the caudal region 
of the left DVMN decreases left ventricular contractility 
Summary data illustrating individual and average (means ± SEM) values of peak changes in 
LVESP and LVdP/dtmax induced by glutamate microinjections into the caudal regions of 
DVMN at resting HR conditions, during atrial pacing and during atrial pacing combined 
with sympathetic blockade (SB). No significant changes in all recorded cardiovascular 
variables were observed following activation of the right DVMN. Therefore, the effects of 
glutamate microinjections were only assessed at resting condition. 
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In animals anaesthetised with urethane (under systemic β-adrenoceptor 
blockade combined with C1 transection), inhibition of the left caudal DVMN 
following microinjections of muscimol increased LVdP/dtmax, LVESP, MAP and HR 
(Figure 3-9; Figure 3-10). Since silencing of the DVMN neurones transduced to 
express AlstR by allatostatin application was not associated with changes in HR, the 
cardiovascular response profile recorded after muscimol microinjections suggested 
potential diffusion and actions of the drug on neurones of the neighbouring brainstem 
structures (e.g. nucleus of the solitary tract). Smaller yet significant increases in 
LVdP/dtmax and LVESP in response to inhibition of the left caudal DVMN were also 
observed during atrial pacing (Table 3-6; Figure 3-9; Figure 3-10). Inhibition of the 
right caudal DVMN following microinjections of muscimol produced no changes in 
cardiovascular variables (Table 3-6; Figure 3-9; Figure 3-10). These data indicate 
that neurones residing in the caudal region of the left DVMN exert direct load- and 
HR-independent tonic control of LV contractility. 
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Table 3-6 The effects of neuronal inhibition in the caudal DVMN regions 
(muscimol microinjections) on cardiovascular variables in conditions of β-
adrenoceptor blockade combined with C1 transection (urethane-anaesthetised 
rats) 
 Left caudal DVMN Right caudal DVMN 
    
 Unpaced Paced Unpaced 
 
n 10 6 10 
 
LVdP/dt max 
(mmHg s
-1
) 
   
Saline 5487 ± 286 4445 ± 196 5582 ± 308 
Muscimol 6360 ± 303 4686 ± 197 5882 ± 368 
Mean Difference 873 ± 151 240 ± 44 299 ± 224 
p 0.0005 0.003 0.3 
    
LVESP 
(mmHg) 
   
Baseline 118 ± 3 113 ± 3 117 ± 4 
Muscimol 134 ± 4 116 ± 3 121 ± 5 
Mean Difference 17 ± 4 3 ± 1 5 ± 5 
p 0.001 0.008 0.5 
    
LVEDP 
(mmHg) 
   
Baseline 4 ± 0 7 ± 1 5 ± 1 
Muscimol 4 ± 0 7 ± 1 4 ± 1 
Mean Difference 0 ± 1 0 ± 1 0 ± 1 
p 0.8 0.7 0.9 
    
MAP 
(mmHg) 
   
Baseline 93 ± 1 95 ± 2 92 ± 1 
Muscimol 103 ± 1 98 ± 2 93 ± 4 
Mean Difference 10 ± 1 2 ± 1 1 ± 3 
p 0.001 0.06 0.8 
    
HR 
(mmHg) 
   
Baseline 343 ± 11  358 ± 11 
Muscimol 356 ± 10  363 ± 11 
Mean Difference 13 ± 5  5 ± 2 
p 0.004  0.4 
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Figure 3-9: Raw traces showing inhibition of neurones in the caudal region of 
the left DVMN increases left ventricular contractility 
Raw traces illustrating recordings of HR, MAP, ABP, LVESP and LVdP/dtmax before and 
after muscimol microinjections into the caudal region of the left DVMN in conditions of 
systemic β-adrenoceptor blockade (atenolol) combined with spinal cord (C1) transection at 
resting HR and during atrial pacing (urethane anaesthesia).  
  
Chapter 3 Control of Ventricular Contractility 73 
 
 
 
 
 
Figure 3-10: Summary data showing inhibition of neurones in the caudal region 
of the left DVMN increases left ventricular contractility 
Summary data illustrating individual and average (means ± SEM) values of peak changes in 
LVESP and LVdP/dtmax resulting from muscimol microinjections into the caudal regions of 
DVMN in conditions of sympathetic blockade at resting HR and during atrial pacing. No 
significant changes in all recorded cardiovascular variables were observed following 
muscimol microinjections into the right caudal DVMN.   
Chapter 3 Control of Ventricular Contractility 74 
 
 
3.4 Discussion 
The study in this chapter tested the hypothesis that tonic parasympathetic 
control of LV contractility is provided by the activity of VPNs, which reside in the 
DVMN. First, using an anaesthetised rat model, the presence of tonic restraining 
muscarinic influence on LV inotropy was confirmed. Next, DVMN neurones were 
targeted to express inhibitory G-protein coupled receptors from insects; their targeted 
reduction in activity following application of the insect peptide allatostatin 
(Mastitskaya et al., 2012) was found to be associated with significant increases in 
LV contractility. Although VPNs residing in the NA are likely to have an impact on 
the LV function, the data obtained in the present study support the hypothesis that a 
significant component of the parasympathetic control of the LV inotropy is indeed 
provided by tonically active neurones of the DVMN. Functional neuroanatomical 
mapping, using glutamate and muscimol microinjections to activate and inhibit 
neuronal cell bodies in distinct locations along the rostro-caudal extent of the left and 
right DVMN, identified the precise anatomical location of VPNs that have an impact 
on LV contractility. These neurones appear to be concentrated in the caudal region of 
the left DVMN. 
The strength and significance of direct tonic parasympathetic control of LV 
inotropic state has remained unknown. Earlier studies conducted using dogs, pigs 
and humans demonstrated that VNS leads to load-independent decreases in LV 
contractility (Eliakim et al., 1961; Degeest et al., 1964; Degeest et al., 1965c; Lewis 
et al., 2001). The evidence of changes in LV inotropy observed in a reverse 
experimental paradigm, i.e. when acute bilateral vagotomy is performed or systemic 
muscarinic receptor blockade is applied, is limited. De Geest et al. reported that 
bilateral vagotomy blocks the negative inotropic effect of peripheral chemoreceptor 
stimulation (Degeest et al., 1965a, b; Lewis et al., 2001). In humans, intracoronary 
administration of ACh attenuated inotropic responses to β-adrenoceptor stimulation 
(dobutamine infusion) (Landzberg et al., 1994). Interestingly, intracoronary atropine 
potentiated dobutamine-induced inotropic responses, and this effect of atropine was 
absent in transplanted (i.e. denervated) hearts (Landzberg et al., 1994). 
Consequently, these findings have demonstrated the existence of a tonic restraining 
parasympathetic influence on LV contractility in humans.  
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A more recent study reported increases in LVESP after acute bilateral 
vagotomy in the arterially perfused working heart-brainstem rat preparation 
(Nalivaiko et al., 2010). Here, using two different measures, the existence of tonic 
negative muscarinic influence on LV contractility in a rat model was confirmed. In 
conditions of systemic β-adrenoceptor blockade, intravenous administration of 
atropine increased LV Ees and LVdP/dtmax (at constant filling times and loading 
conditions). Systemic muscarinic receptor blockade increased LV contractility only 
in animals anaesthetised with urethane, confirming previous reports that urethane 
preserves and pentobarbital reduces (chronotropic) vagal tone (O'Leary & Jones, 
2003). These data illustrate a tonic restraining muscarinic influence on LV 
contractility and sensitivity of this influence to anaesthetic agents which suppress the 
parasympathetic drive. 
In an earlier study it was found that the increased activity of DVMN VPNs 
protects LV cardiomyocytes against acute ischemia/reperfusion injury. This 
cardioprotective effect was found to be mediated by a muscarinic mechanism 
(Mastitskaya et al., 2012). Based on these findings, it was hypothesised that the same 
population of DVMN neurones that exerts powerful cardioprotection may also 
contribute to the control of ventricular contractility. Acute bilateral inhibition of 
AlstR-expressing DVMN neurones along the rostro-caudal extent of the nuclei (by 
allatostatin infusion) increased LV end-systolic pressure and LVdP/dtmax. This effect 
indicated an increase in LV contractility since no changes in LVEDP, HR and MAP 
were observed. Functional neuroanatomical mapping (using microinjections of 
glutamate and muscimol to activate and inhibit DVMN neuronal cell bodies, 
respectively) has further demonstrated that preganglionic neurones responsible for 
parasympathetic control of LV inotropic state are concentrated in the caudal region 
of the left DVMN. 
At resting HR conditions (prior to β-adrenoceptor blockade and spinal cord 
transection), microinjections of glutamate into the left caudal DVMN induced 
profound changes in HR and the MAP, indicative of a sympathetic withdrawal. 
These effects could be explained by glutamate diffusion from the site of 
microinjection and its impact on neurones of the neighbouring nucleus of the solitary 
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tract, which receives inputs from all cardiorespiratory afferents (Spyer, 1994), and/or 
acute recruitment of the inhibitory presynaptic vagal influences, which control 
noradrenaline release from sympathetic terminals innervating the heart. The 
magnitude of the parasympathetic effect on HR is known to depend on the strength 
of the sympathetic tone, indicative of the effective presynaptic interactions (Levy, 
1971b).  
Activation of neurones in the caudal region of the left DVMN led to a 
significant decrease in LV contractility, including in conditions of systemic β-
adrenoceptor blockade and spinal cord transection, suggesting that parasympathetic 
control of LV inotropy originates from this region of the brainstem. Microinjections 
of glutamate trigger transient activation of the neuronal cell bodies in the targeted 
brain area and have no effect on fibres of passage (Goodchild et al., 1982). This was 
important for the design of the current study since axons of VPNs of the NA form 
hairpin loops in the vicinity of the DVMN (Jones, 2001). 
The short duration and unimodal cardiovascular response profile after 
microinjections of glutamate suggested that activation of neurones in neighbouring 
brainstem structures is unlikely. To minimise the likelihood of this, a fifth of 
glutamate concentration originally described in Goodchild et al. (1982) and a tenth 
of glutamate concentration used to recruit VPNs of the NA (Sampaio et al., 2003) 
were used. Interestingly, relative decreases in LV contractility, triggered in response 
to activation of the neuronal cell bodies in the left caudal DVMN, were 
quantitatively similar (~20%) to those observed in rabbits when VNS was combined 
with the anodal block technique for selective stimulation of unmyelinated efferent 
fibres (Garcia Perez & Jordan, 2001). These data support the conclusions of the 
present study; since only DVMN VPNs have C fibre axons (neurones of the NA have 
B fibre axons).  
There is evidence that cardiomyocytes themselves are able to synthesise 
ACh, and ACh synthesis by cardiomyocytes is facilitated by muscarinic receptor 
activation (Kakinuma et al., 2009; Kakinuma et al., 2012; Sun et al., 2013). Despite 
on-going debates on the density of vagal innervation of the LV myocardium, there is 
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strong evidence that VNS is associated with significant increases in LV ACh content 
(Eliakim et al., 1961; Akiyama et al., 1994; Akiyama & Yamazaki, 2001). If 
cardiomyocytes are capable of producing physiologically significant amounts of 
ACh in an autocrine/paracrine manner (sensitive to muscarinic receptor agonism), 
activation of even sparse vagal efferent innervation may have a significant impact on 
LV function. LV cardiomyocytes are protected against ischemia/reperfusion injury 
when the activity of DVMN neurones is selectively recruited using an optogenetic 
approach (Mastitskaya et al., 2012); the data is thus consistent with the evidence of a 
potent cardioprotective effect of ACh (which is as potent as adenosine in reducing 
myocardial injury) reported previously (Richard et al., 1995; Qian et al., 1996; 
Yamaguchi et al., 1997; Cohen et al., 2001). 
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3.5 Study Limitations 
Inhibition of neurones in the left caudal area of the DVMN using 
microinjections of a potent GABAA receptor agonist muscimol increased LV 
contractility, although the magnitude of the observed effects was smaller compared 
to that induced by systemic muscarinic receptor blockade. These data suggest that 
either muscimol microinjections were not sufficient to inhibit the same population of 
DVMN neurones recruited by the actions of glutamate, or VPNs residing in other 
areas of the brainstem (NA, intermediate zone) also contribute to the 
parasympathetic control of LV inotropy, or both.  
With regards to the gene transfer work to silence the DVMN neurones, the 
viral titres for the constructs used were not reliably known. Acceptable expression 
was predetermined by injection in test subjects allowing four weeks prior to 
conducting histology. The extent of expression could have instead been evaluated via 
polymerase chain reaction as titres would inevitably vary, given the titre loss of the 
lentiviral constructs immediately after thawing. 
In summary, the findings of the present study confirm the existence of tonic 
restraining muscarinic influence on LV contractility, which is preserved under 
urethane anaesthesia and is abolished by pentobarbital. Functionally significant 
parasympathetic control of LV contractile function originates from the activity of a 
group of VPNs residing in the caudal region of the left DVMN. 
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 The Vagal mechanisms Controlling Exercise Capacity Chapter 4
4.1 Introduction 
There is significant evidence indicating that the activity of the 
parasympathetic nervous system correlates with exercise capacity (Goldsmith et al., 
1997). Endurance exercise training has been shown to be associated with a lower 
resting HR (al-Ani et al., 1996; Carter et al., 2003) accompanied by changes in 
baroreflex sensitivity, HRV and heart rate recovery (HRR), which are all suggestive 
of a higher vagal tone (Aubert et al., 2003; Niemela et al., 2008; Filliau et al., 2015).  
Higher baroreflex sensitivity, enhanced power of the high frequency 
component of the HRV and rapid HRR following cessation of exercise in athletes in 
training would suggest that there is indeed some degree of plasticity in the central 
nervous control of the heart (Merati et al., 2015), however, the mechanisms 
underlying the effects of exercise and physical activity on vagal tone have never 
being explored. The established concept postulating that exercise training enhances 
vagal tone has been challenged recently by the experimental data obtained through 
rats and mice, showing that exercise alters the expression of the funny channel 
(HCN4) in the SA node (lengthening the hyperpolarisation between action 
potentials) and this process underlies development of bradycardia (at rest) in athletes 
(D'Souza et al., 2014).  
Although this and other data would suggest the effect of exercise training on 
nodal tissue remodelling (D'Souza et al., 2015), an overwhelming body of evidence 
indicates that trained individuals and especially elite athletes exhibit incredibly high 
parasympathetic tone (Sacknoff et al., 1994; Carter et al., 2003). This established 
association between high vagal tone and enhanced exercise capacity suggests that 
either parasympathetic tone can be enhanced by exercise training or high vagal tone 
(due to genetic factors) makes one more tolerant to endurance training regimes, or 
both. Although the mechanisms underlying plasticity of the central parasympathetic 
circuits are unknown, there is significant evidence supporting the first hypothesis, 
e.g. Hepburn et al. (2005) demonstrated that respiratory training, independent of 
physical exercise, increased the high frequency component of HRV at rest. This was 
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accompanied by a decrease in the low frequency peak (an index of sympathetic 
tone). Improvement in HRR was also reported in this study. Consequently, it is clear 
that intact neural pathways are necessary for resting bradycardia and heightened 
baroreflex sensitivity associated with exercise training (Ordway et al., 1982; Ceroni 
et al., 2009).  
There is also evidence supporting the second hypothesis. In a study involving 
adolescent twins (aged 13-22), a significant association was found between RSA and 
exercise behaviour that was concluded to derive entirely from a genetic factor (De 
Geus et al., 2003).  For all the measures, correlations in monozygotic twin pairs were 
larger than those in dizygotic twin pairs, indicating significant genetic influences on 
all traits. This study also concluded that genetic factors determine high levels of 
aerobic fitness causing adolescents to have a higher affinity for and more reliable 
adherence to exercise. Amplitude of the RSA may be used as an indicator of how 
trainable an individual is and there is evidence supporting this hypothesis. For 
example it was shown that individuals with high amplitude RSA display larger 
VO2max during exercise (Boutcher & Stein, 1995).  Exercise training could thus be 
more rewarding and less aversive to those with a genetic make-up that results in 
higher vagal tone.  
This experimental study was designed to directly test the hypothesis that the 
strength of parasympathetic tone determines exercise capacity. If this hypothesis is 
correct, then vagal withdrawal should decrease and vagal recruitment should enhance 
ability to exercise. An experimental model of forced exercise in rodents was used. 
Exercise capacity was determined using specified conditions: (i) unilateral cervical 
vagotomy; (ii) acute and chronic (four hours) systemic muscarinic receptor blockade 
with atropine; (iii) systemic M2 and M3 muscarinic receptor blockade; (iv) nNOS 
blockade; (v) genetic targeting and silencing of VPNs of the DVMN, demonstrated 
in 0 and 2 to control electrical and contractile properties of the ventricle) using a 
pharmacogenetic approach; and (vi) optogenetic activation of the DVMN neurones. 
A separate experiment was conducted in mice with genetically engineered 
impairment of the M3 signalling pathway. The results obtained demonstrate that 
reduced activity of the DVMN neurones dramatically impairs, whereas increased 
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activity of the DVMN enhances exercise capacity and contractile function of the LV 
via downregulation of GRK2 and β-arrestin expression by cardiomyocytes. In 
conclusion, the vagus nerve exerts trophic cardiac effects maintaining the ability of 
the heart to mount an appropriate inotropic response during exercise.  
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4.2 Methods 
All the experiments were performed on rats and mice in accordance with the 
European Commission Directive 2010/63/EU (European Convention for the 
Protection of Vertebrate Animals used for Experimental and Other Scientific 
Purposes) and the UK Home Office (Scientific Procedures) Act (1986) with project 
approval from the Institutional Animal Care and Use Committee. 
4.2.1  Exercise model 
Exercise capacity of rats and mice was determined using a single lane 
treadmill (Panlab Harvard Apparatus, Cambridge, UK) with an electrical shock grid 
set at a minimum threshold of 0.1 mA. The animals were selected for their exercise 
compliance after a three-day recruitment protocol.  Animals were subjected to daily 
recruitment sessions involving running speeds of 20-30 cm s
-1
 over a five minutes 
period after 15 minutes of acclimatisation to the treadmill environment. To determine 
exercise capacity, treadmill speed was raised from 20 cm s
-1
 in increments of 5 cm s
-1
 
every five minutes in rats and every three minutes in mice until the hind limbs made 
contact with the grid four times within a two-minute period - the humanely defined 
point of exhaustion. The distances covered by the animals were recorded and 
exercise capacity was expressed in joules (J or kg m
2
 s
-2
). 
4.2.2  Blood pressure and heart rate recordings in conscious animals 
ABP and HR in conscious rats were recorded using tail cuff plethysmography 
method or biotelemetry monitoring. Blood pressure measurements by tail cuff 
plethysmography were performed at the same time each day for all the rats. Briefly, 
the rats were placed on a heated platform at 37 °C in a quiet, temperature controlled 
(~30 °C) area. The tail was instrumented with a cuff and a volume pressure-
recording sensor (CODA system, Kent Scientific, USA) and a total of 20-30 
measurements were taken over a period of 15 minutes. All animals used in this study 
were acclimatised to the recording environment with 10 control blood pressure 
measurements at the beginning of each recording session. At least 10 additional 
measurements were subsequently taken and recorded values were averaged to 
determine the resting level of the ABP.  
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Biotelemetry was also used to record systemic ABP and HR in conscious 
freely moving animals. The rats were anaesthetised with ketamine (60 mg kg
-1
; i.m.) 
and medetomidine (250 µg kg
-1
; i.m.). Laparotomy was performed and the cannula 
connected to the telemetric pressure transducer (model TA11PA-C40, Data Science 
International, USA) was secured within the lumen of the abdominal aorta. The 
muscle and skin levels of the abdomen were separately sutured. Anaesthesia was 
reversed with atipemazole (1 mg kg
-1
; i.m.) and the animals were allowed to recover 
for at least seven days. For post-operative analgesia, rats were administered with 
buprenorphine (0.05 mg kg
-1
 d
-1
; s.c.) for three days and caprofen (4 mg kg
-1
 d
-1
; i.p.) 
for five days.   
4.2.3 Ultrasound assessment of ejection fraction 
Left ventricular (LV) function was assessed using a Vevo® 2100 high-
resolution ultrasound system with an MS250 13-24MHz linear array transducer 
(VisualSonics, Amsterdam, The Netherlands). Under isoflurane anaesthesia (2% 
isoflurane), baseline ejection fraction and HR (lead II ECG) were determined. 
Dobutamine (0.5 mg kg
-1; i.p.) was administered to determine cardiac responses to β-
adrenoceptor stimulation. Ejection fraction was determined using B-mode 
acquisition of a parasternal long-axis view of the ventricle (in plane so as to dissect 
across the aorta) in order to measure the length of the ventricle during systole and 
diastole. Three short-axis images perpendicular to this were acquired along the 
length of the ventricle to segment the endocardial border. By applying Simpson’s 
rule to approximate ventricular volume, ejection fraction was determined and 
expressed as the percentage of blood at diastole ejected during systole (Figure 4-1) 
(Schiller et al., 1989). 
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Figure 4-1: Ultrasound imaging of the left ventricle 
Example of a B-Mode LV acquisition made to determine the ejection fraction. A parasternal 
view of the long axis was used to determine the length at the LV at systole and diastole. This 
was used in combination with three short axis slices allowing approximation of LV volume 
at these two time points using Simpson’s rule. 
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4.2.4  Haemodynamic measurements 
The animals were anaesthetised with urethane (1.3 g
-1
 kg
-1
; i.v.; following 4% 
isoflurane induction). Adequate anaesthesia was ensured throughout the experiment 
by continuous monitoring of HR and ABP stability and the absence of a withdrawal 
response to a paw pinch. With the animals in a supine position, the femoral artery 
and both femoral veins were cannulated for the measurements of the systemic ABP, 
fluid infusion and administration of drugs. The trachea was cannulated and the 
animals were allowed to freely breathe a supplied gas mixture. Body temperature 
was maintained with a servo-controlled heating pad at 37.0±0.5 °C. Partial pressures 
of O2 and CO2 as well as pH of the arterial blood were measured every hour 
(RAPIDLab 348EX, Siemens, UK). Oxygen was added to the respiratory gas 
mixture (if required) to maintain blood oxygenation within the physiological range. 
A 2F Millar pressure catheter (SPR-320NR, Millar instruments, USA) was advanced 
via the right carotid artery and positioned within the chamber of the LV to monitor 
changes in LVP. Average waveforms of LVP and ABP were used to determine 
LVESP, and the MAP. LVdP/dtmax was derived from the LVP recording using the 
slope function. Atrial pacing at 20% above baseline HR was performed using a 1.6 F 
octapolar electrophysiology catheter (EPR-802, Millar instruments, UK) positioned 
in the right atrium via the jugular vein. Dobutamine (0.5 mg kg
-1
; i.p.) was 
administered to determine cardiac responses to β-adrenoceptor stimulation. 
Cardiovascular variables were recorded using a Power1401 interface and analysed 
off-line using Spike2 software (Cambridge Electronic Design).  
4.2.5  Genetic targeting of the DVMN vagal preganglionic neurones 
Young male Sprague-Dawley rats (50-60 g) were anaesthetised with 
ketamine (60 mg kg
-1
; i.m.) and medetomidine (250 µg kg
-1
; i.m.). Adequate depth of 
surgical anaesthesia was confirmed by the absence of a withdrawal response to a paw 
pinch. With the head fixed prone in a stereotaxic frame, lidocaine (2% solution) was 
injected subcutaneously for pre-operative analgesia before a midline dorsal neck 
incision was made to expose the atlanto-occipital membrane and then the dorsal 
surface of the brainstem. The DVMN was targeted bilaterally with two 
microinjections per side (0.25 µl at a rate of 0.05 µl min
-1
) of a solution containing 
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viral particles of PRSx8-AlstR-eGFP-LVV or PRSx8-eGFP-LVV. The established 
titres at the time of production were within the range of 1 x 10
9
 and 1 x 10
10
 
transducing units ml
-1
.Taking the calamus scriptorius as the reference point, the 
injections were made at 0.5 mm rostral, 0.6 mm lateral, 0.8 mm ventral and at 1.0 
mm rostral, 0.8 mm lateral, 0.6 mm ventral.  
For optogenetic activation, a mutant of channelrhodopsin (ChR) – ChIEF – 
fused with the tandem dimer Tomato (tdTomato) red fluorescent protein was used. 
ChIEF is a chimeric ChR variant constructed from the N-terminal part of the ChR1 
and the C-terminal part of the ChR2 and also incorporates an isoleucine 170 to valine 
mutation. ChIEF combines the reduced inactivation characteristics of ChR1 with 
more favourable cation permeability properties conferred by ChR2 (Lin et al., 
2009). The I170V mutation further improves the channel closure kinetics. ChIEF 
therefore allows a greater temporal control of neuronal activation by blue light pulses 
resulting in cation flow and depolarisation. Its spectral properties are similar to those 
of ChR2, but it shows more efficient membrane expression and trafficking in the 
mammalian cells (Lin et al., 2009). DVMN neurones were targeted using the same 
approach but with one microinjection of PRSx8-ChIEF-tdTomato-LVV (Figure 4-2) 
on each side using the caudal set of coordinates. The established titres at the time of 
production were within the range of 1 x 10
9
 and 1 x 10
10
 transducing units ml
-1
. 
Caudal DVMN neurones were targeted as they have been found to affect LV 
function most significantly (Chapter 2). Anaesthesia was reversed with atipemazole 
(1 mg kg
-1
; i.m.). For post-operative analgesia, rats were administered with 
buprenorphine (0.05 mg
 
kg
-1 
d
-1
; s.c.) for three days and caprofen (4 mg kg
-1
 d
-1
; i.p.) 
for five days.  
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Figure 4-2: PRSx8-ChIEF-tdTomato-LVV Vector circle map 
A vector circle map showing the proteins involved in the construction of the viral plasmid.  
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4.2.6 Cannula and optrode implantations 
Three weeks after microinjections of viral vectors into the DVMN (Figure 
4-3; Figure 4-4), the animals were anaesthetised with ketamine (60 mg kg
-1
; i.m.) and 
medetomidine (250 µg kg
-1
; i.m.) and either a 26-gauge guide injection cannula 
(Plastic Products Co., Roanoke, USA; in animals expressing AlstR or eGFP) or a 
conically tipped optrode (Art Photonics, Berlin, Germany; in animals expressing 
ChiEF-tdTomato or eGFP) was stereotaxically implanted to reach the dorsal aspect 
of the cisterna magna. Two small screws were placed into the skull, and the implant 
was secured in place with dental acrylic. The guide cannula was closed with a 
dummy cannula that extended from the tip of the guide cannula by approximately 0.2 
mm. Anaesthesia was reversed with atipemazole (1 mg kg
-1
; i.m.) and the animals 
were allowed to recover for at least seven days before the experiments took place. 
4.2.7  Knock-in mouse model expressing the phosphorylation-deficient M3-
muscarinic receptors 
The knock-in (KI) mouse strain was generated by Professor Andrew Tobin 
(University of Leicester, UK) via homologous recombination replacing the WT M3 
muscarinic receptor with a phosphorylation deficient form, as described in detail in 
Kong et al. (2010). Previous studies have established that the M3 receptor is 
phosphorylated at multiple serines within the third intracellular loop (Budd et al., 
2000; Torrecilla et al., 2007). This KI model was generated by replacing 15 of these 
serine residues with alanine. Body weight and food consumption of M3 KI animals 
were not significantly different from their WT counterparts (Kong et al., 2010).  
4.2.8 Experiment 1. The effect of unilateral cervical vagotomy on exercise 
capacity 
The resting ABP and exercise capacity were determined in rats five and 32 
days after left (n=6) or right (n=6) cervical vagotomy or sham surgery (n=6). The 
effect of unilateral vagotomy on LV ejection fraction, contractile and HR responses 
to β-adrenoceptor stimulation (dobutamine, 0.5 mg kg-1; i.p.) were determined five 
days after the surgery. 
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4.2.9 Experiment 2. The effects of systemic muscarinic and nNOS blockade on 
exercise capacity 
Exercise capacity was first determined in rats 15 minutes after an acute i.p. 
injection of saline (n=5) or atropine methyl nitrate (2 mg kg
-1
; n=5). Then, sustained 
muscarinic receptor blockade was achieved by infusion of atropine (2 mg kg
-1
 h
-1
; 
i.p.) and exercise capacity was determined four hours after the treatment onset. 
Control animals (n=8) received infusion of saline over the same time period. 
To determine the subtype of muscarinic receptors that potentially mediate 
vagal modulation of exercise capacity, a separate group of rats (n=6) was 
administered with the M2 receptor antagonist AFDX116 (2 mg kg
-1
 h
-1
; i.p.) or 
vehicle (0.1% DMSO) for four hours.  Exercise capacity was also determined in M3 
KI mice (n=6) and their WT counterparts (n=8) before and after systemic treatment 
with the M3 receptor antagonist 4-DAMP (2 mg kg
-1
 h; i.p.) or vehicle for four 
hours.To determine the potential role of NO produced by nNOS, exercise capacity 
was determined in rats 45 min after an acute i.p. injection of 7-NI (30 mg kg
-1
) or 
vehicle (peanut oil) (n=8).  
4.2.10 Experiment 3. The effect of systemic muscarinic receptor blockade on 
cardiovascular response induced by β-adrenoceptor stimulation 
To determine the effect of acute and sustained systemic muscarinic receptor 
blockade on cardiovascular response induced by β-adrenoceptor stimulation, 
dobutamine was given intravenously (infusion 0.5 mg kg
-1
 min
-1
 for 2 min at a rate of 
0.1 ml min
-1
) 15 minutes and four hours after onset of atropine (2 mg kg
-1
 h
-1
 i.v.; 
n=5) or saline (n=5) infusion.  
4.2.11 Experiment 4. The effect of reduced DVMN activity on exercise capacity 
Exercise capacity of animals transduced to express AlstR/eGFP (n=6) or 
eGFP (n=6) by the DVMN neurones was determined over three consecutive days 
(Figure 4-3): day one to determine baseline exercise capacity; day two to determine 
exercise capacity in conditions of reduced DVMN activity (15 minutes following 
delivery of allatostatin [4 µl of 100 µM solution in aCSF] into the cisterna magna); 
and day three to determine exercise capacity after recovery from the treatment (see 
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experimental timeline Figure 4-3). Microinjections into the cisterna magna were 
performed via an internal injection cannula connected to PE-20 tubing attached to a 
50 µl syringe (Hamilton, Reno, NV) driven by a microinfusion pump (Sp210iw 
syringe pump, World Precision Instruments). In a separate experiment, changes in 
blood pressure and HR during and after exercise were determined in six rats 
expressing AlstR/eGFP and six rats expressing eGFP following allatostatin 
application.   
  
Chapter 4 The Vagal mechanisms Controlling Exercise Capacity 91 
 
 
 
 
 
Figure 4-3: Timeline for experiments investing the effect of reduced DVMN 
activity on exercise capacity. 
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4.2.12 Experiment 5. The effect of reduced DVMN activity on cardiovascular 
responses induced by β-adrenoceptor stimulation 
The animals transduced to express AlstR/eGFP (n=6) or eGFP (n=6) by the 
DVMN neurones were anaesthetised with urethane and prepared as described above. 
They were then left to stabilise for 15-30 min after the preparative surgery. To 
determine the effect of reduced DVMN activity on cardiovascular response induced 
by β-adrenoceptor stimulation, dobutamine was given intravenously (infusion 2 mg 
kg
-1
 min
-1
 i.v.; for two minutes at a rate of 0.1 ml min
-1
) before and 15 minutes after 
allatostatin administration into the cisterna magna. The heart was paced at 20% 
above resting HR.  
4.2.13 Experiment 6. The effect of DVMN stimulation on exercise contractile 
responses LV 
Exercise capacity of naïve rats (n=10) and animals transduced to express 
ChiEF-tdTomato (n=9) and eGFP (n=10) by the DVMN neurones was determined 
twice: on day one to determine baseline exercise capacity and on day six to 
determine the effect of treatment. In the interim four days (see the timeline illustrated 
in Figure 4-4), dorsal brainstem of rats expressing ChIEF-tdTomato and eGFP by the 
DVMN neurones was illuminated via a pre-implanted optrode with blue light (445 
nm, 10 ms pulses, 15 Hz) for 15 minutes under mild sedation (1.5 % isoflurane). A 
group of naïve animals were subjected to four sessions of treadmill exercise, training 
over four consecutive days with each session lasting up until the defined point of 
exhaustion. To determine the effect of enhanced DVMN activity and exercise 
training on inotropic response induced by β-adrenoceptor stimulation, LV ejection 
fraction and HR was determined using high-resolution ultrasound before and after 
dobutamine challenge (infusion 2 mg kg
-1
 min
-1
 i.v. for two minutes at a rate of 0.1 
ml min
-1
).  
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Figure 4-4: Timeline and stimulation paradigm for experiments to determine 
the effect of DVMN stimulation on exercise capacity 
A) Timeline illustrating the intervals between stages of animal preparation and acquisition of 
exercise data; B) Timeline illustrating the optogenetic stimulation paradigm in rats 
expressing ChIEF-tdtomato and eGFP as well as the naïve rats that underwent exercise 
training. 
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4.2.14 Humane end-points 
At the end of the experiments the animals were euthanised with an overdose 
of pentobarbitone sodium (200 mg kg
-1
, i.p.). 
4.2.15 Histology 
At the end of the experiments the rats were perfused through the ascending 
aorta with 0.9% NaCl solution followed by 500 ml 4% phosphate-buffered (0.1 M, 
pH 7.4) paraformaldehyde. The brains were then removed and stored in the same 
fixative overnight at 4 °C. After cryoprotection in 30% sucrose, the brainstem was 
isolated and a sequence of transverse slices (30 µm) was cut. The extent of 
AlstR/eGFP, ChiEF-tdTomato or eGFP expression was determined using confocal 
microscopy and mapped using a stereotaxic atlas (Paxinos & Watson, 1998). 
4.2.16 Immunoblotting 
The blots were performed in collaboration with Dr. Gareth Ackland. Cell 
lysates prepared from the LV tissue were immunoblotted with specific primary 
antibodies for GRK2 (C-9; Santa Cruz, sc-13143) and pan-arrestin (Abcam, ab2914) 
for β-arrestin2. Protein loading was assessed using the housekeeping protein α-
tubulin (Santa Cruz, sc53646). Proteins were resolved on SDS-PAGE gels and 
transferred to polyvinylidene difluoride membranes (Amersham Biosciences, 
Piscataway, NJ) according to the manufacturer’s instructions. After antibody 
labelling, detection was performed (ECL detection system, Amersham Biosciences, 
Piscataway, NJ). Densitometry determinations were calculated as the ratio between 
the protein and α-tubulin (Santa Cruz, sc53646) expression.  
4.2.17 Data Analysis 
Differences between the experimental groups were analysed using GraphPad 
Prism six software. Comparisons were made using a two-way ANOVA (followed by 
Sidak’s p value correction for multiple comparisons) or Student’s paired test, as 
appropriate. Data are reported as individual values and means ± s.e.m. Differences 
with P<0.05 were considered to be significant. 
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4.3 Results 
4.3.1  Experiment 1. The effect of unilateral cervical vagotomy on exercise 
capacity 
The rats appeared healthy following unilateral vagotomy. Food and water 
intake were not different from that of sham-operated animals and all rats gained 
similar weight over the course of 32 days after the surgery (Figure 4-5A). Exercise 
capacity was impaired five days after unilateral vagotomy (67±10 vs 134±20 J in 
sham-operated animals; p=0.006; ANOVA; Figure 4-4B). All groups of animals 
displayed similar exercise capacity 32 days after unilateral vagotomy or sham 
surgery (p=0.5; Figure 4-5B). Unilateral vagotomy was not associated with changes 
in resting LV ejection fraction (p=0.9; ANOVA; Figure 4-5C), HR (p=0.8; ANOVA; 
Figure 4-5D) or in contractile and HR responses to β-adrenoceptor stimulation 
(p=0.6; ANOVA; Figure 4-5C and D). Moderate elevation in the systemic ABP was 
observed in vagotomised animals 32 days after the surgery (137±3 vs 116±9 mmHg 
in sham-operated animals; p=0.04; ANOVA; Figure 4-5E).   
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Figure 4-5: The effect of unilateral cervical vagotomy on exercise capacity 
A) Summary data illustrating body weights of rats before as well as five and 32 days after left (n=6) or right (n=6) cervical vagotomy or sham surgery (n=6); 
B) Summary data illustrating exercise capacity of rats before as well as five and 32 days after left or right cervical vagotomy or sham surgery; C) Summary 
data illustrating resting ejection fraction and contractile response to dobutamine in rats five days after unilateral vagotomy or sham-surgery; D) Summary data 
illustrating resting heart rate and heart rate response to dobutamine in rats five days after unilateral vagotomy or sham-surgery. E) Summary data illustrating 
mean arterial blood pressure of rats before as well as five and 32 days after left or right cervical vagotomy or sham surgery. *P<0.05; **P<0.01; ***P<0.001. 
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4.3.2 Experiment 2. The effects of systemic muscarinic and nNOS blockade on 
exercise capacity 
Intraperitoneal administration of atropine 15 minutes prior to running tests 
had no effect on exercise capacity (p=0.865; paired t-test; Figure 4-6A). Sustained 
muscarinic receptor blockade (atropine infusion over a four hour period) was 
associated with a significant reduction in exercise capacity (48±10 vs 87±15 J 
compared to vehicle treatment; paired t-test; p=0.0013; Figure 4-6B). Administration 
of M2 receptor antagonist AFDX116 for the same time period had no effect on 
exercise capacity (93±17 vs 123±18 J compared to vehicle treatment; p=0.15; paired 
t-test; Figure 4-6C). Mice with global deficiency in M3 receptor phosphorylation 
(M3-KI mice) displayed an impaired exercise capacity as compared to their WT 
counterparts (130±18 vs 294±36 J; p=0.0006; ANOVA; Figure 4-6D). M3 receptor 
blocker 4-DAMP reduced exercise capacity in WT but not in M3-KI mice, while both 
groups of animals displayed similar exercise capacity in conditions of systemic 4-
DAMP treatment (p>0.9; Figure 4-6D). Exercise capacity was also dramatically 
reduced following systemic administration of the nNOS inhibitor 7-NI in the rats 
(31±10 vs 117±18 J after vehicle; p=0.0004; paired t-test; Figure 4-6E). 
Biotelemetry recordings confirmed effective systemic muscarinic receptor 
blockade by atropine, with treated animals displaying higher HR and reduced HRR 
after cessation of exercise (P<0.0001; Figure 4-7A). Atropine had no effect on the 
ABP and blood pressure responses to exercise (Figure 4-7B).  
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Figure 4-6: The effects of muscarinic and nNOS blockade on exercise capacity 
A) Summary data illustrating exercise capacity in rats 15 minutes after an acute i.p. injection 
of saline (n=5) or atropine methyl nitrate (2 mg kg
-1
); B) Summary data illustrating exercise 
capacity in conditions of sustained systemic muscarinic receptor blockade (i.p. atropine 
infusion, 2 mg kg
-1
 h
-1
 for 4 hours). C) Summary data illustrating exercise capacity in 
conditions of systemic M2 receptor blockade (i.p. infusion of AFDX116, 2 mg kg
-1
 h
-1
, for 4 
hours); D) Summary data illustrating exercise capacity of mice with global deficiency in M3 
receptor phosphorylation (M3 KI) and their wild type (WT) counterparts before and in 
conditions of systemic M3 receptor blockade (i.p. infusion of 4-DAMP, 2 mg kg
-1
 h
-1
; for 4 
hours). E) Summary data illustrating exercise capacity in rats 45 min after an acute i.p. 
injection of vehicle (peanut oil) (n=8) or nNOS inhibitor 7-NI (30 mg kg
-1
). *P<0.05; 
**P<0.01; ***P<0.001; ****P<0.0001. 
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Figure 4-7: The effect systemic muscarinic receptor blockade on heart rate and 
systemic arterial blood pressure of conscious rats during the course of exercise 
experiments in rats 
A) Summary data illustrating changes in heart rate during exercise in rats following an acute 
i.p. injection of saline or atropine methyl nitrate (2 mg kg
-1
); B) Summary data illustrating 
changes in blood pressure during exercise in rats following an acute i.p. injection of saline or 
atropine methyl nitrate (2 mg kg
-1
).  
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4.3.3 Experiment 3. The effect of systemic muscarinic receptor blockade on 
cardiovascular response induced by β-adrenoceptor stimulation 
Systemic muscarinic receptor blockade increased LVdP/dtmax (11303±160 vs 
10011±119 mmHg s
-1
 at baseline; P<0.0001; ANOVA; Figure 4-8A) and LVESP 
(139±2 vs 132±2 mmHg at baseline; p=0.04; ANOVA; Figure 4-8B). Infusion of the 
vehicle (saline) over the same period of time had no effect on cardiovascular 
variables (Figure 4-8A, B). Administration of dobutamine resulted in significant 
increases in LVdP/dtmax in control conditions (rats treated with saline) (10806±389 
vs 9252±356 mmHg s
-1
 at baseline; p=0.001; ANOVA; Figure 4-8A) as well as in 
animals following acute injection of atropine (11559±191 vs 10011±119 mmHg s
-1
 
at baseline; p=0.008; ANOVA; Figure 4-8A). Dobutamine also increased LVESP in 
control conditions (rats treated with saline) (135±3 vs 123±2 mmHg at baseline; 
p=0.0002; ANOVA; Figure 4-8B) as well as in animals following acute injection of 
atropine (139±5 vs 128±4 mmHg at baseline; p=0.002; ANOVA; Figure 4-8B).  
Under chronic (four hour) muscarinic receptor blockade, dobutamine had no 
further effect on LVdP/dtmax (11557±145 vs 11304±160 mmHg s
-1
 at baseline; 
p=0.2; ANOVA; Figure 4-8A) or LVESP (141±3 vs 139±2 mmHg at baseline; 
p=0.9; ANOVA Figure 4-8B).  In addition to β1-adrenoceptor agonism, dobutamine 
is also known to acts on β2- as well as α1-adrenoceptors (Ruffolo, 1987). This may 
explain the lack of dobutamine effect on ABP because of the resulting vasodilation 
counteracting its effect on the LV inotropic state (Figure 4-9A). HR increases 
induced by dobutamine where similar in control conditions as well as following 
sustained systemic muscarinic receptor blockade (484±4 vs 463±5 bpm at baseline; 
p=0.003; ANOVA; Figure 4-9B). 
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Figure 4-8: The effect of systemic muscarinic receptor blockade on LV contractile response to β-adrenoceptor stimulation 
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A) Summary data illustrating changes in LVdP/dtmax triggered by dobutamine challenge prior to as well as 15 minutes and four hours after the onset of 
atropine (2 mg kg
-1
 h
-1
 i.v.) or saline infusion. B) Summary data illustrating changes in LVESP triggered by dobutamine challenge prior to as well as 15 
minutes and four hours after the onset of atropine (2 mg kg
-1
 h i.v.) or saline infusion. Asterisk denotes significant effect of dobutamine. Plus denotes 
significant effect of atropine. **P<0.01; ***P<0.001; ****P<0.0001; 
+
P<0.05; 
++
P<0.01; 
+++
P<0.001. 
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Figure 4-9: The effect of systemic muscarinic receptor blockade on blood pressure and heart rate responses to dobutamine challenge 
A) Summary data illustrating values of mean arterial blood pressure during dobutamine challenge prior to as well as 15 minutes and four hours after the onset 
of atropine (2 mg kg
-1
 h
-1
 i.v.) or saline infusion.  B) Summary data illustrating changes in HR triggered by dobutamine challenge prior to as well as 15 
minutes and four hours after the onset of atropine (2 mg kg
-1
 h
-1
 i.v.) or saline infusion. Asterisk denotes significant effect of dobutamine. Plus denotes 
significant effect of atropine. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001; 
++++
P<0.001. 
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4.3.4 Experiment 4. The effect of reduced DVMN activity on exercise capacity 
Histological reconstruction has demonstrated strong expression of 
AlstR/eGFP along the rostro-caudal extent of both DVM nuclei. Figure 4-10A 
illustrates AlstR expression in a caudal aspect of the DVMN. Exercise capacity at 
baseline was similar in rats expressing AlstR/eGFP and eGFP (140±15 vs 191±22 J; 
p=0.53; ANOVA; Figure 4-10B). Infusion of allatostatin into the cisterna magna of 
rats expressing AlstR in the DVMN resulted in a dramatic reduction in exercise 
capacity (8±2 vs 202±27 J in rats expressing eGFP; P<0.0001; ANOVA; Figure 
4-10B). Exercise capacity of rats in the treatment group recovered within the next 24 
hour period (152±15 vs 140±15 J at baseline; p=0.7; ANOVA; Figure 4-10B). 
Biotelemetry monitoring has demonstrated that reduced DVMN activity results in a 
small increase in the ABP (111±3 vs 103±4 mmHg at baseline; p=0.03; ANOVA; 
Figure 4-10C), which was found to be independent of HR changes (364±13 vs 
350±12 bpm at baseline; p=0.9; ANOVA; Figure 4-10D). Interestingly, peak 
increases in ABP during exercise were lower in rats expressing AlstR/eGFP 
following application of allatostatin (120±2 vs 135±7 mmHg in rats expressing 
eGFP; p=0.03; ANOVA; Figure 4-10C). Peak HR during exercise was also lower in 
rats expressing AlstR/eGFP (546±12 vs 510±2 bpm in rats expressing eGFP; p=0.03; 
ANOVA; Figure 4-10D). 
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Figure 4-10: The effect of reduced DVMN activity on exercise capacity and 
cardiovascular response to exercise 
Confocal image of a representative coronal section of the rat brainstem showing the 
distribution of vagal preganglionic neurones transduced to express AlstR/eGFP in the caudal 
regions of the left and right nuclei. CC, central canal; B) Summary data illustrating the effect 
of allatostatin infusion into the cisterna magna on exercise capacity in rats transduced to 
express eGFP or Alst/eGFP in the DVMN. C, D) Summary data illustrating the effect of 
allatostatin infusion into the cisterna magna on exercise-induced changes in the systemic 
arterial blood pressure and HR in rats transduced to express eGFP or Alst/eGFP in the 
DVMN. Asterisk denotes significant effect of DVMN silencing. Plus denotes significance 
with respect to eGFP. *P<0.05; ****P<0.0001; 
+
P<0.01. 
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4.3.5 Experiment 5. The effect of reduced DVMN activity on cardiovascular 
response induced by β-adrenoceptor stimulation 
Administration of dobutamine triggered significant increases in LVdP/dtmax 
in rats expressing eGFP (10304±94 vs 9612±216 mmHg s
-1
 at baseline; p=0.03; 
ANOVA; Figure 4-11A) and AlstR/eGFP (11808±356 vs 10744±459 mmHg s
-1
 at 
baseline; p=0.0003; ANOVA; Figure 4-11A) in the DVMN. Dobutamine also 
triggered significant increases in LVESP in rats expressing eGFP (128±7 vs 119±9 
mmHg at baseline; p=0.03; ANOVA; Figure 4-11B) and AlstR/eGFP (169±6 vs 
148±6 mmHg s
-1
 at baseline; p<0.0001; ANOVA; Figure 4-11A) in the DVMN. 
Dobutamine had a similar effect on LVdP/dtmax (10535±211 vs 9836±240 
mmHg s
-1
 at baseline; p=0.03; ANOVA; Figure 4-11A) and LVESP (143±16 vs 
121±10 mmHg at baseline; p=0.02; ANOVA; Figure 4-11B) in rats expressing eGFP 
following allatostatin infusion. In conditions of reduced DVMN activity (allatostatin 
application in rats expressing AlstR/eGFP), dobutamine had no effect on LVdP/dtmax 
(11234±552 vs 11278±540 mmHg s
-1
 at baseline; p>0.9; ANOVA; Figure 4-11A) 
and LVESP (164±6 vs 165±7 mmHg at baseline; p>0.9; ANOVA; Figure 4-11B). 
Dobutamine had no effect on mean ABP in either group of animals prior to and after 
allatostatin application (p>0.1 for all comparisons; Figure 4-11C).  
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Figure 4-11: The effect of reduced DVMN activity on cardiovascular response 
induced by β-adrenoceptor stimulation 
A) Summary data illustrating changes in LVdP/dtmax triggered by dobutamine challenge 
prior to as well as 15 minutes after allatostatin infusion into the cisterna magna of rats 
expressing eGFP or AlstR/eGFP in the DVMN; B) Summary data illustrating changes in 
LVESP during dobutamine challenge prior to as well as 15 minutes after allatostatin infusion 
into the cisterna magna of rats expressing eGFP or AlstR/eGFP in the DVMN C) Summary 
data illustrating MAP changes triggered by dobutamine challenge prior to as well as 15 
minutes after allatostatin infusion into the cisterna magna of rats expressing eGFP or 
AlstR/eGFP in the DVMN. Asterisk denotes significant effect of dobutamine. *P<0.05; 
**P<0.01; ***P<0.001; ****P<0.0001. 
 Chapter 4 The Vagal mechanisms Controlling Exercise Capacity 107 
 
 
4.3.6 Experiment 6. The effect of DVMN stimulation on exercise capacity and 
contractile properties of the LV 
Strong expression of ChIEF-tdTomato by the DVMN neurones (Figure 4-
12A, B) resulted in insertion of light sensitive ChIEF-tdTomato along the length of 
the neuronal axons reaching the level of the cervical vagus (Figure 4-12C). Rats 
expressing ChIEF-tdTomato by the DVMN neurones displayed significantly higher 
exercise capacity of 15 minutes of optogenetic stimulation (daily) after four days 
(94±11 vs 47±6 J in rats expressing eGFP; p=0.002; ANOVA; Figure 4-13A). This 
improvement in exercise capacity was similar to that observed in the naïve rats that 
underwent exercise training to the defined point of exhaustion over the same time 
period (105±16 vs 47±6 J in rats expressing eGFP; p<0.0001; ANOVA; Figure 4-
13A). Thus, optogenetic stimulation of the DVMN neurones and exercise training 
over the course of four days appear to have a similar effect on exercise capacity 
(p=0.8; ANOVA).  
Furthermore, ultrasound assessment of LV function demonstrated that 
baseline ejection fraction was increased as a result of four days of optogenetic 
DVMN stimulation (75±2% in rats expressing ChIEF-tdTomato vs 62±1 % in rats 
expressing eGFP; p<0.0001; ANOVA; Figure 4-13B). The ejection fraction was 
unchanged in rats that underwent exercise training to the defined point of exhaustion 
over the same time period (67±2 vs 62±1 % in rats expressing eGFP; p=0.09; Figure 
4-13B). Optogenetic stimulation of the DVMN also resulted in a significantly higher 
ejection fraction during the dobutamine challenge (93±1 vs 84±2% in rats expressing 
eGFP; p=0.003; ANOVA; Figure 4-13B). Interestingly there were no significant 
differences in HR between all groups of animals either at baseline or during 
dobutamine challenge (Figure 4-13C).  
Western blot analysis has demonstrated that optogenetic recruitment of the 
DVMN activity is associated with downregulation of GRK2 expression in the LV 
(normalised to the expression of α-tubulin) when compared to that in animals 
expressing eGFP (0.45±0.42 vs 0.97±0.19; Figure 4-14A) or rats that underwent 
exercise training (0.45±0.42 vs 1.37±0.15; p=0.004; t-test; Figure 4-14A). Similarly, 
optogenetic recruitment of the DVMN activity led to downregulation of β-arrestin 
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expression in the LV when compared to that in animals expressing eGFP (0.49±0.07 
vs 0.88±0.07; Figure 4-14B) or rats that underwent exercise training (0.49±0.07 vs 
1.10±0.08; p=0.004; t-test;  Figure 4-14B).   
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Figure 4-12: Targeting DVMN neurones to express ChIEF-tdTomato 
A) Confocal image of a coronal section of the rat brainstem targeted to express ChIEF-
tdTomato by the DVMN neurones. Neurones display membrane localisation of the 
transgene. Ventrally projecting axons (arrow) of the DVMN neurones transduced to express 
ChIEF-tdTomato; B) Low-magnification image illustrating unilateral expression of ChIEF-
tdTomato by the DVMN neurones. CC, central canal.; C) Axons (arrows) of the DVMN 
neurones transduced to express ChIEF-tdTomato visualised in the whole mount preparation 
of the left vagus nerve. ChIEF-tdTomato is eventually inserted along the whole length of the 
neuronal axons.
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Figure 4-13: The effect of DVMN stimulation on exercise capacity and contractile properties of the LV 
A) Summary data illustrating exercise capacity of rats transduced to express ChiEF-tdTomato (n=9) and eGFP (n=10) by the DVMN neurones before and 
after four days of light stimulation of the dorsal brainstem via a pre-implanted optrode (daily sessions each lasting 15 minutes), as well as of a separate group 
of naïve animals before and after four daily sessions of treadmill exercise training. B, C) Summary data illustrating LV ejection fraction and HR at baseline 
and during dobutamine challenge (infusion 0.5 mg kg
-1
 min
-1
, two minutes at a rate of 0.1 ml min
-1
) in rats transduced to express ChiEF-tdTomato or eGFP by 
the DVMN neurones before and after four days of light stimulation, as well as in naïve animals before and after four daily sessions of treadmill exercise 
training. Asterisk denotes significant effect of DVMN stimulation. Plus denotes significant effect of dobutamine. **P<0.01; ****P<0.0001; 
+++
P<0.001; 
++++
P<0.0001. 
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Figure 4-14: The effect of DVMN stimulation on GRK2 and pan-arrestin 
expression in the LV 
Representative immunoblots and summary data illustrating GRK2 (A) and pan-arrestin (B) 
(for βarrestin2) expression in the LV of rats transduced to express ChIEF-tdTomato (ChIEF) 
and eGFP by the DVMN neurones after four days of light delivery to the dorsal brainstem, 
as well as of naïve animals after four daily sessions of treadmill exercise training. Asterisk 
denotes significant effect of DVMN stimulation. *P<0.01. 
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4.4 Discussion 
4.4.1 The effects of unilateral vagotomy and systemic treatment with atropine 
This experimental study was designed to test the hypothesis that the strength 
of parasympathetic cardiac tone determines exercise capacity. It was predicted that 
vagal withdrawal decreases and vagal recruitment enhances ability to exercise. Based 
on the results of the experiments reported in Chapters 1 and 2 suggesting that the 
DVMN neuronal projections control electrical and contractile properties of the LV, it 
was therefore hypothesised that the activity of this population of VPNs determines 
exercise capacity. 
A significant reduction in exercise capacity was observed in rats following 
unilateral vagotomy, sustained (four hours) systemic muscarinic receptor blockade or 
inhibition of the neuronal NOS. Exercise capacity was also reduced in mice deficient 
in M3 muscarinic receptor-mediated signalling and in WT mice in conditions of 
systemic M3 muscarinic receptor blockade. Acute reduction in the activity of the 
DVMN neurones using a pharmacogenetic approach resulted in a dramatic lowering 
of exercise capacity and inability of the LV to mount a contractile response to β-
adrenoceptor stimulation. Optogenetic recruitment of the DVMN activity improved 
exercise capacity and contractile properties of the LV, and this was associated with 
downregulation of the ventricular GRK2 and β-arrestin expression. 
Unilateral vagotomy reduced exercise capacity in rats by approximately 50% 
when assessed five days after the surgery. Exercise capacity was similar in 
vagotomised and sham-operated animals 32 days after the surgery. Ultrasound 
assessment showed no significant changes in LV ejection fraction or HR as a result 
of unilateral vagotomy when measured after five days. Recovery of exercise capacity 
at 32 days post-surgery could be explained by functional compensation by the 
remaining intact nerve or (partial) re-innervation of the resected side. There is 
evidence that re-innervation may occur as shown by observations in heart transplant 
patients who display low amplitude RSA two weeks after the surgery (Zbilut et al., 
1988) and exhibit a dramatic (>200%) increase in power of the high frequency 
component of the HRV (as a measure of cardiac vagal tone) 28 months following 
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transplantation. Significant recovery of the high frequency component of the HRV 
cannot be explained by the intrinsic HR response to myocardial wall stretch 
(Bernardi et al., 1989) and suggests functional parasympathetic innervation of the 
transplanted heart.  
Systemic muscarinic receptor blockade (administration of atropine methyl 
nitrate) lasting 15 minutes had no effect on exercise capacity. However, 
administration of atropine for four hours (sustained muscarinic blockade mimicking 
chronic vagal withdrawal) reduced exercise capacity by approximately 40%. It was 
hypothesised that sustained muscarinic blockade impairs the ability of LV to mount 
an appropriate contractile response to sympathetic stimulation. In rats kept under 
urethane anaesthesia, atropine infusion increased LV contractility (as assessed by 
recordings of LVdP/dtmax and LVESP) and no further increase was observed during 
dobutamine challenge. Inability of the LV to respond to sympathetic stimulation may 
be responsible (at least in part) for impaired exercise capacity following four hours 
of atropine infusion. However, since atropine infusion for four hours was associated 
with significant increases in HR and LV inotropy at baseline, which may have also 
resulted in systemic toxic effects (Zhang et al., 2001), a different experimental 
approach (acute and reversible manipulation of ventricular vagal innervation) was 
required. 
This effect of systemic muscarinic receptor antagonism on exercise capacity 
was further investigated using the genetic and pharmacological blockade of M2 and 
M3 receptor-mediated signalling. Systemic administration of M2 receptor blocker 
AFDX116 for four hours had no effect on exercise capacity suggesting that M2 
receptor antagonism is not responsible for the observed effects of atropine. On the 
other hand, exercise capacity was found to be significantly impaired in mice with 
global deficiency in M3 receptor phosphorylation, with similar reductions in exercise 
capacity being observed in WT mice in conditions of systemic M3 receptor blockade 
(infusion of 4-DAMP for four hours). These data suggest that the detrimental effect 
of systemic atropine infusion on exercise capacity is likely due to blockade of a 
mechanism involving M3 receptor-mediated signalling. 
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M2 receptors are Gi-coupled and constitute the most abundant type of cardiac 
muscarinic receptors. M3 receptors signal via Gq proteins and have been 
demonstrated to be involved in smooth muscle relaxation and glandular secretion 
(Kruse et al., 2012), including insulin secretion (Kong et al., 2010). M3 receptor 
expression in the mammalian heart has also been demonstrated (Wang et al., 2004) 
(Liu et al., 2005; Liu et al., 2008; Pan et al., 2012; Hang et al., 2013).  
Potential mechanisms of how M3 receptor-mediated signalling determines 
exercise capacity is discussed in terms of its potential role in the control of perfusion, 
contractile function and metabolism.  
4.4.2 Crosstalk between M3 and β2-adrenoceptor signalling 
Functional interactions between M3 muscarinic and β2-adrenoceptor mediated 
signalling pathways have been demonstrated (Budd et al., 1999) and can provide a 
plausible explanation for impaired exercise capacity in conditions of either genetic or 
pharmacological blockade of M3 signalling. G protein-coupled receptor kinase 2 
(GRK2) activity is modulated by Gβγ and phosphatidylinositol 4,5-bisphosphate 
(Krasel et al., 2005), as well as stimulation of β2-adrenoceptors (Sallese et al., 2000). 
GRK2 phosphorylation of β2-adrenoceptor increases the affinity for binding of β-
arrestins 1 and 2 with subsequent desensitisation and internalisation of this receptor 
complex (Krasel et al., 2005).  
Under normal conditions, phospholipase C recruitment downstream of M3 
receptor activation increases intracellular Ca
2+
 (Tobin et al., 1992; Willars et al., 
1996). Raised intracellular Ca
2+ 
activates protein kinase C, which increases GRK2 
activity (Sallese et al., 2000). Under conditions of prolonged M3 receptor blockade, 
adaptive down-regulation of β2-adrenoceptor expression could occur given that they 
exhibit higher constitutive activity (basal cAMP levels are five times higher than that 
associated with constitutive activity of β1-adrenoceptors) in addition to robust 
internalisation (Engelhardt et al., 2001). The lowered threshold would thus reduce 
the cAMP response, limiting the magnitude of vasodilation due to activation of β2-
adrenoceptors (Ruffolo, 1987). During exercise, sympathetic signalling via vascular 
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β2-adrenoceptors is believed to contribute significantantly to coronary vasodilation 
(Duncker et al., 1998; Gorman et al., 2000). If M3 receptor blockade impairs the 
efficacy of β2-adrenoceptor-mediated signalling (via GRK2 up-regulation) then 
coronary vascular response may be compromised and insufficient to meet the 
increased metabolic demands of the myocardium during exercise. 
Blockade of M3-meidated signalling may also be associated with reduced 
activity of protein kinase D1 (PKD1). There is evidence that uncoupling of M3 
receptor from its cognate proteins upon activation (Kong et al., 2010) may result in 
recruitment of intracellular signalling pathways independent of those mediated by G-
proteins. This occurs predominantly through β-arrestin dependant signalling 
(Kreienkamp, 2002; Bockaert et al., 2004; Lefkowitz et al., 2006; Reiter & 
Lefkowitz, 2006) involving activation of PKD1 (Kong et al., 2010). In the cardiac 
muscle, PKD1 plays an important role in mediating glucose uptake by translocation 
of the glucose transporter GLUT4 (Dirkx et al., 2012). GLUT4 is responsible for the 
majority of glucose uptake in both cardiac (Dirkx et al., 2012) and skeletal muscles 
(Richter & Hargreaves, 2013). Despite being responsible for most of glucose uptake, 
it is mostly stored within intracellular vesicles due to its high affinity for glucose 
(Montessuit & Lerch, 2013). Assuming this hypothesis were true, it would be 
unsurprising that unilateral vagotomy would not affect baseline cardiac parameters 
given the ventricular capacity for autocrine release of ACh under normal and 
ischaemic challenge (Akiyama et al., 1994; Kawada et al., 2009).  
Brack et al. (2009) demonstrated that coronary infusion of ACh triggers NO 
production from a non-neuronal source, which they suggest to be eNOS. As the 
endocardial layers are more metabolically demanding (Kainulainen et al., 1990) it 
would be very interesting to study the metabolic dynamics of this layer with regard 
to NO, given that the endocardium is subject to the most distension, which can affect 
the production of NO (Pinsky et al., 1997). The transmural β2 heterogeneity between 
the subepicardium and the subendocardium in particular (Hein et al., 2004) results in 
a somewhat counterintuitive shunting to the less metabolically demanding 
epicardium in both normal and infarcted hearts (Berdeaux et al., 1979; Domenech & 
MacLellan, 1980). 
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Systemic blockade of nNOS (using 7-NI) was found to have the most 
significant detrimental (reduction by >70%) effect on exercise capacity. NO 
produced by nNOS expressed by cardiac parasympathetic fibres is known to 
facilitate presynaptic release of ACh and nNOS blockade was previously found to 
disrupt muscarinic transmission (Choate et al., 2001; Danson et al., 2004). There is 
also evidence that exercise training increases nNOS expression at cardiac vagal 
presynaptic terminals (Danson & Paterson, 2003). Inhibition of endothelial NOS 
(eNOS) may also (in part) explain the effect of 7-NI on exercise capacity.  
Compromised coronary (and possibly skeletal) perfusion (Hein & Kuo, 1999; 
Paterson, 2001) and glucose uptake could explain the dramatic effects of 7-NI on 
exercise capacity. NO also appears to have a significant positive lusitropic effect 
(Pinsky et al., 1997). NO improves ventricular relaxation (Smith et al., 1991) (Shah, 
1996), therefore, blockade of NO production may compromise effective ventricular 
filling required to increase cardiac output during exercise. 
4.4.3 The DVMN has a source of acetylcholine and nitric oxide 
Acute inhibition of the DVMN VPNs targeted to express AlstR was 
associated with dramatic (by 87%) reduction of exercise capacity already 15 minutes 
after allatostatin application. Full recovery of exercise capacity was observed within 
the next 24 hours. Inhibition of DVMN neurones had no effect on HR but resulted in 
a small increase in MAP (by 7 mmHg). Importantly, in rats kept under urethane 
anaesthesia combined with atrial pacing, stimulation of β-adrenoceptors with 
dobutamine had no effect on LVdP/dtmax and LVESP when the activity of DVMN 
neurones was reduced.  
These results, considered together with data obtained in pharmacological 
experiments involving systemic muscarinic and nNOS blockade, argue in favour of a 
critical role played by vagal innervation of the ventricle, which maintains the ability 
of the LV to mount an appropriate contractile response to sympathetic stimulation. 
Acute nNOS inhibition and acute DVMN silencing were found to have quantitatively 
similar detrimental effects on exercise capacity. This suggests that the DVMN 
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neuronal projections control LV function and exercise capacity, using NO as a 
signalling molecule. The concept of a direct NO-mediated vagal control of the 
ventricle is supported by the data presented in Chapter 2 of this thesis as well as in 
previous studies (Brack et al., 2009; Brack et al., 2011). Conflicting with this is a 
previous exercise study which has shown that mice deficient in nNOS (nNOS-/-) do 
not appear to have a compromised exercise capacity (Wadley et al., 2007). This 
could be explained by a compensatory overexpression of the remaining functional 
isoforms. 
Vagal innervation of the LV mediated by muscarinic mechanisms is 
hypothesised to provide a trophic influence, the significance of which becomes clear 
over a longer period of time. Optogenetic recruitment of the DVMN neurones (four 
daily sessions of 15 minute long stimulations) improved exercise capacity and 
contractile function of the LV. The degree of exercise capacity improvement was 
quantitatively similar to that observed in a group of naïve rats subjected to exercise 
training over the same time period. However, no improvement in LV contractile 
function was observed in the latter group of rats. Changes in LV inotropy following 
optogenetic DVMN recruitment were not associated with any significant changes in 
HR. Preliminary blots conducted in collaboration with the research group of Dr. 
Gareth Ackland have demonstrated that optogenetic stimulation of the DVMN 
results in down regulation of GRK2 and pan-arrestin expression in the LV 
myocardium. There is evidence that reduced expression of GRK2 unmasks the 
significant contractile effect of β2–adrenoceptor stimulation, which is either weak or 
absent under normal conditions (Salazar et al., 2013). Increased vagal efferent 
activity and recruitment of PKD1 via activation of the M3 receptor had also been 
shown to promote cardiac hypertrophy and angiogenesis (Rozengurt, 2011). 
Increased efficacy of β2–adrenoceptor-mediated signalling in LV cardiomyocytes 
may therefore explain changes in resting inotropic state underlying the ability of the 
LV to mount a stronger inotropic response during exercise.  
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4.4.4 Vagal tone and plasticity 
These data show that the strength of vagal tone supplied to the LV by the 
DVMN neurones determines the ability of cardiomyocytes to respond to sympathetic 
stimulation and would, therefore, determine exercise capacity. Nevertheless, 
differences in individual ability to exercise may reflect varying levels of DVMN 
activity. High vagal tone provided by the DVMN neuronal projections to the LV in 
elite athletes could make them highly tolerant to intense exercise regimes. 
Conversely, the loss of exercise capacity with age has been associated with a decline 
in autonomic function (De Meersman & Stein, 2007). Neurones such as those of the 
DVMN have long projecting axons with no myelination and require more energy for 
impulse propagation and are the most susceptible to metabolic stress (Kapfhammer 
& Schwab, 1994). DVMN dysfunction has already been associated with a host of 
autonomic abnormalities (Braak et al., 2002; Goldberg et al., 2012) and may 
contribute to a progressive decline in exercise capacity during aging and in various 
disease states. 
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4.5 Study Limitations 
With regards to the gene transfer work to silence the DVMN neurones, the 
viral titres for the constructs used were not reliably known. Acceptable expression 
was predetermined by injection in test subjects allowing four weeks prior to 
conducting histology. The extent of expression could have instead been evaluated via 
polymerase chain reaction as titres would inevitably vary, given the titre loss of the 
lentiviral constructs immediately after thawing.  
In view of the current debate as to whether parasympathetic tone exhibits a 
certain degree of plasticity (Coote & White, 2015; D'Souza et al., 2015) in such a 
way that exercise may entrain a high resting vagal tone calls for an additional line of 
inquiry. It may well be that exercise and/or optogenetic stimulation could be 
modulating lower vagal interneuron circuitry or even be eliciting changes within the 
pacemaker itself. It would be important, then, to perform electrophysiological 
recordings from the DVMN neurones firstly in an anaesthetised preparation during 
simulated exercise. Such simulations could involve passive limb movement, femoral 
or sciatic nerve stimulation or dobutamine challenges. To test the hypothesis that 
regular exercise increases DVMN activity, experimental animals could be provided 
with an opportunity to exercise (e.g. running wheels in home cages). Running wheels 
can be used to quantify and correlate exercise capacity with spiking activity and 
excitability of the DVMN neurones. Voluntary running wheels would also be a 
superior method of exercising rodents given the additional stress that is inevitably 
experience with forced running experiments.  
In summary, the data reported in this chapter confirms the validity of the 
hypothesis that the strength of parasympathetic tone determines exercise capacity. 
The results show that reduced activity of the DVMN VPNs impairs and increased 
activity of the DVMN enhances exercise capacity and contractile function of the LV. 
These effects are mediated by the actions of ACh and NO and may involve 
alterations in the expression of important regulatory proteins, namely GRK2 and β-
arrestin, by cardiomyocytes. In his work Vagus as a regulator of systemic arterial 
blood pressure Ivan Pavlov concluded that “the vagus nerve exerts trophic influence 
 Chapter 4 The Vagal mechanisms Controlling Exercise Capacity 120 
 
 
on the ventricle and prepares it for action” (Khaiutin & Lukoshkova, 1995). Indeed, 
results of this study obtained using pharmacological blockade, M3-KI genetic mouse 
model, pharmaco- and optogenetic approaches to alter the activity of the DVMN 
VPNs reveal that vagal supply to the LV maintains the ability of the heart to mount 
an appropriate inotropic response during increased activity and exercise. 
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 Enhancing Vagal Activity in Heart Failure Chapter 5
5.1 Introduction 
Ischaemic heart disease is one of the most common causes of morbidity and 
mortality in the developed world. Occlusion of a major coronary artery is followed 
by myocardial metabolic and functional changes that develop rapidly after cessation 
of the blood flow (Jennings et al., 1990). Despite rapid reperfusion of the ischaemic 
area by primary percutaneous coronary intervention (preferred current treatment of 
an acute MI), many patients develop large infarcts, progress to chronic heart failure 
and have a poor prognosis. Manifestations of myocardial injury include arrhythmias, 
contractile and endothelial dysfunction and lethal reperfusion injury of 
cardiomyocytes (Hearse & Bolli, 1992; Hearse, 1998; Sanada et al., 2011). The latter 
contributes approximately 50% to the resultant infarct size (Hausenloy & Yellon, 
2008). 
VNS has been shown to reduce the extent of MI and slow the progression of 
myocardial remodelling and dysfunction in several animal models of chronic heart 
failure (Jones et al., 2009; Katare et al., 2009; Calvillo et al., 2011; 
Shinlapawittayatorn et al., 2013). Although there is a clear clinical association 
between low (chronotropic) vagal tone and poor cardiovascular outcomes (La Rovere 
et al., 1998; Nolan et al., 1998; Schwartz, 1998; Schwartz et al., 2004; Schwartz, 
2012), the precise mechanisms underlying the beneficial effect of VNS during heart 
failure are poorly understood.  
A potential benefit of VNS has been recently explored in 32 patients with 
chronic heart failure, using implantable devices capable of delivering low current 
pulses to stimulate the right vagus nerve. Reported results showed improvements in 
NYHA class quality of life and LV function (De Ferrari et al., 2011) and led to 
multicentre clinical trials (NECTAR-HF, INOVATE-HF) designed to test VNS 
efficacy in large cohorts of patients (Hauptman et al., 2012). However, these trials 
were initiated without full understanding of the underlying mechanism(s). In the 
CardioFit preliminary trial (De Ferrari et al., 2011), 26 serious adverse events 
occurred in 13 of 32 patients enrolled (41%), including three deaths within the first 
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three months. The NECTAR-HF study (Zannad et al., 2015) was the first 
randomised controlled trial evaluating the safety and efficacy of VNS applied to the 
right vagus nerve. Enrolling 96 heart failure patients, no improvements in the 
objective measures of cardiac function were found after six months of stimulation. 
However, a marginal improvement in quality of life was reported (Zannad et al., 
2015).  
The vagus nerve is one of the most complex nerves; it contains sensory and 
motor fibres which conduct impulses from and to the majority of the internal organs. 
It is not clear whether the beneficial effects of VNS are due to activation of the 
efferent or afferent fibres. Recently it was found that stimulation of approximately 
300-400 vagal preganglionic DVMN neurones is capable of reducing acute 
myocardial ischaemia/reperfusion injury in an animal model (Mastitskaya et al., 
2012), providing direct evidence of potent cardioprotection via stimulation of the 
efferent vagus.  
Further refinement of VNS allowing selective recruitment of a particular 
population of vagal fibres is expected to maximise efficacy and limit side effects that 
include cough, dysphonia, sleep apnoea and others (Parhizgar et al., 2011). It was 
hypothesised that the beneficial effect of the VNS in heart failure is conferred by the 
vagal efferent fibres which innervate the LV. The data reported in Chapters 2 to 4 
suggest that functionally significant vagal innervation of the ventricle originates in 
the DVMN. This chapter describes the results of the experiments aimed to determine 
whether optogenetic recruitment of the DVMN activity slows the remodelling 
process and improves LV function post-MI in a rat model.  
Clinically, the assessment of diastolic function is routinely performed using 
Doppler echocardiographic recordings of the blood flow velocity across the mitral 
valve (Poulsen et al., 1999). In this chapter, Doppler recordings of mitral flow were 
used to assess global, systolic and diastolic function. Diastolic dysfunction 
contributes to the aetiology of congestive heart failure, being present in 
approximately 40% of heart failure patients (van Kraaij et al., 2002). LV relaxation 
is an energy-dependent process that requires dissociation of the bridges formed 
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between actin and myosin filaments during contraction. This can only occur when 
cystolic Ca
2+
 is actively removed by sarcoplasmic reticulum calcium transporting 
ATPase. A mechanism in which function is impaired due to compromised supply of 
energy substrates in the failing heart (Frank et al., 2002), leading to diastolic 
dysfunction (Aroesty et al., 1985).  
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5.2 Methods 
All the experiments were performed on rats in accordance with the European 
Commission Directive 2010/63/EU (European Convention for the Protection of 
Vertebrate Animals used for Experimental and Other Scientific Purposes) and the 
UK Home Office (Scientific Procedures) Act (1986) with project approval from the 
UCL Animal Care and Use Committee. 
5.2.1 Genetic targeting of the DVMN vagal preganglionic neurones 
Young male Sprague-Dawley rats (100-150 g, n=68) were anaesthetised with 
ketamine (60 mg kg
-1
; i.m.) and medetomidine (250 µg kg
-1
; i.m.). Adequate depth of 
surgical anaesthesia was confirmed by the absence of a withdrawal response to a paw 
pinch. With the head fixed prone in a stereotaxic frame, lidocaine (2% solution) was 
injected subcutaneously for pre-operative analgesia before a midline dorsal neck 
incision was made to expose the atlanto-occipital membrane and then the dorsal 
surface of the brainstem. The DVMN was targeted bilaterally with one 
microinjection per side (0.25 µL at a rate of 0.05 µL min
-1
) of a solution containing 
viral particles of PRSx8-ChIEF-tdTomato-LVV or PRSx8-eGFP-LVV. Taking the 
calamus scriptorius as the reference point, the injections were made at 0.5 mm 
rostral, 0.6 mm lateral, 0.8 mm ventral. Only caudal populations of DVMN neurones 
were targeted as they have been shown to exert the most significant impact on LV 
function (Chapter 2 and 3) and their optogenetic stimulation was found to increase 
LV inotropy and improve exercise capacity (Chapter 4). Anaesthesia was reversed 
with atipemazole (1 mg kg
-1
; i.m.). For post-operative analgesia, rats were 
administered with buprenorphine (0.05 mg
 
kg
-1 
d
-1
; s.c.) for three days and caprofen 
(4 mg kg
-1
 d
-1
; i.p.) for five days. The established titres at the time of production 
were within the range of 1 x 10
9
 and 1 x 10
10
 transducing units ml
-1
. 
5.2.2 Optrode implantations 
Two weeks after microinjections of viral vectors into the DVMN (Figure 
5-2), the animals were anaesthetised with ketamine (60 mg kg
-1
; i.m.) and 
medetomidine (250 µg kg
-1
; i.m.), and a conically tipped optrode (Art Photonics) was 
stereotaxically implanted under the occipital bone to reach the dorsal aspect of the 
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cisterna magna. Two small screws were placed in the skull, and the implant was 
secured in place with dental acrylic. Anaesthesia was reversed with atipemazole (1 
mg kg
-1
; i.m.) and the animals were allowed to recover for the next seven days. 
5.2.3 Myocardial infarction 
Myocardial infarctions were performed with the help of Dr. Svetlana 
Mastitskaya. Myocardial infarction (MI) leading to LV remodelling and dysfunction 
was induced using a left anterior descending (LAD) artery occlusion technique 
described in detail in the scientific literature (Pfeffer et al., 1979). One week 
following optrode implantations (Figure 5-2), the rats were anaesthetised with 
ketamine (60 mg kg
-1
; i.m.) and medetomidine (250 µg kg
-1
; i.m.). For efficient 
intubation and in order to minimise trauma to tracheal soft tissue, the rats were pre-
treated with atropine methyl nitrate (2 mg
-1
 kg
-1
; i.p.; 15 minutes before anaesthesia 
induction) to reduce bronchial secretions and spasms (Wu et al., 1992). In addition, 
lidocaine (2% solution) was applied to the throat using a cotton bud applicator 
immediately prior to endotracheal intubation on a custom designed vertical stand 
(Vet-Tech, UK).  
The animals were mechanically ventilated with oxygen-enriched air (tidal 
volume 0.8 ml/100 g of body weight, 60-80 breaths min
-1
). A left thoracotomy was 
performed through the fourth intercostal space to expose the heart, the pericardium 
was opened and the heart was exteriorised. The LAD coronary artery was ligated 
below the left atrial appendage using a 4-0 merisilk suture. Successful LAD 
occlusion was confirmed by pallor of the anterior wall of the LV. Sham surgery 
involved the same sequence of procedures including exposure of the heart and 
placement of suture around the LAD artery without occlusion. The heart was then 
returned to the chest cavity, the incision was closed, and the endotracheal tube was 
removed. Anaesthesia was reversed with atipemazole (1 mg kg
-1
; i.m.) and rats were 
kept for two hours in a recovery chamber set at 30 °C supplied with 1:1 O2/air 
mixture. For post-operative analgesia, rats were administered with buprenorphine 
(0.05 mg
 
kg
-1 
d
-1
; s.c.) for five days. To prevent infections, the rats were also treated 
with enrofloxacin one day prior to and three days after the surgery (0.05 mg
 
kg
-1 
d
-1
; 
s.c.). Postoperative mortality within the first 48 hours post-MI was 23%. None of the 
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animals that survived beyond 48 hours died during the remaining study period (six 
weeks post-MI or sham surgery).    
After 48 hours, the distribution of animals between experimental groups were 
as follows: (1) post-MI/ChiEF-tdTomato (n=19) – animals with permanent LAD 
occlusion expressing ChiEF-tdTomato in the DVMN; (2) post-MI/eGFP (n=13) – 
rats with permanent LAD occlusion expressing eGFP in the DVMN; (3) sham-
MI/ChiEF-tdTomato (n=10) – sham-operated animals expressing ChiEF-tdTomato in 
the DVMN; and (4) sham-MI/eGFP (n=8) – sham-operated rats expressing eGFP in 
the DVMN. 
5.2.4 Optogenetic Stimulation 
The dorsal brainstem of rats expressing ChiEF-tdTomato or eGFP by the 
DVMN neurones was illuminated (via a pre-implanted optrode) with blue light (445 
nm, 10 ms pulses, 15 Hz) for 15 minutes every 48 hours for four weeks commencing 
two days after LAD occlusion or sham surgery (Figure 5-2). Light stimulation was 
performed under mild sedation (1% isoflurane). 
5.2.5 Assessment of heart failure phenotype 1: Evaluation of exercise capacity 
The exercise capacity of post-MI and sham-MI rats was assessed using a 
single lane treadmill (Panlab Harvard Apparatus, Cambridge, UK) with an electrical 
shock grid set at a minimum threshold of 0.1 mA, as described in detail above 
(Chapter 4). The body weight of each animal was recorded and the rat was placed on 
a treadmill. To determine exercise capacity, the treadmill speed was raised from the 
initial 20 cm s
-1
 in increments of 5 cm s
-1
 every 5 min until the animal’s hind limbs 
made contact with the grid four times within a two minute period - the humanely 
defined point of exhaustion. The distance covered by the animal was recorded and 
exercise capacity was expressed in joules (J or kg m
2
 s
-2
). 
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5.2.6 Assessment of heart failure phenotype 2: Ultrasound evaluation of 
systolic and global function 
LV function was assessed using a Vevo® 2100 high-resolution ultrasound 
system with an MS250 13-24MHz linear array transducer (VisualSonics, 
Amsterdam, The Netherlands). The rats were kept under isoflurane anaesthesia (2% 
isoflurane), and baseline ejection fraction and HR (lead II ECG) were first 
determined. Ejection fraction was determined using B-mode acquisition of a 
parasternal long-axis view of the LV (in plane so as to dissect across the aorta, 
(Figure 4-1; Page 84) in order to measure the length of the LV at systole and 
diastole. Three short axis slice images were also acquired along the length of the 
ventricle to segment the endocardial border (Figure 4-1; Page 84). Applying 
Simpson’s rule to approximate ventricular volume, ejection fraction was determined 
as the percentage of blood at diastole ejected at systole (Schiller et al., 1989).  
Global LV function was also assessed using the LV myocardial performance 
index (LV MPI) (Tei et al., 1995). Using Doppler echocardiographic recordings of 
blood flow velocity across the mitral valve from the apical four-chamber view 
(Figure 5-1), LV MPI was calculated from the sum of isovolumetric contraction time 
(IVCT) and the isovolumetric relaxation time (IVRT) divided by the LV ejection 
time (LV ET): 
LV MPI =
IVCT + IVRT
LV ET
 
 
5.2.7 Assessment of heart failure phenotype 3: Ultrasound evaluation of 
diastolic function 
 There are two identified filling phases during diastole of the LV. Active 
relaxation of the LV myocardium and visco-elastic properties of the myocardium 
(i.e. wall compliance) contribute to early filling (E). The second phase of LV filling 
(A) is due to atrial contraction. Under normal conditions the transmitral E/A ratio in 
a healthy heart is >1, i.e. E>A (Galderisi, 2005). Slowing of normal ventricular 
relaxation contributes to mild forms of diastolic dysfunction (van Kraaij et al., 2002). 
Less blood entering the ventricle during early filling phase would require a more 
forceful atrial contraction to compensate. Transmitral E/A ratio of less than 1 (i.e. 
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E<A) would indicate diastolic dysfunction (van Kraaij et al., 2002). The early wave 
deceleration time (DT) would also be prolonged as a result, as would the IVRT 
(Galderisi, 2005). More severe diastolic dysfunction is characterised by restrictive 
filling pattern and manifested by short, high velocity early phase of filling and 
reduced atrial filling. Higher filling pressures produce a steep pressure gradient 
across the mitral valve resulting in its premature opening and allowing for higher 
early filling velocity (Mandinov et al., 2000). Due to reduced wall compliance as a 
result of increased collagen content (Zile & Brutsaert, 2002; Zile, 2003), the pressure 
within the LV rapidly rises equalling that of the atrium. This prevents further filling 
and produces a short early filling phase (Mandinov et al., 2000). This results in an 
extreme transmitral E/A ratio of >2 and shortening of both DT and IVRT (van Kraaij 
et al., 2002). 
 
Doppler echocardiographic recordings of blood flow velocity across the 
mitral valve were used to determine (Figure 5-1): 
 E/A Ratio: The ratio of the early and late phases of diastolic filling (Galderisi, 
2005).  
 DT: The deceleration time (in ms) of the early phase of filling (Cerisano et al., 
1999). 
 Deceleration slope: The rate of change in blood velocity (cm s-2) during the early 
phase of filling. Considered to be a better index of diastolic function compared to 
the one-dimensional measurement of deceleration time (Mishra et al., 2007). 
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Figure 5-1: Doppler echocardiographic measurements 
A) Scheme showing trans-mitral Doppler measurements. A, Atrial Filling; DT, Deceleration time; E, Early Filling; ICRT, Isovolumetric contraction time; 
IVRT, Isovolumetric relaxation time; LV ET, Left ventricle ejection time; B) Scheme of the showing early (E) and atrial (A) filling in normal, impaired 
diastolic dysfunction and extreme dysfunction restrictive filing patterns. C) Left, Coloured Doppler image showing an apical 4 chamber view; Right, 
Ultrasound Doppler showing transmural flow recording.  
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5.2.8 Assessment of heart failure phenotype 4: Haemodynamic evaluation 
Doppler echocardiography does not provide a direct measure of LV pressure 
changes (Tschope & Paulus, 2009) and degree of LV remodelling cannot be reliably 
assessed using this method. Therefore, six weeks post MI or sham surgery (Figure 
5-2), all animals underwent haemodynamic assessment under urethane (1.3 g kg
-1
, 
i.p.) anaesthesia. Adequate anaesthesia was ensured by maintaining stable levels of 
arterial blood pressure and HR and monitored by the absence of a withdrawal 
response to a paw pinch. Body temperature was maintained with a servo-controlled 
heating pad at 37.0±0.5 °C. Partial pressures of O2 and CO2 as well as pH of the 
arterial blood were taken and recorded (RAPIDLab 348EX, Siemens, UK). The 
femoral artery was cannulated for measurement of ABP. To evaluate LV contractile 
function, a 2F Millar pressure catheter (SPR-320NR, Millar instruments, USA) was 
advanced via the right carotid artery and positioned within the chamber of the LV to 
monitor changes in LVP. After the preparative surgery the animal was left to 
stabilise for 30 min. LVP, ABP, and standard lead II ECG were then recorded for 15 
minutes using a Power1401 interface and Spike2 software (Cambridge Electronic 
Design). Average waveforms were used to determine LVESP and LVEDP. LVdP/dt 
was derived from the LVP recording using the slope function. From ABP 
measurements, average wave forms were used to determine MAP and pulse pressure 
(PP). 
5.2.9 Assessment of heart failure phenotype 5: Ex vivo evaluation of LV 
pressure-volume relations 
Six weeks following LAD occlusion (Figure 5-2), ex vivo LV pressure-
volume curves were obtained using a method described in Fletcher et al. (1981). At 
the end of the hemodynamic studies, the heart was arrested by KCl, excised and a 
double-lumen catheter (PE-50 inside PE-200) was inserted into the LV via the 
ascending aorta. The right ventricle was incised (and weighed), atrioventricular 
groove was ligated, and isotonic saline was infused into the LV at a rate of 0.7 ml 
min
-1
 via one lumen, while intraventricular pressure was recorded through the other 
lumen from 0 to 30 mmHg. At least three measurements of pressure-volume 
relationships were obtained. The atria were then excised, the weight of LV recorded 
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and infarct size was measured. The stiffness, constant k, was calculated by fitting one 
exponential function (Fletcher et al., 1981) of the form using pressure (P) and 
volume (v) and the additional constant (b): 
𝑃 = 𝑏𝑒𝑘𝑣 
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Figure 5-2: Timeline for experiments investing effects of enhanced DVMN 
activity following myocardial infarction 
Timeline illustrating the interval duration between stages of animal preparation and 
acquisition of data for rats expressing ChIEF-tdTomato or eGFP. 
  
Chapter 5 Enhancing Vagal Activity in Heart Failure 133 
 
 
5.2.10 Assessment of heart failure phenotype 6: lung water content, body and 
ventricles weights 
As an additional measurement to assess the degree of LV dysfunction, the 
lungs were excised and water content was determined to establish the presence of 
pulmonary oedema (Mullertz et al., 2011). Lungs were weighed immediately after 
extraction and again after 72 hours of drying at a temperature of 40±1 °C to establish 
the lung fluid content. Weights of left and right ventricles were expressed as a ratio 
to body weight (mg kg
-1
). 
5.2.11 Infarct size calculation 
After fixation, the extent of MI was determined as described in detail 
previously (Pfeffer et al., 1979; Fletcher et al., 1981). The LV was cut from the apex 
to the base into transverse slices of identical thickness (1.5 mm). In each slice, the 
length of the scar and non-infarcted muscle for endocardial and epicardial surfaces 
were determined by computerised planimetry. Infarct size (in %) was calculated as 
an average of infarcted endo- and epicardial surfaces. This method of calculating the 
infarct size was compared to the infarct estimation using three ultrasound-acquired 
short axis B-mode images of the LV. The average angle created by the arcs of 
infarcted circumference out of 360° (Figure 5-11) was used to estimate infarct size 
(%).  
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Figure 5-3: Ultrasound estimation of infarct size 
A) Scheme of a short axis view of the LV. From the three acquired slices, the average angle 
created by the arcs of infarcted circumference out of 360° were used to estimate infarct size 
(%); B) Example of angular measurement on a B-mode slice. 
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5.2.12 Data Analysis 
Differences between the experimental groups were assessed for statistical 
significance using GraphPad Prism 6 software. Comparisons were made using a one-
way ANOVA (followed by Sidak’s p value correction for multiple comparisons) or 
Student’s t-test, as appropriate. To compare how accurate ultrasound measurements 
could estimate the actual infarct size, a correlation analysis was conducted to 
compute the value of Pearson’s correlation coefficient. The results are reported as 
individual values and means ± s.e.m. Differences with p<0.05 were considered to be 
significant. 
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5.3 Results 
5.3.1 Infarct size calculation and comparison 
Infarct sizes ranged between 17% and 40% (n=19) in post-MI/ChiEF-
tdTomato group and between 19% and 43% (n=13) in post-MI/eGFP group when 
assessed using computerised planimetry. No infarcts were noted in sham-operated 
animals. 
A significant correlation was found between infract size values obtained 
using ultrasound and computerised planimetry (Figure 5-4C; r=0.54; p=0.001). A 
linear regression analysis has demonstrated that the ultrasound method used 
overestimated the actual infarct size by approximately 10%, producing the following 
equation where x is the percentage of non-contractile perimeter measured using 
ultrasound and y is the planimetry-derived infarct size: 
𝑦 = 0.8968 𝑥 + 0 
 
The data obtained in animals with infarct sizes >30% were taken for 
subsequent analysis (Zhang et al., 2001). Nine animals with infarct sizes of 30-40% 
formed post-MI/eGFP group (average infarct size 36±1%), and twelve rats with 
infarct sizes of 30-40% formed post-MI/ChiEF-tdTomato group (average infract size 
33±1%). There were no differences in infarct sizes between these two experimental 
groups of animals (p=0.1; t-test; Figure 5-4B).  
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Figure 5-4: Assessment of infarct size  
A) Images illustrate representative sections of the LV from a sham-operated animal and an 
animal six weeks after LAD occlusion. Computerised planimetry was used to calculate 
infarct size as described in detail in the Methods; B) Summary data illustrating infarct sizes 
determined using computerised planimetry of LV sections of rats transduced to express 
eGFP or ChiEF-tdTomato by the DVMN neurones six weeks after LAD occlusion; C) 
Correlation between infract size (IS) values obtained using analysis of three short axis B-
mode images acquired using ultrasound and computerised planimetry.  
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5.3.2 Assessment of heart failure phenotype 1: evaluation of exercise capacity 
Strong expression of ChIEF-tdTomato by the DVMN neurones in the caudal 
aspect of the left and right nuclei was observed six weeks after microinjections of the 
virus (Figure 5-5). Exercise capacity was reduced six weeks post-MI in rats 
expressing eGFP in the DVMN when compared to sham-operated animals (28±3 vs 
56±8 J; p=0.04; ANOVA; Figure 5-6). Optogenetic stimulation of the DVMN 
neurones expressing ChIEF-tdTomato enhanced exercise capacity in sham-operated 
animals (105±11 vs 56±8 J in sham-operated rats expressing eGFP; p=0.001; 
ANOVA; Figure 5-6) and improved exercise capacity in post-MI animals (56±4 vs 
28±3 J in post-MI rats expressing eGFP; p=0.02; ANOVA; Figure 5-6). Thus, in rats, 
optogenetic recruitment of the DVMN activity for 15 minutes every 48 hours for 
four weeks after LAD occlusion restores exercise capacity to the level of sham-
operated animals. 
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Figure 5-5: Targeting DVMN neurones to express ChIEF-tdTomato 
Confocal image of a coronal section of the rat brainstem targeted to express ChIEF-tdTomato by the DVMN neurones. Ventrally projecting axons (arrow) of 
the DVMN neurones transduced to express ChIEF-tdTomato. CC, central canal. 
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Figure 5-6: The effect of enhanced DVMN activity on exercise capacity of rats 
six weeks after LAD occlusion or sham-surgery 
Summary data illustrating exercise capacity of rats transduced to express ChIEF-tdTomato 
(ChIEF) or eGFP by the DVMN neurones after four weeks of light (445 nm, 10 ms pulses, 
15 Hz) delivery to the dorsal brainstem for 15 minutes every 48 hours commencing two days 
after LAD occlusion (MI) or sham surgery. Asterisk denotes significant effect of optogenetic 
DVMN stimulation. Plus denotes significant effect of LAD occlusion. *P<0.05; 
***P<0.001; 
+
P<0.01; 
+++
P<0.001. 
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5.3.3 Assessment of heart failure phenotype 2: Ultrasound evaluation of 
systolic and global function 
LV ejection fraction was reduced six weeks post-MI in rats expressing eGFP 
in the DVMN when compared to sham-operated animals (33±3 vs 50±5%; p=0.01; 
ANOVA Figure 5-7A). Optogenetic stimulation of the DVMN neurones expressing 
ChIEF-tdTomato increased ejection fraction both in sham-operated animals (76±2 vs 
50±5% in sham-operated rats expressing eGFP; p<0.0001; ANOVA; Figure 5-7A) 
and in post-MI rats (49±3 vs 33±3% in post-MI rats expressing eGFP; p=0.005; 
ANOVA; Figure 5-7A).  
Isovolumetric contraction time (IVCT) was found to be prolonged six weeks 
post-MI in rats expressing eGFP in the DVMN when compared to sham-operated 
animals (24±1 vs 15±1 ms; p<0.0001; ANOVA; Figure 5-7B). Optogenetic 
stimulation of the DVMN neurones expressing ChIEF-tdTomato shortened IVCT 
both in sham-operated animals (13±1 vs 15±1 ms in rats expressing eGFP; p=0.04; 
ANOVA; Figure 5-7B) and in post-MI rats (15±1 vs 24±1 ms in post-MI rats 
expressing eGFP; p<0.0001; ANOVA; Figure 5-7B).  
LV myocardial performance index (LV MPI) (an established method for 
assessing global myocardial function through the ratio of isovolumetric times to left 
ventricular ejection time) (Tei et al., 1995) was increased post-MI in rats expressing 
eGFP (0.74±0.03 vs 0.53±0.03 in sham-operated rats; p<0.0001; ANOVA; Figure 
5-7C). Optogenetic stimulation of the DVMN resulted in a significant lowering of 
LV MPI both in sham-operated animals (0.41±0.02 vs 0.53±0.03 in rats expressing 
eGFP; p=0.006; ANOVA; Figure 5-7C) and in rats post-MI (0.57±0.02 vs 0.74±0.03 
in post-MI rats expressing eGFP; p<0.0001; ANOVA; Figure 5-7C).  
Under isoflurane anaesthesia, HR was similar in all four experimental groups 
(p=0.4; ANOVA; Figure 5-7D). These data suggest that in rats, optogenetic 
recruitment of the DVMN activity for 15 minutes every 48 hours for four weeks after 
LAD occlusion is sufficient to maintain a normal ejection fraction, reduce IVCT and 
improve LV-MPI to the levels of sham-operated animals. Significant improvement 
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of LV function as a result of DVMN recruitment was also observed in sham-operated 
animals.  
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Figure 5-7: The effect of enhanced DVMN activity on indices of LV systolic and global function in rats six weeks after LAD occlusion or 
sham-surgery (isoflurane anaesthesia) 
Summary data illustrating A) LV ejection fraction; B) IVCT; C) LV-MPI; and D) HR of rats transduced to express ChIEF-tdTomato (ChIEF) or eGFP by the 
DVMN neurones after four weeks of light (445 nm, 10 ms pulses, 15 Hz) delivery to the dorsal brainstem for 15 minutes every 48 hours, commencing two 
days after LAD occlusion (MI) or sham surgery. Asterisk denotes significant effect of optogenetic DVMN stimulation. Plus denotes significant effect of LAD 
occlusion. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001; 
+
P<0.01; 
++++
P<0.0001. 
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5.3.4 Assessment of heart failure phenotype 3: ultrasound evaluation of 
diastolic function 
LV diastolic function was assessed using pulsed wave Doppler of transmitral 
flow velocities in the apical four-chamber view (Figure 5-1C). Six weeks post-MI 
the E/A ratio was reduced both in rats expressing eGFP (0.88±0.09 vs 1.21±0.12 in 
sham-operated rats; p=0.04; ANOVA; Figure 5-8A) and ChIEF-tdTomato 
(1.20±0.10 vs 1.57±0.09 in sham-operated rats; p=0.02; ANOVA; Figure 5-8A) 
indicative of an “impaired” filling (van Kraaij et al., 2002). Optogenetic stimulation 
of the DVMN (rats expressing ChIEF-tdTomato in the DVMN) increased E/A ratio 
both in sham-operated animals (1.57±0.09 vs 1.21±0.12 in rats expressing eGFP in 
the DVMN; p=0.03; ANOVA; Figure 5-8A) and in rats post-MI (1.20±0.10 vs 
0.88±0.09 in rats expressing eGFP in the DVMN; p=0.03; ANOVA; Figure 5-8A).  
DT was similar six weeks post-MI in rats expressing eGFP in the DVMN 
when compared to sham-operated animals (24±3 vs 27±3 ms in sham-operated rats; 
p=0.1; ANOVA; Figure 5-8B). Optogenetic stimulation of the DVMN neurones 
expressing ChiEF-tdTomato increased DT in sham-operated animals only (28±3 vs 
36±3 in sham operated rats; p=0.03; ANOVA; Figure 5-8B). 
The deceleration slope was steeper six weeks post-MI in rats expressing 
eGFP in the DVMN when compared to sham-operated animals (-3581±352 vs -
2473±286 mm s
-2
 in sham-operated rats; p=0.02; ANOVA; Figure 5-8A). 
Optogenetic stimulation of the DVMN neurones expressing ChIEF-tdTomato did not 
affect the deceleration slope in sham-operated animals (-1885±102 vs -2473±286 
mm s
-2
 in rats expressing eGFP; p=0.3; ANOVA; Figure 5-8C), but broadened the 
slope in rats post-MI (-2690±256 vs -3581±352 mm s
-2
 in rats expressing eGFP; 
p=0.04; ANOVA; Figure 5-8C).   
IVRT was similar six weeks post-MI in rats expressing eGFP in the DVMN 
when compared to sham-operated animals (21±2 vs 21±2 in sham-operated rats; 
p>0.9; ANOVA; Figure 5-8D). Optogenetic stimulation of the DVMN neurones 
expressing ChIEF-tdTomato reduced IVRT in sham-operated animals only (15±2 vs 
21±2 in rats expressing eGFP; p=0.03; ANOVA; Figure 5-8D), with no effect on rats 
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post-MI (23±2 vs 21±2 in rats expressing eGFP; p=0.8; ANOVA; Figure 5-8D).  
These data suggest that in rats, optogenetic recruitment of the DVMN activity for 15 
minutes every 48 hours for four weeks after LAD occlusion is sufficient to maintain 
normal diastolic function of the LV. 
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Figure 5-8: The effect of enhanced DVMN activity on indices of left ventricular diastolic function in rats six weeks after LAD occlusion 
or sham-surgery (isoflurane anaesthesia) 
Summary data illustrating A) ratio of early (E) and atrial (A) filling velocities during diastole; B) the early wave deceleration time; C) the early wave 
deceleration slope; and D) the isovolumetric relaxation time (IVRT) of rats transduced to express ChIEF-tdTomato (ChIEF) or eGFP by the DVMN neurones 
after four weeks of light (445 nm, 10 ms pulses, 15 Hz) delivery to the dorsal brainstem for 15 minutes every 48 hours, commencing two days after LAD 
occlusion (MI) or sham surgery. Asterisk denotes significant effect of optogenetic DVMN stimulation. Plus denotes significant effect of LAD occlusion. 
*P<0.05; **P<0.01; 
+
P<0.01. 
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5.3.5 Assessment of heart failure phenotype 4: Haemodynamic evaluation 
 
LV dP/dtmax was reduced six weeks post-MI in rats expressing eGFP in the 
DVMN when compared to sham-operated animals (5690±444 vs 7472±381 mmHg s
-
1
 in sham-operated rats; p=0.009; ANOVA; Figure 5-9A). Optogenetic stimulation of 
the DVMN neurones expressing ChIEF-tdTomato increased LV dP/dtmax both in 
sham-operated animals (8980±411 vs 7472±381 mmHg s
-1
 in rats expressing eGFP; 
p=0.04; ANOVA; Figure 5-9A) and in rats post-MI (7673±332 vs 5690±444 mmHg 
s
-1
 in rats expressing eGFP; p=0.001; ANOVA; Figure 5-9A).  
LVESP reduced six weeks post-MI in rats expressing eGFP in the DVMN 
when compared to sham-operated animals (106±3 vs 122±4 mmHg in sham-operated 
rats; p=0.04; ANOVA; Figure 5-9B). Optogenetic stimulation of the DVMN 
neurones expressing ChIEF-tdTomato increased LVESP both in sham-operated 
animals (138±4 vs 122±4 mmHg in rats expressing eGFP; p=0.04; ANOVA; Figure 
5-9B) and in rats post-MI (122±4 vs 106±3 mmHg in rats expressing eGFP; p=0.02; 
ANOVA; Figure 5-9B). 
LV dP/dtmin was reduced six weeks post-MI in rats expressing eGFP in the 
DVMN when compared to sham-operated animals (-4348±275 vs -6136±269 mmHg 
s
-1
 in sham-operated rats; p=0.0004; ANOVA; Figure 5-9C). Optogenetic stimulation 
of the DVMN neurones expressing ChIEF-tdTomato did not affect LV dP/dtmin in 
sham-operated animals (-6774±391 vs -6136±269 mmHg s
-1
 in rats expressing 
eGFP; p=0.5; ANOVA; Figure 5-9A), but was improved in rats post-MI (-5550±176 
vs -4348±274 mmHg s
-1
 in rats expressing eGFP; p=0.003; ANOVA; Figure 5-9C).  
LVEDP was increased six weeks post-MI in rats expressing eGFP in the 
DVMN when compared to sham-operated animals (7±1 vs 4±1 mmHg in sham-
operated rats; p=0.004; ANOVA; Figure 5-9D). Optogenetic stimulation of the 
DVMN neurones expressing ChIEF-tdTomato had no effect on sham-operated 
animals (3±2 vs 4±1 mmHg in rats expressing eGFP; p=0.2; ANOVA; Figure 5-9D), 
but decreased LVEDP in rats post-MI (5±2 vs 7±1 mmHg in rats expressing eGFP; 
p=0.01; ANOVA; Figure 5-9D). 
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These data suggest that in rats, optogenetic recruitment of DVMN activity for 
15 minutes every 48 hours for four weeks after LAD occlusion reduces LVEDP and 
maintains normal levels of LVdP/dtmax, LVESP and LVdP/dtmin. 
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Figure 5-9: The effect of enhanced DVMN activity on indices of left ventricular systolic and diastolic function in rats six weeks after 
LAD occlusion or sham-surgery under urethane anaesthesia 
Summary data illustrating values of the A) maximum first differential of left ventricular pressure (LVdP/dtmax); B) left ventricular end systolic pressure 
(LVESP); C) the minimum first differential of left ventricular pressure (LVdP/dtmin); and D) left ventricular end diastolic pressure (LVEDP) in rats transduced 
to express ChIEF-tdTomato (ChIEF) or eGFP by the DVMN neurones after four weeks of light (445 nm, 10 ms pulses, 15 Hz) delivery to the dorsal 
brainstem for 15 minutes every 48 hours, commencing two days after LAD occlusion (MI) or sham surgery. Asterisk denotes significant effect of optogenetic 
DVMN stimulation. Plus denotes significant effect of LAD occlusion. *P<0.05; **P<0.01; 
+
P<0.01; 
++
P<0.01; 
+++
P<0.01. 
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MAP was reduced six weeks post-MI in rats expressing eGFP in the DVMN 
when compared to sham-operated animals (66±3 vs 78±3 mmHg in sham-operated 
rats; p=0.04; ANOVA; Figure 5-10A). Optogenetic stimulation of the DVMN 
neurones expressing ChIEF-tdTomato had no effect on sham-operated animals (84±4 
vs 78±3 mmHg in rats expressing eGFP; p=0.6; ANOVA; Figure 5-10A), but was 
higher in rats post-MI (78±3 vs 66±3 mmHg in rats expressing eGFP; p=0.03; 
ANOVA; Figure 5-10A). 
PP was reduced six weeks post-MI in rats expressing eGFP in the DVMN 
when compared to sham-operated animals (36±4 vs 52±4 mmHg in sham-operated 
rats; p=0.04; ANOVA; Figure 5-10B). Optogenetic stimulation of the DVMN 
neurones expressing ChIEF-tdTomato had no effect on sham-operated animals (51±2 
vs 52±4 mmHg in rats expressing eGFP; p>0.9; ANOVA; Figure 5-10B), but was 
higher in rats post-MI (51±5 vs 36±4 mmHg in rats expressing eGFP; p=0.03; 
ANOVA; Figure 5-10B). 
HRs were not affected six weeks post-MI in rats expressing eGFP in the 
DVMN when compared to sham-operated animals (362±17 vs 371±15 bpm in sham-
operated rats; p>0.9; ANOVA; Figure 5-10C). Optogenetic stimulation of the 
DVMN neurones expressing ChIEF-tdTomato did not affect HR in sham-operated 
animals (380±19 vs 371±15 bpm in rats expressing eGFP; p>0.9; ANOVA; Figure 
5-10C) or post-MI rats (380±13 vs 362±17 bpm in rats expressing eGFP; p>0.9; 
ANOVA; Figure 5-10C). These data suggest that in rats, optogenetic recruitment of 
DVMN activity for 15 minutes every 48 hours for four weeks after LAD occlusion is 
sufficient to maintain normal MAP and normal PP.  
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Figure 5-10: The effect of enhanced DVMN activity on systemic arterial blood pressure and heart rates in rats six weeks after LAD 
occlusion or sham-surgery (urethane anaesthesia) 
Summary data illustrating values of mean arterial pressure (MAP, A), pulse pressure (B) and heart rate (C) in rats transduced to express ChIEF-tdTomato 
(ChIEF) or eGFP by the DVMN neurones after four weeks of light (445 nm, 10 ms pulses, 15 Hz) delivery to the dorsal brainstem for 15 minutes every 48 
hours, commencing two days after LAD occlusion (MI) or sham surgery. Asterisk denotes significant effect of optogenetic DVMN stimulation. Plus denotes 
significant effect of LAD occlusion. *P<0.05; 
+
P<0.01. 
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5.3.6 Assessment of heart failure phenotype 5: ex vivo evaluation of LV 
pressure-volume relations 
 
The index of myocardial wall compliance, the stiffness (constant k) was not 
changed six weeks post-MI in rats expressing eGFP in the DVMN when compared to 
sham-operated animals (3.9±0.3 vs 3.4±0.1 in sham-operated rats; p=0.4; ANOVA; 
Figure 5-8D). Optogenetic stimulation of the DVMN neurones expressing ChIEF-
tdTomato increased k in sham-operated animals (4.8±0.3 vs 3.8±0.3 in rats 
expressing eGFP; p=0.01; ANOVA; Figure 5-8D), but did not affect rats post-MI 
(3.2±0.1 vs 3.4±0.1 in rats expressing eGFP; p=0.9; ANOVA; Figure 5-8D).   
These data suggest that in rat hearts excised six weeks following LAD 
occlusion, optogenetic recruitment of DVMN activity for 15 minutes every 48 hours 
for four weeks improves stiffness constants in sham-operated animals only.  
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Figure 5-11: The effect of enhanced DVMN activity after six weeks in sham and 
post-MI operated rats on LV pressure-volume relations 
A) Summary data illustrating the pressure volume relations of the left ventricle (LV) 
immediately after excision in rats transduced to express ChiEF-tdTomato and eGFP by the 
DVMN neurones after one month of light stimulation of the dorsal brainstem via a pre-
implanted optrode (for 15 minutes every 48 hours for four weeks commencing two days after 
LAD occlusion or sham surgery); B) Summary data illustrating the pressure constant, k. 
Asterisk denotes significant effect of optogenetic DVMN stimulation. Plus denotes 
significant effect of optogenetic stimulation. ****P<0.0001; 
+
P<0.01.  
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5.3.7 Assessment of heart failure phenotype 6: lung water content, body and 
ventricles weights 
Body weights were not affected six weeks post-MI in rats expressing eGFP in 
the DVMN when compared to sham-operated animals (453±18 vs 431±18 kg in 
sham-operated rats; p=0.9; ANOVA; Figure 5-12A). Optogenetic stimulation of the 
DVMN neurones expressing ChIEF-tdTomato reduced body weights in rats post-MI 
only (391±5 vs 453±19 mg kg
-1
 in rats expressing eGFP; p=0.04; ANOVA; Figure 
5-12A). There were no differences in lung water content between all the 
experimental groups (p>0.9; ANOVA; Figure 5-12B). 
LV to body mass ratios were not different six weeks post-MI in rats 
expressing eGFP in the DVMN when compared to sham-operated animals 
(2.19±0.08 vs 2.12±0.07 mg kg-1 in sham-operated rats; p=0.5; ANOVA; Figure 
5-12C). Optogenetic stimulation of the DVMN neurones expressing ChIEF-
tdTomato increased LV to body mass ratios in sham-operated animals (1.91±0.06 vs 
2.12±0.07 mg kg-1 in rats expressing eGFP; p=0.04; ANOVA; Figure 5-12C), but 
did not in rats post-MI (2.24±0.05 vs 2.19±0.08 mg kg-1 in rats expressing eGFP; 
p=0.03; ANOVA; Figure 5-12C).  
RV to body mass ratios were not different six weeks post-MI in rats 
expressing eGFP in the DVMN when compared to sham-operated animals 
(0.42±0.02 vs 0.38±0.01 mg kg-1 in sham-operated rats; p=0.4; ANOVA; Figure 
5-12D). Optogenetic stimulation of the DVMN neurones expressing ChIEF-
tdTomato had no effect on sham-operated animals (0.37±0.01 vs 0.38±0.01 mg kg-1 
in rats expressing eGFP; p=0.7; ANOVA; Figure 5-12D), but increased RV to body 
mass ratio in rats post-MI (0.36±0.02 vs 0.42±0.02 mg kg-1 in rats expressing eGFP; 
p=0.03; ANOVA; Figure 5-12D). 
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Figure 5-12: The effect of enhanced DVMN activity on body weight, lung fluid content, left and right ventricular weights in rats six 
weeks after LAD occlusion or sham-surgery 
Summary data illustrating the A) body weights; B) lung fluid content (in %); C) LV to body weight ratio and D) RV to body weight ratio in rats transduced to 
express ChIEF-tdTomato (ChIEF) or eGFP by the DVMN neurones after four weeks of light (445 nm, 10 ms pulses, 15 Hz) delivery to the dorsal brainstem 
for 15 minutes every 48 hours, commencing two days after LAD occlusion (MI) or sham surgery. Asterisk denotes significant effect of optogenetic DVMN 
stimulation. Plus denotes significant effect of LAD occlusion. *P<0.05; 
+++
P<0.01. 
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5.4 Discussion 
This study was designed to test the hypothesis that experimental 
(optogenetic) enhancement of DVMN activity would be sufficient to slow left 
ventricular dysfunction and remodelling developing after a MI. This study builds 
upon the results of the experiments presented in Chapters 2 and 3, suggesting that 
DVMN neurones provide functional innervation of the left cardiac ventricle and 
control its electrical and contractile properties. Results of the experiments described 
in Chapter 4 also demonstrated that the activity of this population of VPNs 
determines LV responsiveness to β-adrenoceptor stimulation and exercise capacity. 
Clear improvement in exercise capacity and LV contractility after four daily sessions 
(15 minutes each) of DVMN stimulations (Chapter 4) suggested that the same 
treatment delivered over a longer period of time may slow or even prevent LV 
dysfunction and heart failure development after permanent coronary artery occlusion.     
To test this hypothesis an experiment was designed involving four groups of 
animals. Rats transduced to express either eGFP (control) or ChIEF-tdTomato 
(optogenetic construct) by the DVMN neurones underwent LAD occlusion or sham 
surgery. All animals were subjected to four weeks of light stimulation of the dorsal 
brainstem via a pre-implanted optrode for 15 minutes every 48 hours commencing 
two days after LAD occlusion or sham surgery. LV systolic and diastolic functions 
were then assessed using different methods, including high-resolution ultrasound. 
Only rats with infarct sizes of more than 30% were included in this study to allow 
comparisons between control (post-MI/eGFP) and experimental (post-MI/ChIEF-
tdTomato) groups with similar infarcts. Permanent LAD occlusion with infarct sizes 
of 30-40% reduced exercise capacity and impaired LV function when assessed six 
weeks after the infarction (Figure 5-4A; Figure 5-6). Ventricular chamber to body 
weight ratios and lung fluid percentages were then used to assess hypertrophy 
(Lamas, 1993) and pulmonary oedema (Mullertz et al., 2011).  
It was found that optogenetic stimulation of DVMN over the course of four 
weeks following LAD occlusion maintained exercise capacity at the level exhibited 
by sham-operated animals expressing eGFP. Significant improvement in exercise 
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capacity was also noted in sham-operated rats as a result of optogenetic stimulation, 
an observation concordant with the data reported in Chapter 4.  
Ultrasound assessment of cardiac performance and, more precisely, of LV 
systolic and diastolic function reflected these significant improvements in exercise 
capacity. Optogenetic stimulation of the DVMN increased ejection fraction of the 
infarcted myocardium by approximately 20%. A 20% improvement is highly 
significant given that the average baseline ejection fraction is approximately 30% in 
rats expressing eGFP post-MI. The LV IVCT was also significantly reduced (by 
approximately 9 ms).  
The LV myocardial global performance index (LV MPI) is used to quantify 
energetics of ventricular wall contraction and relaxation during systole and diastole 
of each cardiac cycle, assessed independently of (although potentially dependant on) 
HR. Optogenetic DVMN stimulation resulted in a clear beneficial effect on LV 
contractility in post-MI rats, with significant improvements also noted in sham-
operated animals. Doppler measurements of transmitral blood flow velocities were 
made to comprehensively evaluate the LV diastolic function. Optogenetic DVMN 
stimulation was sufficient for maintaining a normal E/A ratio (i.e. >1), while in post-
MI rats expressing eGFP in the DVMN the average ratio was 0.9 (and would be 
considered in a clinical setting as evidence of a mild diastolic dysfunction). These 
observations were interpreted as rats expressing ChIEF-tdTomato post-MI having a 
normal E/A ratio, as opposed to a pseudo-normalised E/A filling pattern, an unlikely 
scenario in the context of other ultrasound assessments (in a clinical setting, this 
would be differentiated using the Valsalva manoeuvre and ultrasound Doppler of the 
pulmonary vein (Paulus, 1998) to reveal an impaired filling pattern).  
In addition to E/A ratio, other parameters of the early filling wave were 
assessed as indices of myocardial wall compliance and lusitropic function.  
Optogenetic stimulation of the DVMN improved early wave DT in sham-operated 
animals only. The negative gradient of the E wave, i.e. the deceleration, is clinically 
shown to be a better index of diastolic function and predictor of cardiovascular 
outcomes than one of its constitutive one-dimensional components, such as 
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deceleration time (Mishra et al., 2007). Optogenetic stimulation of the DVMN in 
post-MI rats was found to significantly improve the deceleration slope. Ultrasound 
assessment of LV function is clinically useful and allows for longitudinal studies. 
Ultrasound measurements are based on the assumptions of a “normal” LV shape 
allowing the use of Simpson’s rule for calculating ejection fraction from b-mode 
acquisitions (Schiller et al., 1989). This may become less reliable in pathological 
conditions as ventricular hypertrophy and wall thinning can result in an abnormal 
chamber shape. However, good concordance has been found between non-invasive 
and invasive assessment of LV function in animal models (Schober et al., 2003) and 
humans (Sarma et al., 1974; Sokolski et al., 2011).  
Following MI, optogenetic stimulation of the DVMN in rats expressing 
ChiEF-tdTomato preserved inotropic function as assessed by LVdP/dtmax. This was 
in agreement with peak LV end systolic pressures, which were higher in rats 
expressing ChIEF-tdTomato both in the sham and post-MI groups. Optogenetic 
stimulation of the DVMN lowered LVEDP and also normalised LVdP/dtmin, 
indicative of the beneficial effect of the treatment on LV lusitropy.  
It was noted that in all the animals the consistent induction of surgical 
anaesthesia required a higher dose of urethane (1.4 g kg
-1
, i.p.). As a result, the mean 
arterial pressures in animals of all experimental groups were below 100 mmHg. 
Nevertheless, optogenetic stimulation of the DVMN of infarcted rats resulted in a 
MAP of a more normotensive range possibly reflecting maintained inotropic 
function. Pulse pressures were also compared. Clinically, a narrow pulse pressure is 
used as a prognostic marker of poor cardiovascular outcomes (Yildiran et al., 2010). 
Optogenetic stimulation of the DVMN was found to maintain normal pulse pressure 
in post-MI rats, which is suggestive of a preserved systolic function as also reflected 
by the maintained LVESP.  
An ex vivo analysis of LV pressure volume curves demonstrates that 
optogenetic stimulation of DVMN enhanced myocardial wall compliance in sham-
operated animals only. No significant shift of the LV pressure-volume curve was 
observed as a result of MI when assessed six weeks after LAD occlusion. Classical 
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earlier studies assessing LV remodelling in rats have found that generally more 
severe infarctions are required to produce significant rightward shifts in LV pressure 
volume curves (Pfeffer et al., 1991). However, previous work conducted in this 
laboratory (Marina et al., 2013) involving male Sprague-Dawley rats obtained from 
UCL colony which underwent LAD occlusion, resulting in a marginally lower 
average infarct size (approximately 30%), reported a significant rightward shift of 
LV pressure volume curves. An important difference between these two studies was 
that in this experiment the animals had recurrent (every 48 hours) exposure to 
isoflurane anaesthesia required for optogenetic DVMN stimulation. Moderate LV 
remodelling observed in both groups of post-MI animals could be explained by 
potent cardioprotective action of isoflurane (Belhomme et al., 1999). Collectively 
these data indicate that optogenetic stimulation of the DVMN over the course of four 
weeks post-MI prevents cardiac dysfunction, as is evident from improved/maintained 
exercise capacity and LV systolic and diastolic function. Concordant improvements 
were observed in most of the assessed indices of contractile (ejection fraction, IVCT, 
LVdP/dtmax and LVESP) and diastolic (E/A ratio, deceleration slope, LVdP/dtmin and 
LVEDP) function. DT and IVRT were not significant between animals post-MI, 
likely due to the inherent lack of sensitivity of these measurements (Mishra et al., 
2007).  
Normalised LV MPI reflected the improvements in the aforementioned 
systolic and diastolic indices as a result of optogenetic stimulation of the DVMN 
after the MI. No differences in HR were observed between all four experimental 
groups either under urethane or isoflurane anaesthesia. This is relevant to the 
assessment of LV inotropy and lusitropy due to strong force-frequency relations in 
the rat’s heart (Nalivaiko et al., 2010). No significant differences in lung water 
content were observed between sham-operated and post-MI rats, consistent with 
previous work involving similar infarct sizes (Marina et al., 2013). There was, 
however, evidence of right ventricular hypertrophy in post-MI rats expressing eGFP 
in the DVMN, which was prevented by optogenetic stimulation of this population of 
VPNs. 
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As discussed in Chapter 4, preliminary blots conducted in collaboration with 
the research group of Dr. Gareth Ackland demonstrate that optogenetic stimulation 
of the DVMN results in down regulation of GRK2 and pan-arrestin expression in the 
LV. Reduced expression of GRK2 had been shown previously to unmask the 
significant contractile effect of β2–adrenoceptor stimulation, which is either weak or 
absent under normal conditions (Salazar et al., 2013). Increased activity of β2–
adrenoceptor in the intact myocardium may therefore explain preserved inotropic 
function post-MI. It is also possible that this mechanism unlocks the angiogenic 
potential of β2–adrenoceptor (Rengo et al., 2012). 
Stimulation of β2-adrenoceptors also specifically elicits dilation of coronary 
high resistance vessels (subendocardial and subepicardial arterioles) through the 
opening of ATP-sensitive potassium channels (Hein et al., 2004). Hence, optogenetic 
stimulation of the DVMN may increase/improve myocardial perfusion via 
downregulation of important intracellular proteins which control signalling mediated 
by β-adrenoceptors.  
A direct parasympathetic effect on coronary blood flow may also underlie 
beneficial effects of DVMN stimulation of LV function. Vagal innervation of the 
coronary vessels has been a subject of scientific scrutiny since the mid-1800s 
(Panum, 1858). Parasympathetic fibres were found to follow the coronary vessels 
into the myocardium (Woollard, 1926). Both electrical stimulation of the vagus 
nerve and coronary ACh perfusion have been shown to trigger the release of nitric 
oxide within the ventricles (Brack et al., 2009). NO was found to be produced within 
the heart by either constitutive or inducible NO synthases (Schulz et al., 1992; 
Balligand et al., 1993; Pinsky et al., 1994; Sessa, 1994). Since NO is also produced 
in response to distension (Pinsky et al., 1997), it is less surprising that the 
subendocardium, subject to the most stretch, may have lower β2–adrenoceptor 
expression (Hein et al., 2004) and, therefore, more NO mediated vasodilation. There 
is also evidence that β2-adrenoceptor stimulation leading to KATP channel opening 
(Hein et al., 2004) may contribute to NO production (Ming et al., 1997). These 
potential mechanisms are hypothesised to improve cardiac perfusion during periods 
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of DVMN optogenetic stimulation – this may have a significant beneficial effect on 
the contractile properties of the viable myocardium in the long term.   
A dramatic improvement of the LV function as a result of optogenetic 
stimulation of the DVMN in rats allows informed criticisms of on-going clinical 
trials of VNS efficiency in heart failure. Recently published results of NECTAR-HF 
trial demonstrated no effect of VNS on any objective measures of LV function, 
although a marginal improvement in the quality of life was reported (Zannad et al., 
2015).  
Both NECTAR-HF and the on-going INOVATE-HF were designed to 
determine whether VNS would attenuate cardiac remodelling, improve cardiac 
function and increase exercise capacity in symptomatic heart failure patients. 
NECTAR-HF trial recruited patients with ejection fraction of ≤35% and VNS was 
applied to the right vagus nerve. Right VNS was chosen as having a more profound 
effect on HR (via strong innervation of the SA node by the right vagus) with the 
resulting bradycardia having a therapeutic effect. Indeed, lowering HR was found to 
be beneficial in heart failure patients in clinical trials with ivabradine that typically 
excluded patients with HR ranges of <70 bpm (SHIFT study, (Swedberg et al., 2010) 
(Zugck et al., 2014). Both NECTAR-HF and INOVATE-HF trials did not exclude 
patients with low resting heart rates and allowed normal medication including β 
blockers.  
Collectively, the data presented in this thesis demonstrate significant 
functional innervation of the LV by the neuronal projections of the DVMN. DVMN 
neurones control electrical and contractile properties of the LV and provide crucial 
trophic innervation of the LV, which is required to mount an appropriate contractile 
response to β-adrenoceptor stimulation. Selective optogenetic recruitment of these 
projections has a dramatic beneficial effect on healthy ventricles (enhanced function) 
as well as ventricular myocardium compromised by occlusion of a major coronary 
artery (preserved/restored function). These data suggest that the design of future 
clinical trials of VNS in heart failure could be significantly improved by targeting the 
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left vagus nerve with additional modifications allowing selective recruitment of C 
fibre efferents originating from the DVMN. 
 163 
 General Discussion and Summary Chapter 6
The experimental studies described in this thesis aimed to determine the 
functional significance of cardiac innervation provided by projections of VPNs 
residing in the dorsal vagal motor nucleus (DVMN). The parasympathetic nervous 
system develops first in evolution of vertebrates, with the sympathetic nervous 
system appearing relatively late (cardiac sympathetic innervation is not present in 
elasmobranch fish) (Taylor et al., 1999). Therefore, the DVMN is probably the most 
(evolutionary) ancient central nervous structure that harbours autonomic motor 
neurones. During transition from water to air breathing, a group of DVMN neurones 
migrate ventrally and give rise to compact formation of the NA, which acquires 
respiratory modulation of activity from the neighbouring respiratory network 
(Burggren & Infantino, 1994; Burggren, 1995; Taylor et al., 1999; Jones, 2001). 
Given the evolutionary origin of the cardiorespiratory system it is inconceivable that 
the DVMN has no role in autonomic control of the heart, although the functional 
significance of cardiac innervation by the DVMN has been repeatedly questioned 
(Jones et al., 1998; Jones, 2001). This study used contemporary methods of 
molecular neuroscience (including pharmaco- and optogenetics) applied in carefully 
designed and executed physiological experiments conducted using animal (rat and 
mouse) models. Collectively, this thesis demonstrates that the DVMN neuronal 
projections control electrical and contractile properties of the LV, determine exercise 
capacity and have a major impact on the progression of left ventricular dysfunction 
post-MI.   
Experiments described in Chapter 2 were designed to determine the role of 
DVMN neurones in controlling electrical properties of the ventricle. The preliminary 
aims of the experiments for this chapter were: 
 To determine the effect of systemic muscarinic and neuronal NO synthase 
(nNOS) blockade on the electrical properties of nodal and ventricular tissue 
 To determine the effect of DVMN silencing on the electrical properties of nodal 
and ventricular tissue 
 To determine the effect of synuclein pathology on DVMN activity and 
ventricular electrical stability.  
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The data obtained demonstrates that the DVMN VPNs provide functional, 
tonic innervation of the ventricle. The experiments on rats under urethane 
anaesthesia in conditions of systemic β-adrenoceptor blockade with subsequent 
muscarinic and nNOS synthase blockade confirmed the existence of a tonic 
parasympathetic control of cardiac excitability mediated by the actions of ACh and 
NO. Acute DVMN silencing led to shortening of the ventricular effective refractory 
period, lowering threshold for triggered ventricular tachycardia and prolonging the 
corrected QT interval. Lower resting activity of the DVMN neurones in aging 
synuclein deficient mice was found to be associated with ventricular effective 
refractory period shortening and corrected QT interval prolongation.  
These findings imply that the activity of the DVMN VPNs is responsible for 
tonic parasympathetic control of ventricular excitability, likely to be mediated by 
NO. Vagal influence on the atria and conductive tissue is assumed to be mediated via 
a muscarinic mechanism from a neuronal source other than the DVMN. These 
findings provided the first insight into the central nervous substrate that underlies 
functional parasympathetic innervation of the ventricles and highlighted its 
vulnerability in neurodegenerative disease(s). 
Having established the presence of functional innervation of the ventricle by 
the DVMN neuronal projections, the experiments described in Chapter 3 were 
designed to determine the functional significance of this innervation concerning the 
control of left ventricular contractility. The preliminary aims of the experiments for 
Chapter 3 were: 
 To determine the effects of systemic muscarinic blockade on left ventricular 
contractility 
 To determine the effect of reduced DVMN activity on left ventricular 
contractility 
 To identify the anatomical location of DVMN neurones that control left 
ventricular contractility. 
It was found that under systemic β-adrenoceptor blockade combined with 
spinal cord transection (to remove sympathetic influences), intravenous 
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administration of atropine increases left ventricular contractility in rats anaesthetised 
with urethane, but not in animals anaesthetised with pentobarbital. These 
observations are consistent with the previously published data showing that cardiac 
vagal tone is preserved under urethane anaesthesia and abolished by pentobarbital 
(O'Leary & Jones, 2003).  
Increased left ventricular contractility in rats anaesthetised with urethane was 
observed when the activity of DVMN neurones, targeted bilaterally to express an 
inhibitory Drosophila allatostatin receptor, was reduced by application of an insect 
peptide allatostatin. No significant changes in heart rate were observed following 
DVMN inhibition, an observation concordant with the large body of evidence 
indicating that chronotropic vagal tone is provided by VPNs of the NA (Spyer, 
1994). 
Microinjections of glutamate and muscimol to activate or inhibit neuronal 
cell bodies in distinct locations along the rostro-caudal extent of the left and right 
DVMN demonstrate that VPNs that have an impact on left ventricular contractility 
are located in the caudal region of the left DVMN. Changes in left ventricular 
contractility were only observed when this subpopulation of DVMN neurones was 
activated or inhibited. These data confirmed the existence of a tonic inhibitory 
muscarinic influence on ventricular inotropy. The results obtained also suggest that 
the activity of this subpopulation of DVMN neurones provides functionally 
significant parasympathetic control of the left ventricular contractile function. 
Therefore, the subsequent experiments described in Chapters 3 and 4 targeted VPNs 
residing in the caudal aspects of the DVMN. 
Having demonstrated that DVMN neurones contribute to the autonomic 
control of the electrical and contractile properties of the LV, subsequent experiments 
described in Chapter 3 were designed to test the hypothesis that the strength of 
cardiac parasympathetic tone determines exercise capacity. It was hypothesised that 
vagal withdrawal decreases and vagal recruitment enhances the ability to exercise. 
Previous studies conducted in this laboratory demonstrated that DVMN activity 
mediates the phenomenon of remote ischaemic preconditioning (when cycles of 
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ischaemia/reperfusion applied to the tissue/organ remote from the heart protect 
cardiomyocytes from lethal ischaemia/reperfusion injury) (Mastitskaya et al., 2012). 
Increasing DVMN activity mimics the effect of remote preconditioning on the heart 
(Mastitskaya et al., 2012), while remote preconditioning was found to improve both 
aerobic and anaerobic exercise capacity in humans (Salvador et al., 2015). 
Combined, these data suggest that recruitment of common mechanisms may underlie 
the effect of remote ischaemia/reperfusion on myocardial injury and ventricular 
performance. An experimental model of forced exercise in rodents was used and 
exercise capacity was determined in conditions of  
 Unilateral cervical vagotomy 
 Acute and chronic systemic muscarinic receptor blockade  
 Systemic M2 and M3 muscarinic receptor blockade 
 nNOS blockade 
 Genetic targeting and silencing of DVMN neurones 
 Optogenetic activation of the DVMN neurones. 
Significant reduction in exercise capacity was observed in rats following 
unilateral vagotomy, sustained (four hours) systemic muscarinic receptor blockade or 
inhibition of the neuronal NOS. Exercise capacity was also reduced in mice deficient 
in M3 muscarinic receptor-mediated signalling and in WT mice in conditions of 
systemic M3 muscarinic receptor blockade. Acute reduction in the activity of the 
DVMN neurones using a pharmacogenetic approach resulted in a dramatic lowering 
of exercise capacity and inability of the LV to mount a contractile response to β-
adrenoceptor stimulation.  
These results argue in favour of an essential role played by vagal innervation 
of the ventricle which maintains the ability of the LV to mount an appropriate 
contractile response to sympathetic stimulation. Acute nNOS inhibition and acute 
DVMN silencing were found to have quantitatively similar detrimental effects on 
exercise capacity, suggesting that the DVMN neuronal projections control left 
ventricular function and exercise capacity using NO as a signalling molecule. The 
concept of a direct nitrergic NO-mediated vagal control of the ventricle input is 
supported both by the data presented in Chapter 2 of this thesis and available 
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literature data (Brack et al., 2009, 2011). Vagal innervation of the LV mediated by 
muscarinic mechanisms is hypothesised to provide trophic influences, the 
significance of which becomes clear over a longer time period. Optogenetic 
recruitment of the DVMN neurones (four daily sessions of 15 minute-long 
stimulations) markedly improved exercise capacity and contractile properties of the 
LV. The degree of exercise capacity improvement was quantitatively similar to that 
observed in a group of naïve animals subjected to exercise training over the same 
time period. However, no improvement in ventricular contractile function was 
observed in the latter group of rats.  
Changes in left ventricular inotropy following optogenetic DVMN 
recruitment were not associated with any significant changes in heart rate. It was also 
found that optogenetic stimulation of the DVMN results in down regulation of GRK2 
and pan-arrestin expression in the LV. Reduced expression of GRK2 had previously 
been shown to unmask a significant contractile effect of β2–adrenoceptor stimulation, 
which is either weak or absent under normal conditions (Salazar et al., 2013). 
Increased vagal efferent activity and potentially enhanced recruitment of PKD1, via 
activation of the M3 receptor, had also been shown to promote cardiac hypertrophy 
and angiogenesis (Rozengurt, 2011). Increased efficacy of β2–adrenoceptor mediated 
signalling in ventricular cardiomyocytes may therefore explain changes in resting 
inotropic state and the ability of the LV to mount a stronger inotropic response 
during exercise.  
Together, the results in Chapter 4, obtained using pharmacological blockade, 
M3-KI genetic mouse model, pharmaco- and optogenetic approaches to alter the 
activity of the DVMN VPNs, have demonstrated that the vagal supply to the LV 
maintains the ability of the heart to mount an appropriate inotropic response and 
determines exercise capacity. Experimental studies described in Chapter 5 were 
designed to test the hypothesis that increasing activity of DVMN neurones might be 
sufficient to slow left ventricular dysfunction and remodelling developing after a MI. 
This hypothesis was based on the results of the experiments presented in Chapters 2 
and 3, suggesting that DVMN neurones provide functional innervation of the left 
cardiac ventricle, controlling its electrical and contractile properties. The results of 
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the experiments described in Chapter 4 have also demonstrated a clear improvement 
in exercise capacity and left ventricular contractility after four daily sessions (15 
minutes each) of DVMN stimulations, suggesting that the same treatment delivered 
over a longer period of time may slow or even prevent left ventricular dysfunction 
and heart failure development after permanent coronary artery occlusion.  
To test this hypothesis an experimental design was created involving four 
groups of animals: rats transduced to express either eGFP (control) or ChIEF-
tdTomato (optogenetic construct) by the DVMN neurones that underwent left 
anterior descending artery occlusion or sham surgery. All animals were subjected to 
four weeks of light stimulation of the dorsal brainstem via a pre-implanted optrode 
for 15 minutes every 48 hours, commencing two days after left anterior descending 
occlusion or sham surgery. Left ventricular systolic and diastolic functions were then 
assessed using different methods, including high-resolution ultrasound. 
The data obtained has demonstrated that optogenetic stimulation of the 
DVMN over the course of four weeks post-MI prevents cardiac dysfunction, as 
evident from improved/maintained exercise capacity and left ventricular systolic and 
diastolic function. Concordant improvements were observed in most of the assessed 
indices of contractile (ejection fraction, IVCT, LVdP/dtmax and LVESP) and diastolic 
(E/A ratio, deceleration slope, LVdP/dtmin and LVEDP) function.  
Collectively, the data presented in this thesis has demonstrated significant 
functional innervation of the LV by projections of VPNs residing in the DVMN 
(Figure 6-1). DVMN controls the electrical and contractile properties of the LV and 
provide crucial trophic innervation, which is required to mount an appropriate 
contractile response to β-adrenoceptor stimulation.  
Strength of vagal tone supplied to the LV by the DVMN neurones determines 
the ability of cardiomyocytes to respond to sympathetic stimulation and, therefore, 
determines exercise capacity. These data imply that differences in individual ability 
to exercise may reflect varying levels of DVMN activity due to multitude of genetic 
and environmental factors. High vagal tone provided by the DVMN neuronal 
projections to the ventricular system in elite athletes could make them highly tolerant 
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to intense exercise regimes. On the other side of the spectrum, loss of exercise 
capacity with age has been found to be associated with a progressive decline in 
autonomic function (De Meersman & Stein, 2007). Neurones such as those of the 
DVMN have long projecting axons with no myelination and require more energy for 
impulse propagation and are susceptible to metabolic stress (Kapfhammer & 
Schwab, 1994). DVMN dysfunction has already been associated with a host of 
autonomic abnormalities (Braak et al., 2002; Goldberg et al., 2012) and may 
contribute to progressing decline in exercise capacity during aging and in various 
disease states.  
In practical terms, the data showing that relatively very short (15 minutes) 
sessions of optogenetic DVMN stimulation delivered every 48 hours are sufficient to 
preserve left ventricular function and exercise capacity post-MI may inform further 
development of VNS technology for heart failure treatment. Selective optogenetic 
recruitment of DVMN projections has a dramatic beneficial effect on healthy 
ventricles as well as ventricular myocardium compromised by occlusion of a major 
coronary artery. This thesis thus identifies the source and provides a comprehensive 
analysis of the functional role of ventricular vagal innervation. It further suggests 
that the design of future clinical trials of VNS in heart failure could be significantly 
improved by targeting the left vagus nerve with additional modifications allowing 
selective recruitment of C fibre efferents originating from the DVMN.  
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Figure 6-1: Scheme of sensory and efferent neural pathways controlling the 
heart 
Dashed lines represent hypothesised projections. AN, afferent (sensory) neurones; DVMN, 
dorsal vagal motor nucleus; EPN, efferent parasympathetic neurones; ESN, efferent 
sympathetic neurones; IN, interneurones; NA, nucleus ambiguus, SN, sympathoexcitatory 
neurones; VPN, vagal (parasympathetic) preganglionic neurones. 
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